var title_f13_12_13504="Digit symbol test";
var content_f13_12_13504=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F74553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F74553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Digit symbol test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 227px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADjAgIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDzrQNW8X6xo9pqKaloMK3MYkER0qZymexb7SM/XArQ83xj/0GPD/AP4J5v8A5Kqn8P8A/kStF/69k/lXIfGz4k33gLS2/srQru7umRHW9lt2axhBcgq7qwO/jhePvA57EA7vzfGP/QY8P/8Agnm/+Sqq3WreKNNuNOe8v9Furee9gtpI4dNlifbJIFJVjcMARnPINP8ABGqz694O0XVrxIkuL2ziuJFiBCBnUEhQSSBz3JpPFf8Aq9I/7C1n/wCj0oAveJtV1qLxLZaZos+n2yy2ctzJJd2jzklXRQAFljx98nJzUPm+Mf8AoMeH/wDwTzf/ACVTtc/5KLp3/YKuP/R0NV/GF/qmm+Hrm50DThqWqB4khtWbaHLSKpJbsAGLZ6ADmgCbzfGP/QY8P/8Agnm/+SqPN8Y/9Bjw/wD+Ceb/AOSq8pu/iP4z8IeMdA0jx5puhPaay4iim0lpcxsWCndvJzgsvGOnQmvaqAKeha3qNz4Q1S/vjavf2cl3EGgiaONjEzqp2lmIztHG41m6bceK7zTrW6OuaahniSUqNMJxkA4z53vT9A/5ELxN/wBfOpf+jJKteHf+Rf0z/r1i/wDQRQBH/wAVX/0HtO/8FZ/+PUf8VX/0HtO/8FZ/+PVzPinUvH0viOTT/B2laMljDEjtf6u8uyRznKIsfJIwOeRWX8FviLqPjd9cstZ0+2t7/SpVikms2LQSElh8uSe6E9SCDQB2sWo+IbHxBoNvfalY3dpf3b20iR2RiZQLeaUEN5jd4gMY6GtLxfqmq2eoaPZaNLYwSXrS75bu2acKEUHAVZE557ms7V/+Rm8Hf9hST/0huqt+MP8Aka/C/wBbr/0WKAIfN8Y/9Bjw/wD+Ceb/AOSqPN8Y/wDQY8P/APgnm/8AkqtSvCNZ+Nt+/wATNG0bw7ZWU3h+71GLTmv50djM3mIspiIYDC7wASDzz0oA9j83xj/0GPD/AP4J5v8A5Kq/4K1PUtQOtQaxJaS3Gn3otVktIGhR1NvDLnazuQcykde1S1T8B/8AIT8Yf9hZP/SG0oAzNP1bxVqYvJ7XUNDtreO9uraOOXTJZXCw3EkQLMLhQSQmeFHWrfm+Mf8AoMeH/wDwTzf/ACVVbwd/yDL7/sL6n/6XT1558YfiRrnhHxloWiaL/YEMWoxFnudX8xY4juIyzq4CrgdcGgD0zzfGP/QY8P8A/gnm/wDkqs/X9W8X6Po93qL6loMy20ZkMQ0qZC+Owb7ScfXBrJ+HOq+KdYknuNdv/Bt/pewrFL4fmllPmZHDFiVxjPTnNbXxA/5ErWv+vZ/5UAb/AI11O/0uwszpT2sdzc3kVsHuYmlRA2cnarqSeP7wrM83xj/0GPD/AP4J5v8A5Kq18Q/+PXRP+wrB/wCzVJeXMNlaT3V1IIreCMyyO3RFUEkn24zQBR83xj/0GPD/AP4J5v8A5Ko83xj/ANBjw/8A+Ceb/wCSq8csfi34i8UXDz+Gm8HaNpjTGG1PiK9ZJ7sjAyiIwPU+hGTgEkGvc7bzvs0X2ry/P2DzPLzt3Y5257Z9aAIPCuqaxceIdV0zWriwuPstrbXMclpavB/rXnUqwaR848kHII61QOq+Jr7WNZi0690e2tbK7+zIk+nSzOw8tHJLCdB1fGAKteG/+Sg6/wD9gvT/AP0beVV0L/kMeKf+wqf/AERDQBN5vjH/AKDHh/8A8E83/wAlUeb4x/6DHh//AME83/yVWX40/wCE032n/CE/8I9tw/2n+1/Pznjbs8v/AIFnPtivOPBXxI8a6r8W38Ianb+Hbi3sw7X9zpqT4jCr0DO3XeUU5Xrn60Aem61qXjHTNHv7/wDtTw/J9lgebZ/ZMy79qk4z9pPpjOK3PFer39h4ds7rTTapeXM9tAGnjaSNPNdVJKhlJxu6bhWZ40/5E7Xf+vC4/wDRbVP40/5FXRf+v/T/AP0alADfN8Y/9Bjw/wD+Ceb/AOSqPN8Y/wDQY8P/APgnm/8AkqtKVxHG7kEhQWIUZJ47Cvnqz+M3i7X9H13xB4d0/wANRaNpJ3S2l7NIbx48gll2sF6Hv3yBuPFAHufm+Mf+gx4f/wDBPN/8lVN4d1XW38TTaXrNxptzGLQXKPaWjwEHftIIaV8j8qyfhz4mPjHwXpmvGzazN2hJhY52lWKkg45B25Bx0rS0n/kosn/YKH/o2gCCXVfEl5r+u22mX2j2tpp90lsi3Gnyzu+beGUsWE6DrKRgL0FS+b4x/wCgx4f/APBPN/8AJVRaR/yM3jH/ALCkf/pDa1x/xZ+It14T1DRND0GwivvEGsSCO3W4YrFHlgqs2ME5YgYyOMnPqAdr5vjH/oMeH/8AwTzf/JVVdRvvGNnp91df2r4ffyInl2/2RMN20E4/4+uOlcL4Q+ImvJ8R5PBHjqx02HVJYvOtbnTGfyZBtLYw5J6BueOVxjvXo/iL/kX9T/69Zf8A0E0AdLo9zJeaRZXUoUSTwJKwXgAsoJx7c1drN8Mf8i3pP/XpF/6AK0qACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPPvh/wD8iVov/Xsn8q8w/an8TaRbeB7rw5Pd7dZuvJuIbfy3O6MS8ndjaPutwTmu68D+I9EtvCOkw3Gs6bFNHbqrJJdRhlOOQRng1uf8JV4f/wCg7pP/AIGR/wDxVAHJ/ArxRo+veAdJsNJvPPu9KsbaC8j8t08p9mMZZQG5VuVJFdT4r/1ekf8AYWs//R6U/wD4Srw//wBB3Sf/AAMj/wDiqytf17SL59GgstV0+5nOq2ZEcVyjsR56HoDQBua5/wAlF07/ALBVx/6Ohqn438U6f4N8N3WtasZDbwAAJGuWkcn5VHbk8ZPAo8WajZab8QNMk1G8trWNtLuFV55VQE+bEcDJ68VL/wAJV4f/AOg7pP8A4GR//FUAfMvhjxx4c8W/EOLxh8RNcjszZSBdM0eO3mlEWDlWZlQqeeeuSeuAAK+s6xv+Eq8P/wDQd0n/AMDI/wD4qj/hKvD/AP0HdJ/8DI//AIqgBugf8iF4m/6+dS/9GSVa8O/8i/pn/XrF/wCgiqHhiaK5+HviKa3ljlhkuNSZHRgysPMk5B7iqGg+M/C0Wh6ckniTREdbaNWVr6IFTtAII3cGgDlPif4u8Dzald+FviRZ3UFhC8dxbzskxinbYPutENwZdzAjp754GB+zHFqEVx4n+xxXkXgxrgvpQu1wxyx5Ukc/JtzzjPvmvWP+E38Kf9DPof8A4Hxf/FUf8Jv4U/6GfQ//AAPi/wDiqALGr/8AIzeDv+wpJ/6Q3VW/GH/I1+F/rdf+ixXPv4i0TV/FvhC30nWNNvp11GV2jtrqOVgosrkZwpPGSOfetfx7e2th4i8MT31zBbQBrkGSZwi58sYGSaAMv4o6NrniDwXfaX4YvbezvrrEbTTsygR5+cZVWIJHHSvnLx/pHi7QPF3w00u8g8LQT2tzHHpUdh5/kh/Oj5n3/MQX2kleT8x619P/APCVeH/+g7pP/gZH/wDFUf8ACVeH/wDoO6T/AOBkf/xVAGjp32v+z7X+0vs/27yk+0fZ8+X5mBu2Z525zjPOOtR+A/8AkJ+MP+wsn/pDaVS/4Srw/wD9B3Sf/AyP/wCKqb4cXdve3fi24s54riB9WXbLE4dWxZWo4I69MUAVfB3/ACDL7/sL6n/6XT1xfxG8VeCNK8VxWHj/AEK2eL7Kstvqd1p4uo+WYGL7jFT8ueMg55x36Lwxr+j2VpqNveatp9vOmraluiluURlzezkcE8cHNa3/AAlXh/8A6Duk/wDgZH/8VQB4l+z5phl+JnivXvDdncWXgu4jMVskiFElbcpUoD1Aw59gwHevZviB/wAiVrX/AF7P/Kp/+Eq8P/8AQd0n/wADI/8A4qsPxx4j0S58I6tDb6zpss0luyqkd1GWY44AGeTQB1fxD/49dE/7CsH/ALNWf420ybWvBuu6XakLcXtjPbx5OBueMgZPpzVr4l3ENrp2kTXUscMKapAWkkYKqjnkk9Krf8JV4f8A+g7pP/gZH/8AFUAfI0D+Hbb4S3/hXUvDzp8Q0u9kEf2BvtL5kBzvC5wF3DbnnsO9fVXwwsNR0v4e+H7LWt4v4LNElVzkoccKfcDA/Cr/APwlXh//AKDuk/8AgZH/APFUf8JV4f8A+g7pP/gZH/8AFUAWfDf/ACUHX/8AsF6f/wCjbyquhf8AIY8U/wDYVP8A6IhpPBl/Z6j478QTafd291ENN09S8EiyAHzbvjI74Iqhp+t6Vp+v+KIb/U7G1mOpltk1wsbY8iHnBPTigCj8Y/GsfgXwPeakrL/aEo8izQ4O6ZgcEg9QuCx+mO9c7+zj4Mfw74NOrakpbWdbIupnfJZYzyinvnBLH3bHavQf+Eq8P/8AQd0n/wADI/8A4qj/AISrw/8A9B3Sf/AyP/4qgA8af8idrv8A14XH/otqn8af8irov/X/AKf/AOjUrC8X+JtCl8J61HFrWmPI9jOqot3GSxMZwAM8nNbHjuaK28H6RNcSxxQx31gzyOwVVHmpyT2FAF/UGuEsLl7JEe7ETGJHOAz4O0E56ZxXxR9j8L3vh3xC3jT+09P+IbXMklvbRWjRrM5A2p5aptAL7s9DzkZ6V9jf8JV4f/6Duk/+Bkf/AMVR/wAJV4f/AOg7pP8A4GR//FUAc/8ABNtdb4a6P/wlMckeoBCoWVdjiMMRHuXHB2gds4xnmun0n/kosn/YKH/o2oP+Eq8P/wDQd0n/AMDI/wD4qovDWpWOpfEGZtOvba7VNLCsYJVkCnzenBoAl0j/AJGbxj/2FI//AEhta83/AGg9H8NSjQtZ1zxHceG9Us5iLG+jtXuRkENgoozkEZByMe9dxb61peneK/GEOoalZWsp1KJgk9wqEj7FagEAnpkHmtD/AISrw/8A9B3Sf/AyP/4qgDwb4W6Tq/jD4yQeLrm+vtT0nTLYxpql3ZraC7YxsoEcagYX52bucDk/MBX0D4i/5F/U/wDr1l/9BNV/+Eq8P/8AQd0n/wADI/8A4qqGv+JtAk0LUkTW9KdmtpFAW7jJJ2kAAZoA7fwx/wAi3pP/AF6Rf+gCtKs3wx/yLek/9ekX/oArSoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5L4cWVq/gTQme2hZjaISSgJPH0q74pv8AR/DOgXusanbwJaWke9sRruY9lX1JOAPeovhr/wAiDoP/AF6J/KuJ8YIvj/4l2PhML5mhaHt1DVu6yyn/AFUJ/MkjuM9xQB6Tpy6XqVhb31jFazWtxGssUioCHVgCCOPSsXxtaW0VnpTxW8SONWsuVQA/69K5L4dzS+CPGF54Bv3c6dNvvdBmkJO6Ikl4M+qHJ+mT3Fdp48/48NL/AOwtY/8Ao9KAI76GOb4jWCzRpIo0q4IDqCB++groPsFn/wA+lv8A9+x/hWHcf8lIsP8AsE3H/o6Cua+Iei+C73XY5vFPiQ6XfGBQkJ1cWm6PLYbZuGedwz7e1AHoP2Cz/wCfS3/79j/Cj7BZ/wDPpb/9+x/hXjH/AAjPwt/6Hr/y5V/+Lr0D4cWXhzT9NuofCmsjVbYzb5X+3i7KNtAxuBOOB0oAq6Oip4J8UqihVW71MAAYAHmSV0WhTxWvhPTp7iRYoIrKN3kcgKqiMEknsPesDSv+RL8Vf9fep/8AoySuZ+Lk0kXwPto1laC3uEsoLmVeDHCzIGP07fQ0AWoviPrniF5ZPAfhC41XTI3Kf2hd3S2kUpBI/dhhlh7/AJitbwn8Qk1PXT4f8Q6Tc+H/ABFs8xLS5dZEnXnmKQcP0PT3xnBx2mn2lvYWMFpZRJDbQII4o0GAqgYAFebfH6OODw7o+rQ4TV7DVbY2Dj7zOzgMg9QVySO+2gDrfFn/ACHvBn/YWk/9Ibuo/EcUc3jHwusqI6/6UcOAR/qx2qTxZ/yHvBn/AGFpP/SG7o17/kc/C/8A29f+ixQBFf674e0/xXY+Hr6KKDUL6Iy2xkgAilwcbFfGN3fH9SM77WNkqkta2wUDJJjXAH5ViePvC+k+K/D81lrWIo4wZorpSFe1YD/WK3bH5Y614TofirWPHWqWHgbXNfih0cSSwvq0AaNtZVCFESMRgEg8+vufvAHu/hbWfD3iiC8n0Rbe6t7W4a2eVYMIzgDO1iMMOeo4png+NItb8ZJEioo1ZMBRgD/QbStjRdKstF0u207S7WO1s7dQkcUYwFH9T6nqTyayvCf/ACHvGf8A2Fo//SG0oAqeCILUeHr+ee3icrquqMxKAkgX09crZ/Fjw3e2yXFn4V8R3FvIMpLFpG9GGccEHmus8If8ifqv/YR1b/0tuKzPgD/ySDw3/wBcX/8ARr0AZM/xU8P28Ek1x4T8SxQxKXeSTR8KigZJJJ4HHWtzxZLp+q/Cu+1WytY0hu9N+1Q7o1DhXQMv0ODWt8Tf+SbeLP8AsE3f/ol65lP+TebL/sXoP/RC0AdJ45RZE0FJFDKdVtwQwyD97tVfxjr2meFRaNc6DqF+twXA/s6xE+wrj72Omd3H0NWvG/8AzAP+wvb/APs1dLQB5Z/ws7Qv+hO8Uf8AglP+NX/DPj3w94g8RQ6LFoWp2N7LG8yC/wBPEAZV6kZNeiV5pr3/ACXvwv8A9gm6/wDQhQB0WlQxw/EfXlhjRAdJ08kKAB/rr2meFLW3m1LxQ00ETt/apGWQE/6iH2qfT/8AkpOu/wDYJ0//ANHXtHg7/kIeKf8AsLN/6IgoA3PsFn/z6W//AH7H+FYnhLVNG8U6ImqaZZhbZ5HjAlhVWyjFTxz3FdJXmv7PP/JMrX/r7uv/AEe9AHS+OLK0XwV4gZbWAEafcEERgHPlt7VU8WIr+G9CV1DKdQ08EEZBHnJWp46/5EjxD/2Drj/0U1Zvin/kXtA/7COn/wDo5KAOl+wWf/Ppb/8Afsf4VzGu6zaaV4z8L6B/ZNvL/bn2r9/wvk+TGH+7tO7OcdRj3qDxL4p8S6Xq8trpXgi71a0VVK3UV7FEHJHI2tzx0rzPxZ4q8TXHxM8BXdx4HvLa8tvt/wBns2vYi11ugAbDdF2jnnr2oA96+wWf/Ppb/wDfsf4Vz0MEUHxHIhijjB0nJCKBn99WLY+M/F9xfW8M/wAO762gkkVJJm1CFhGpOCxA64HOBW//AM1J/wC4T/7WoAh8M2sE3iDxm00EUjDVYxlkBP8Ax42ldF9gs/8An0t/+/Y/wrD8J/8AIe8Z/wDYWj/9IbSuloA4/wAAazZ+LdGnv/7JgtPKu5rXZxJny227s7R164xxWp4lsbQeHNVItbcEWkpBEY/uH2rkfgD/AMibff8AYWvP/RhruPE//It6t/16S/8AoBoAPDH/ACLek/8AXpF/6AK0qzfDH/It6T/16Rf+gCtKgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDjPCFxdWnwq064061N5eRacHhtwwHmuFJVckjGTgVF8JfDNz4d8LeZrB36/qcrX2oytgkzPzt+ijAx0znHWrGleGNa0rTrexsvErpbW6CONWsY2IUds55q3/Y/iL/oaP/KfH/jQBn/FTwpN4m0COXSX8nxBpkgvNNnBAKzL/CSeMMBjnjOCelP8Ry3k/hrw/JqcC29++oae1xDG29Y5POTcobuAcjNXf7H8Rf8AQ0f+U+P/ABqCfw3qt5Laf2l4ha4t7e5iuTEtnHHvMbBlBYHgZFAE9x/yUiw/7BNx/wCjoKuat4Y0HWroXOsaLpmoXCoIxJdWkcrBckhQWBIGSTj3qDW9Du73WbXUtO1RrC4hge2P7hZQ6uyMeD05QVF/Y/iL/oaP/KfH/jQAf8ID4O/6FPw//wCC2H/4mtPR9E0nRIpI9G0yx0+ORtzpaQLCGPqQoGTWZ/Y/iL/oaP8Aynx/40f2P4i/6Gj/AMp8f+NAGbpX/Il+Kv8Ar71P/wBGSVpRaPZ+IPANtpWpx+ZaXdhHFIBwcFByD2IOCD2NTaT4f+xaBe6bc3kly129xJLPsCEmVizEKOB96qdp4a1e0tYbeDxZqCxQoI0BtbY4AAAH+r9qAOQ0tfiR4LtU0uDSbTxfpsPyWtwL5bS4WMfdWTeMEgccZ+tWtJ8LeI/FHiew17x/9ltbbTX82w0a0cyIkvaWV/4mHbHH05B6v+wdb/6G7UP/AAEtf/jdH9g63/0N2of+Alr/APG6ADxZ/wAh7wZ/2FpP/SG7o17/AJHPwv8A9vX/AKLFMh8NXj6rpl7qPiC9vlsJmuIoZIIUUuYniySiA/dkbv1q54h0WfU7vTrqz1FrG5smco4iWQMHXBBBoA5Px14e1/xp4ij0S6b7B4KiVZbqSGUebfvnPleqoMc+v8t7xR4F0TxD4Wj0Ka1W1tbdR9ka3AR7VlHytGexH696l/sfxF/0NH/lPj/xo/sfxF/0NH/lPj/xoAr/AA6TxPbaVPYeL/JnubOUxQX8bZ+2RADa7Ln5W7HP/wBc2PCf/Ie8Z/8AYWj/APSG0o/sfxF/0NH/AJT4/wDGrXhvRZdI/tKS5vmvbm/uhdSymMRgERRxABRxjbEv40AZvg1Wk8J6miDc7alqqgDufttxxXnnw48Q+J/CfgrTNEuPAGuXEtmjK0kbRgNly3AJ/wBqvQrPw1q1h9pj07xE0FtLdXFysTWUblDNK8rDcTyAzn8Ks/2P4i/6Gj/ynx/40AcH4r8X+Jdb8LazpUXw912KS+s5rVZGeMhS8ZUE89Oa3bu0nsPgPFZ3kTQ3NvoUUUsbdUdYVBB9wRit/wDsfxF/0NH/AJT4/wDGqmq+GNa1XTrixvfErvbXCGORVsY1JU9s54oAt+N/+YB/2F7f/wBmrpax/E2jyazaW0cF41nNb3CXMcqoHwy5wCp4I5ql/Y/iL/oaP/KfH/jQB0tcNquh6lcfF3Qtait92mWunTwSzb1G12I2jbnJ+oGK1P7H8Rf9DR/5T4/8aP7H8Rf9DR/5T4/8aADT/wDkpOu/9gnT/wD0de0eDv8AkIeKf+ws3/oiCpdB0O6sNXv9Sv8AU2v7m7ggtyfIWIIsTSsOB1yZWqt/wjmp2+o6jcaZrzWsV7P9oeFrRJNrbEThic4wgoA53/hZuo/9E98Yf+Ai/wDxVcn8MPE+teEfCUOk3vgTxVPMk00paK1G3DyFgOSOea9S/sfxF/0NH/lPj/xo/sfxF/0NH/lPj/xoAy7vXZ/EHw38S3dzo2paOyWlzEINQjCSMBCTuABPy84+oNW/FP8AyL2gf9hHT/8A0clGpeG9c1HTrqyufE7GC5ieGQLYRg7WBBwc+hrT17Q21PR7eyhu2tpLeWGaOYIHIaJgy5U8HlaANuvNfHMbt8Y/hk6oxRf7T3MBkLm3XGfSul/sfxF/0NH/AJT4/wDGj+x/EX/Q0f8AlPj/AMaAOlrmv+ak/wDcJ/8Aa1H9j+Iv+ho/8p8f+NSaPoV5a63Jqepas1/M1uLZR9nWIKu7dnjqc0AR+E/+Q94z/wCwtH/6Q2ldLXLSeHdSi1bVLzS9dazj1CdbiSE2iSBWEMcXBPOMRKfrUn9j+Iv+ho/8p8f+NAHN/AWN4/B18siOhOq3hAYEHHmHmu38T/8AIt6t/wBekv8A6AazP7H8Rf8AQ0f+U+P/ABqC88P69d2k9tN4oJimjaNgLCMHBBB7+9AG14Y/5FvSf+vSL/0AVpVW061Flp9raIxZYIliDHqQoAz+lWaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAGO6opZyFUDJJOABXO/8ACfeDv+hs8P8A/gyh/wDiq29V/wCQXef9cX/9BNcf4L/5E7Qv+vC3/wDRa0Aav/CfeDv+hs8P/wDgyh/+Ko/4T7wd/wBDZ4f/APBlD/8AFVm6v4l0LRZFj1jWtMsHb7q3d1HET34DEetXrC+tNRtY7rT7mG6tpAGSWBxIjDsQwODQBJ/wn3g7/obPD/8A4Mof/iqP+E+8Hf8AQ2eH/wDwZQ//ABVYWtf8jd4b/wC3n/0WK6GgCP8A4T7wd/0Nnh//AMGUP/xVH/CfeDv+hs8P/wDgyh/+KrJufFfh211Eafc6/pMN+XEf2Z7yNZSxOAuwtnOeMYraoAj/AOE+8Hf9DZ4f/wDBlD/8VR/wn3g7/obPD/8A4Mof/iqwvDH/ACG/F3/YUT/0ita3bmeG1tpbi6ljhgiQySSyMFREAyWYnoABnJoAP+E+8Hf9DZ4f/wDBlD/8VR/wn3g7/obPD/8A4Mof/iqh0zUbLVbJLzS7y2vbSTIWe2kWRGIJBwwJB5BHWqHjT/kTtd/68Lj/ANFtQBq/8J94O/6Gzw//AODKH/4qj/hPvB3/AENnh/8A8GUP/wAVUenf8g+1/wCuSfyFU9Z8RaJojRprWsabp7yDKC7uo4Sw9QGIzQBof8J94O/6Gzw//wCDKH/4qj/hPvB3/Q2eH/8AwZQ//FUW80VzCk1vLHLC4DK8bAqw7EHuKwta/wCRu8N/9vP/AKLFAG7/AMJ94O/6Gzw//wCDKH/4qj/hPvB3/Q2eH/8AwZQ//FUy9u7awtJbq+uIra2iUtJNM4REHqzE4A9zWB/wsDwb/wBDb4e/8GUP/wAVQB0X/CfeDv8AobPD/wD4Mof/AIqj/hPvB3/Q2eH/APwZQ/8AxVSVz3hP/j98S/8AYUb/ANEQ0Abv/CfeDv8AobPD/wD4Mof/AIqj/hPvB3/Q2eH/APwZQ/8AxVSVm6Pr2j62066NqthqDQECUWlykxiJzjdtJxna3X0NAF7/AIT7wd/0Nnh//wAGUP8A8VR/wn3g7/obPD//AIMof/iqwviL/wAk+8T/APYLuv8A0U1dDQBH/wAJ94O/6Gzw/wD+DKH/AOKo/wCE+8Hf9DZ4f/8ABlD/APFVz2sePPCmjX5stU8Q6ZbXgOGikuFDIf8AaGfl/HFb9pdQXttHcWc8VxbyqGjliYOjj1BB5H0oAd/wn3g7/obPD/8A4Mof/iqP+E+8Hf8AQ2eH/wDwZQ//ABVYWqf8jvoH/Xrefzhrenmit4mlnkSOJRlncgAD3PagBP8AhPvB3/Q2eH//AAZQ/wDxVH/CfeDv+hs8P/8Agyh/+KrJ03xZ4d1S8+yaZr+kXl1gnybe8jkfAPPyhie9bVAEf/CfeDv+hs8P/wDgyh/+Ko/4T7wd/wBDZ4f/APBlD/8AFVheDv8AmOf9hSf+la2p6lY6VaG61S9trK2UgGW5mWNAewLEgUAT/wDCfeDv+hs8P/8Agyh/+Ko/4T7wd/0Nnh//AMGUP/xVVtJ1bTtZtvtGkahZ38AJUy2s6ypnuMqTzWX8Qv8AkSNb/wCvV/5UAbv/AAn3g7/obPD/AP4Mof8A4qj/AIT7wd/0Nnh//wAGUP8A8VUlFAEf/CfeDv8AobPD/wD4Mof/AIqj/hPvB3/Q2eH/APwZQ/8AxVSVz19/yUHRf+wXf/8Ao20oA3f+E+8Hf9DZ4f8A/BlD/wDFUf8ACfeDv+hs8P8A/gyh/wDiqLieK2haa4ljiiX7zyMFA5wMn61l6R4n0DWp2g0fXNKv51G4x2l3HKwHqQpPFAGp/wAJ94O/6Gzw/wD+DKH/AOKo/wCE+8Hf9DZ4f/8ABlD/APFVJXPeCf8Ajy1L/sKXv/o96AN3/hPvB3/Q2eH/APwZQ/8AxVH/AAn3g7/obPD/AP4Mof8A4qs7WfEeiaHJEmtazpunPICyLd3UcJcA4yAxGR9KZo/ijQNbuWt9G1zS9QuFQyNFaXcczhcgFiFJwMkDPvQBqf8ACfeDv+hs8P8A/gyh/wDiqP8AhPvB3/Q2eH//AAZQ/wDxVYXxC/5EjW/+vV/5V0NAEf8Awn3g7/obPD//AIMof/iqP+E+8Hf9DZ4f/wDBlD/8VVTV9Z0vRYVm1nUrKwiY4V7u4WIE8cAsRnrUml6lY6tZpd6Ve217aOSFmtpVkRiDgjcpIPPFAE//AAn3g7/obPD/AP4Mof8A4qj/AIT7wd/0Nnh//wAGUP8A8VWFP/yUGy/7Bdx/6NhrflkSKN5JXCRoCzMxACjGSSewoAb/AMJ94O/6Gzw//wCDKH/4qj/hPvB3/Q2eH/8AwZQ//FVj2fi7w3e3wsrLxDo9xeFiogivYnkJBwRtDZznjFblAEf/AAn3g7/obPD/AP4Mof8A4qj/AIT7wd/0Nnh//wAGUP8A8VWF4C/5FtP+vq6/9KJK6GgCP/hPvB3/AENnh/8A8GUP/wAVR/wn3g7/AKGzw/8A+DKH/wCKqSue8e/8i2//AF9Wv/pRHQBu/wDCfeDv+hs8P/8Agyh/+Ko/4T7wd/0Nnh//AMGUP/xVSVQ1HWdM0y4tINS1Gys57t/Lt47idY2mbIG1ASNxyyjA9RQBb/4T7wd/0Nnh/wD8GUP/AMVR/wAJ94O/6Gzw/wD+DKH/AOKqSue/5qD/ANwv/wBq0Abv/CfeDv8AobPD/wD4Mof/AIqj/hPvB3/Q2eH/APwZQ/8AxVJc3ENrbvPdTRwwRjc0kjBVUepJ6VR0bxDo2uGQaLq+nagY/vi0uUm2/XaTigC//wAJ94O/6Gzw/wD+DKH/AOKrcsby2v7WK6sbiG5tpV3RywuHRx6hhwRWPUPwz/5EfTPo/wD6MagDp6KKKAKuq/8AILvP+uL/APoJrj/Bf/InaF/14W//AKLWuw1X/kF3n/XF/wD0E1x/gv8A5E7Qv+vC3/8ARa0AcX8QPCFpDe3uvad4FtPF2s6gyxzpeXMaLDGsYVWQSAj+EdPmJPXFcr+yalrB4f8AEEMdxKL9bwG6sChUWhwQoBJOc7WGevy4PSuw1vwF4jfxBqWo+GPHd7osOoOHmtHso7qNW2quUDMNp+XqOfetH4XfDyw+H9heJa3VxfX99IJbu7nwGkYZxgdh8zHkk5J5oA1da/5G7w3/ANvP/osVzvx+1288PfCzWLzTJGhu5NlusqEgoHcBiD2OCRnsa6LWv+Ru8N/9vP8A6LFW/FWgWPijw/faNqyF7O7j2PsIDKcgqy5GMggEcdRQB8xafJdfDbwh4T8Q6n4P8Jalot8YpDdbWmvxI6eYGMjjCtgEgKCAVxnPJ+r7eZLi3iniO6OVA6npkEcH8q8Zg+B01zbaZpXiLxfe6p4a01zJbaaLVYiOejSBiWGMjpwDxtr2lVCqFUBVUYAHAAoA5/wx/wAhvxd/2FE/9IrWuW+P/h9dX+HuqXb6nqtoNOtJphBaXGyK5OAQsy4O9Rt4GRjJrqfDH/Ib8Xf9hRP/AEitaz/iZ4V1fxfpA03S/Ef9i2c0ckV4n2FLj7QjAADJYFMYbleTn2oA579mb/kjOif79x/6Peu58af8idrv/Xhcf+i2rlfhT4D1jwHbDT7jxR/amixROsFl/Z6QeW7PuL79zMf4hg8c+1dV40/5E7Xf+vC4/wDRbUAaOnf8g+1/65J/IV8wW0uiaf8AG3xivxYspJxetJHpz3FpJcIYy3yeWqqxzs2AEDjBGQa+n9O/5B9r/wBck/kK4jxh4P8AFev6jeraePLjS9DuVVDYW+nRF0TaAwWfcHBJDHPbOOlAHC/si3lxL4T1uzaSR7G1vsW3mfw7lywx26A49SfWvWNa/wCRu8N/9vP/AKLFL4G8J6Z4K8PQaPoqMIIyXd5CC8rnGWbAxngDgYwMUmtf8jd4b/7ef/RYoAT4h6Jc+JPBGtaPYvElze2zRRvMSqAnoWIBOPoDXzxqGm6l8IdF0dfGHg3wRrujGU273kNr5l0zMWfDPIoydobHy4wAMivo/wAZaEPE3hy70k3txYmfYy3FucSRlHVwVPY5UV53d/CHU/ENzpy+PPGt3r+m2Lh0s1sY7UOwH8bKx3ehJ5xnkZoA9at5kuLeKeI7o5UDqemQRwfyrC8J/wDH74l/7Cjf+iIa6BVCqFUBVUYAHAArn/Cf/H74l/7Cjf8AoiGgDhPjH4xibVbXwNaava6PPqCeZqGpXM6wraW3OQpYgGRgCAAeB9cjif2WLjSdO8V+OdMtb622y3MSWKGdS88aNPynPzgLtJIzwc17xqvhTw7rF2brVtA0m/uioUzXVnHK+B0G5lJxXH/DX4T6f4I8Qa3q3m2l9LezCS0H2FYjYLmTckbbjgEOF4A4Xp6AHU/EX/kn3if/ALBd1/6KauhrnviL/wAk+8T/APYLuv8A0U1dAQCCCMg8EHpigD4uslnsF8eyaX4csvGejzPLG2smFmkt2YMQ6krnjO4kDGQDuxg19B/s3rp8fwp06PS7+S9RZJPOLoUMUhbLR7cnAGRznnOe9YFr8GNd0D+1LLwb42l0vRNSJ821kslmKAjHDE9cHGRtPTJr0T4beC7DwH4Yj0bTZJJl8wzSzOAGkkYAFsduFUY9BQBZ1T/kd9A/69bz+cNXPFOg2PifQrjSNWR3sbgoZURipYK4cDPYZUDjnFU9U/5HfQP+vW8/nDT/ABt4ebxPoEmnR6jdabMZY5orq1OJI2RgwI/L1oA+bvinpkGm+LvDP9peErbwRo1telE1WxaOZrhVYFWYR42nC5+bLDOecGvq+vIbz4P6l4iv9Ofx740u9fsLBt8doljHahjx98qx3ZxjJ5xnkZr16gDnvB3/ADHP+wpP/SvFv2hD9m+KfhC/8UW81x4KgRfNHls8Syb237gOCceXx3Axg817T4O/5jn/AGFJ/wClReNNG8R6t9j/AOEY8Vf8I/5e/wA//iXx3fnZ27fvkbduG6dd3tQB4f8AC6/0xf2j9Uj8Fgw+Hr6y8xoEhaCP/Vo2VjYKQN2ccfxHHBr3X4hf8iRrf/Xq/wDKsf4e/Duz8IXuoapPf3Wr6/qGPtOoXWAzDIO1V/hXIBxk9BzgCtj4hf8AIka3/wBer/yoA6GvB/jx4Q+H/hvw3q/iO+0NJtcv5GEBa7nHmXD5JYqJAMDliBxxjvXvFeR+P/htrPjj4laNqGsXNh/wiWm4K2YkcyyH7zbl2BfmYKp+b7o9aALH7OHg+bwp8PIXvg63uqP9tkjb/lmpUBFx/u4J9zjtXZ33/JQdF/7Bd/8A+jbSuhAAGBwBXPX3/JQdF/7Bd/8A+jbSgC34o0Cw8UaHPpOsRvLYTvG0sasV3hJFcLn0JUA45x6V88+LdM0fUfjt4V0r4b6fbWtzpMqvqU9hGEiRVcFg23glVDAk9SwUnPFe/eONF1DxB4autM0nWZNGuJwFN3HF5jKmfmAG5cEjjIIIrzPwd8H/ABN4Pt5Lfw98QIrSKVw8uNAgd5PZnZyxHsTgdqAPaq57wT/x5al/2FL3/wBHvXQ1z3gn/jy1L/sKXv8A6PegDgvjP8ONb8Y+J/D2q6KdEePTATJb6r5hjlO4EKyqp3KcYIyKzfhB4gjt/iPq3hTWfCHh7RPEVrAT9q0a1WJJY/kYqeM4KsjDnBxyAcV2/jHwZrGreIoNc8N+LLrQL1LYWsirarcRSoGdgWjYgFsv1OcdutQfD34aweFdb1HXtS1W41rxFfgrPfTRiMBcg4VATt+6vc8AAYFAG/8AEL/kSNb/AOvV/wCVdDXPfEL/AJEjW/8Ar1f+VdDQB8paLb+IPH3xI8catbaXoOs3emTGGC21wyPFHHukCpHEOGYiPGWIAPPVsj2L4A+L7Lxb4KZ7PSLLR3s5zDLa2UYjh3EBtyKOgO7p1znmqet/CO5HijVtb8HeKbnw5NqyMl9EtotwkhbqVyy7STk55IJJBFdb8N/BGm+AfDo0nSWlkVpDNNPKQXlkIAycDgYAGB0Hvk0AWZ/+Sg2X/YLuP/RsNX/EejWviDQ7zSdQ8w2l3GYpRG2CVzyAccVQn/5KDZf9gu4/9Gw1Z8X6GPEfh280o3lxZGcLtuLc4kjKsHDKexyooA+afjjoVvpk+k2z+C7bwroFvqBhXXrJo55ZkwcEohDdBu+ck8cHqD9U2jpLaQvDIZImjDK5OSwwCDn9a8k1T4Qaz4lFlaeNvHd7rGkWjiVbSOxS3LsBgFnDEscZGSCeTgivXYIkghjhhUJHGoVVHRQBwB+FAGD4C/5FtP8Ar6uv/SiSuA+K2s33iu61HwV4Xm8uG1t2uNcv1+7DFgkW6n+++OR2H/Asd/4C/wCRbT/r6uv/AEokrmvE3wa8F65PqV/NoofVbzfIZ2u5wDKwJDEB8DnnAGPagDnP2Sv+SWS/9hGb/wBBSvSPHv8AyLb/APX1a/8ApRHXHfAv4YH4f6XcyaotpLrs7lXubWaRkMPBVcMFAOQTnb+Ndj49/wCRbf8A6+rX/wBKI6AOhr5j+NWgLpHxm8DXg1PVL19Q1NJTHeT+YluPtEZCRDA2p8x45r6crx7xv8JNe8V+KLbWbnxx5RsLgz6dF/ZEZ+yguGVd28b8FV5YHOKAPYa57/moP/cL/wDatX/DlpqNhottba1qf9q6hGCJbz7OsHmncSDsU4XAIHHpmqH/ADUH/uF/+1aAPLP2r4dSk8M6LJBFczaLFdM+opDk/LgbC2Og4fk8A4riZdW8Mn41eA7/AOGkX2a0udltcpDavbo67yrcFRuO0nJGRlRk5r6Q8W6drGp6UIPD2uf2HeiQMbr7IlzlcHK7HIHJI59q5Xwl8NBpvir/AISjxNrl14i8QohiiuZoVhjhU5HyRqSFOCR1xyeOaAPRKh+Gf/Ij6Z9H/wDRjVNUPwz/AORH0z6P/wCjGoA6eiiigCrqgzpt2PWJ/wD0E15/4P0rxQ/hLRGg1DRFhNjAUD2cpIHljGT5gzXoOp/8g27/AOuT/wAjXn+q+J5PCXwa0nUrWIT37WNpb2kLdHmdFVR16d/oKANOXTfFEKgy6r4fQE4BazlAPt/rak/sjxb/ANBLQv8AwCl/+O1zukfB/Sr+AXvj17jxDr8y5nnnndY4yeSkaqQAo6D9MdBny2Fx8JvEmjvpd5czeC9UuksJrG4kMn2GV87HjYnIQnqD+pIwAaWsaX4mHivw6sl/oplb7R5ZWzlAH7sZyPM5/Aiug/sjxb/0EtC/8Apf/jtXde/5HPwv/wBvX/osVV8XeFtU1zUIrnTvFep6LGkQjMFqqFXOSdxyOvOPwoAZ/ZHi3/oJaF/4BS//AB2j+yPFv/QS0L/wCl/+O1jf8K88Rf8ARR/EH/fuP/Cq3w/Os6Z8Ttf0DVPEF9rNtb2EFxG10FBVnY5xge1ADvDemeJm1nxWsV/oyuupoJS9nKQzfY7Y/L+84GNoxzzk+w6D+yPFv/QS0L/wCl/+O1d8J/8AIe8Z/wDYWj/9IbSqPxW8Ty+FvCcs2np5usXki2WnQqMl53OFwO+OT+GO9AC/2R4t/wCgloX/AIBS/wDx2sfxhpXihPCWttPqGiNCLGcuEs5QSPLOcHzDiqnwf1XVNJu7vwH4tm83WdNjE9rcFiRdWrHggnrtPy/Tj+E13Pjr/kSPEP8A2Drj/wBFNQBg6fpPis2FsV1HQwvlLgGylJxgf9Nasf2R4t/6CWhf+AUv/wAdrqdM/wCQbaf9ck/kK8++Ov8AyBvDP/Yw2P8A6EaANj+yPFv/AEEtC/8AAKX/AOO1z+saX4mHivw6sl/oplb7R5ZWzlAH7sZyPM5/AivUq5rXv+Rz8L/9vX/osUAUv7I8W/8AQS0L/wAApf8A47R/ZHi3/oJaF/4BS/8Ax2uyooA43+yPFv8A0EtC/wDAKX/47XP+FtL8TNe+IhDf6MGXUiJN1pKct5MXT95wMEcHNepVzXg7/kIeKf8AsLN/6IgoApf2R4t/6CWhf+AUv/x2j+yPFv8A0EtC/wDAKX/47XZUUAeW/EDTPE0fgTxI9zf6K8C6ZcmRY7OUMVETZAJkOD7kGug/sjxb/wBBLQv/AACl/wDjtXfib/yTbxZ/2Cbv/wBEvXS0Acb/AGR4t/6CWhf+AUv/AMdo/sjxb/0EtC/8Apf/AI7XZUUAeW6npfiYeNNCV7/RjMba7KEWkoUDMO7I8zryO9dB/ZHi3/oJaF/4BS//AB2rurf8j94d/wCvS9/nBXS0Acb/AGR4t/6CWhf+AUv/AMdo/sjxb/0EtC/8Apf/AI7XZUUAeW+EtL8TP/bPkX+jLjU5g++zlOW4zj94MD2roP7I8W/9BLQv/AKX/wCO1d8Ef8x//sL3H/stdLQBxv8AZHi3/oJaF/4BS/8Ax2uf8faX4mj8F6y1zf6M8ItnLhLSUMRjsTIcH8K9SrmviV/yIOvf9ej/AMqAKX9keLf+gloX/gFL/wDHaP7I8W/9BLQv/AKX/wCO12VFAHG/2R4t/wCgloX/AIBS/wDx2ufvdM8TDx5o6Nf6KZzpl8UYWcu0KJbTdkebyeV5zxz1zx6lXNah/wAlJ0L/ALBOof8Ao6yoApf2R4t/6CWhf+AUv/x2j+yPFv8A0EtC/wDAKX/47XZUUAcb/ZHi3/oJaF/4BS//AB2uf8G6Z4mez1Hyb/RlUandht9pKct5zbiP3g4z2r1Kua8B/wDHhqn/AGFr7/0e9AFL+yPFv/QS0L/wCl/+O0f2R4t/6CWhf+AUv/x2uyooA8t8faX4mj8F6y1zf6M8ItnLhLSUMRjsTIcH8K6D+yPFv/QS0L/wCl/+O1d+JX/Ig69/16P/ACrpaAON/sjxb/0EtC/8Apf/AI7R/ZHi3/oJaF/4BS//AB2uyooA8tm0vxN/wnlmhv8ARvPOmTkN9kl27fNiB48zryOc10H9keLf+gloX/gFL/8AHau3H/JSLD/sE3H/AKOgrpaAON/sjxb/ANBLQv8AwCl/+O0f2R4t/wCgloX/AIBS/wDx2uyooA8t8DaX4mfw8ht7/Rkj+03Qw9pKxz9okzz5g4znt0roP7I8W/8AQS0L/wAApf8A47V34d/8iun/AF93n/pVLXS0Acb/AGR4t/6CWhf+AUv/AMdrn/HOl+Jk8PObi/0Z4/tNqMJaSqc/aI8c+YeM47dK9SrmviJ/yK7/APX3Z/8ApVFQBS/sjxb/ANBLQv8AwCl/+O0f2R4t/wCgloX/AIBS/wDx2uyooA43+yPFv/QS0L/wCl/+O1z/APZfif8A4TvZ9v0Xz/7Mzu+xy7dvm46eZ19816lXNf8ANSf+4T/7WoApf2R4t/6CWhf+AUv/AMdo/sjxb/0EtC/8Apf/AI7XZUUAcb/ZHi3/AKCWhf8AgFL/APHasfC9ZF8C6Ws7I0gEgYoCAT5jdMk11Vc18OP+RN07/tp/6MegDpaKKKAK2p/8g27/AOuT/wAjXl/i/R7/AFb4KaDLo0Rm1LTILHUbeEDJkaJVJXHc7S3Hc8V6hqXOnXQHXyn/AJGuL8HeM/Ddr4R0S3uNasY5orGBHR5QCrCMAgjtyMUAbXg3xfpHi/Sor3R7qN2Kgy27MBLA3dXXqCDx6HqMiuE+I2rW3jTxHoXg3w9Kl7JHfRX2pzQnfHbQRHJVmHAZiQAPXg9ad4i0j4ReIr9r3Vho8l05LPJFctCzk928tl3H3PNb3hvVfh74Ysja6Be6PYwEgsIpAC56ZZurH3OaANnXv+Rz8L/9vX/osV0tedaz4x8OS+KvDs8es2TQw/aPMcSAhMxjGT2roP8AhO/C3/Qe0/8A7+igDpa800H/AJL34o/7BNr/AOhGum/4Tvwt/wBB7T/+/orKt9c8DW/iK71yHWbEajdQpbyyfachkQ5Ubc479RQBq+E/+Q94z/7C0f8A6Q2lcXoJHj34sXeuH59C8MF7GxB5WW7P+tkHqFGAP+AkVp+GvGPh2DWfFkk+s2SR3GppLCWlAEifY7Zcj23Iw+oNaGh+IvA2g6elho+p6XaWaszLFFKAAWJJPX1NAFD4veH7y4s7PxP4dX/iotBc3MAUZM8WP3kJHcFc8dew61oXfiCz8UfCbUtZ01s293pdw4BOSjeWwKn3BBH4Vof8J34W/wCg9p//AH9Fc5r/AIj8H23gnW7DRdQ0uES2lwI7e2KqGkdG6KOpJP4mgDv9M/5Btp/1yT+Qrz746/8AIG8M/wDYw2P/AKEa3dP8c+F0sbZX12wVljUEGUcHArD8b6p4U8U2emwSeJ7G2Fnfw34KuG3mMkhTkjAOetAHpNc1r3/I5+F/+3r/ANFij/hO/C3/AEHtP/7+iuf1nxj4cl8VeHZ49Zsmhh+0eY4kBCZjGMntQB6LRXNf8J34W/6D2n/9/RR/wnfhb/oPaf8A9/RQB0tc14O/5CHin/sLN/6Igo/4Tvwt/wBB7T/+/ornvC3jHw7b3viN59Yso1n1IyxlpAN6+TENw9RlSPwoA9Gormv+E78Lf9B7T/8Av6KP+E78Lf8AQe0//v6KAD4m/wDJNvFn/YJu/wD0S9dLXnPxB8Y+Hb3wF4ltbTWLKa5n0y5iijjlBZ2aJgqgepPFdD/wnfhb/oPaf/39FAHS0VzX/Cd+Fv8AoPaf/wB/RR/wnfhb/oPaf/39FABq3/I/eHf+vS9/nBXS151qXjHw7J400K4TWLJreK1u1eQSAhCxh2g+mdrflXQf8J34W/6D2n/9/RQB0tFc1/wnfhb/AKD2n/8Af0Uf8J34W/6D2n/9/RQAeCP+Y/8A9he4/wDZa6WvOvCPjHw7bf219o1myi83UppU3SgblOMMPaug/wCE78Lf9B7T/wDv6KAOlrmviV/yIOvf9ej/AMqP+E78Lf8AQe0//v6K5/x/4x8O3ngvWre01mymuJLV1SNJASxx0AoA9Formv8AhO/C3/Qe0/8A7+ij/hO/C3/Qe0//AL+igDpa5rUP+Sk6F/2CdQ/9HWVH/Cd+Fv8AoPaf/wB/RXPXvjHw6/j3RrpdYsjbR6bfRPKJRtVmltCqn3IRz/wE0AejUVzX/Cd+Fv8AoPaf/wB/RR/wnfhb/oPaf/39FAHS1zXgP/jw1T/sLX3/AKPej/hO/C3/AEHtP/7+iuf8GeMfDtrZailzrFlEz6ndyqHlA3K0zsrD2I5oA9Formv+E78Lf9B7T/8Av6KP+E78Lf8AQe0//v6KAD4lf8iDr3/Xo/8AKulrzrx/4x8O3ngvWre01mymuJLV1SNJASxx0AroP+E78Lf9B7T/APv6KAOlormv+E78Lf8AQe0//v6KP+E78Lf9B7T/APv6KAC4/wCSkWH/AGCbj/0dBXS151P4x8Onx5Z3Q1iyNummzxNL5o2hjLEQufUhSfwroP8AhO/C3/Qe0/8A7+igDpaK5r/hO/C3/Qe0/wD7+ij/AITvwt/0HtP/AO/ooAPh3/yK6f8AX3ef+lUtdLXnXgbxj4dtPDyQ3Ws2UUoubptjyAHDXEjKce4INdB/wnfhb/oPaf8A9/RQB0tc18RP+RXf/r7s/wD0qio/4Tvwt/0HtP8A+/orn/HPjHw7d+HnhtdZspZTc2rbEkBOFuI2Y49gCaAPRaK5r/hO/C3/AEHtP/7+ij/hO/C3/Qe0/wD7+igDpa5r/mpP/cJ/9rUf8J34W/6D2n/9/RXP/wDCY+Hf+E9+1f2xZfZv7N8rzfNG3d5udufXHNAHotFc1/wnfhb/AKD2n/8Af0Uf8J34W/6D2n/9/RQB0tc18OP+RN07/tp/6Mej/hO/C3/Qe0//AL+im/DZg/gnTGU5VldgfUGRiDQB09FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In digit symbol tests, subjects are provided nine digit symbol pairs (top)&nbsp;and are then asked to write the correct symbol for a series of digits (below). The test is scored based on speed and accuracy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_12_13504=[""].join("\n");
var outline_f13_12_13504=null;
var title_f13_12_13505="IL-23 and entheseal T cells in SpA pathogenesis";
var content_f13_12_13505=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F87848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F87848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 622px\">",
"   <div class=\"ttl\">",
"    Interleukin-23 and entheseal-resident T cells in the pathogenesis of spondyloarthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 602px; height: 281px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Various pathways may lead to elevated IL-23 expression, and IL-23 can activate resident T cells within the enthesis, the region in which tendons and ligaments insert into bone.",
"    <sup>",
"     [1]",
"    </sup>",
"    These activated T cells can then promote local inflammation and bone remodeling through a variety of effector mediators, including IL-17 and IL-22. The net result of these actions is the typical ankylosed appearance of the spine.",
"    <div class=\"footnotes\">",
"     IL: interleukin; HLA: human leukocyte antigen; TNF: tumor necrosis factor; UPR: unfolded protein response.",
"    </div>",
"    <div class=\"reference\">",
"     Reference:",
"     <br/>",
"     <ol>",
"      <li>",
"       Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-&gamma;t+ CD3+CD4-CD8- entheseal resident T cells. Nat Med 2012; 18:1069.",
"      </li>",
"     </ol>",
"     Reprinted by permission from: Macmillan Publishers Ltd: Nature Medicine. Lories RJ, McInnes IB. Primed for inflammation: enthesis-resident T cells. Nat Med 2012; 18:1018. Copyright &copy; 2012.",
"     <a href=\"file://www.nature.com/nm\" style=\"font-style: italic;\" target=\"_blank\">",
"      www.nature.com/nm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_12_13505=[""].join("\n");
var outline_f13_12_13505=null;
var title_f13_12_13506="Patient information: Hairy cell leukemia (The Basics)";
var content_f13_12_13506=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?12/39/12914\">",
"         Patient information: Chronic lymphocytic leukemia (CLL) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/40/24194\">",
"         Patient information: Leukemia in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/21/25939\">",
"         Patient information: Medical care during advanced illness (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/16/37121\">",
"         Patient information: What are clinical trials? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?6/10/6309\">",
"         Patient information: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Hairy cell leukemia (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/hairy-cell-leukemia-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H543324948\">",
"      <span class=\"h1\">",
"       What is hairy cell leukemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Hairy cell leukemia is a rare type of blood cancer that grows very slowly.",
"     </p>",
"     <p>",
"      Blood is made up of different types of cells. These cells are made in the middle of your bones, in a part called the bone marrow. When people have hairy cell leukemia, their bone marrow makes abnormal blood cells. These abnormal blood cells grow out of control, get into the blood, and travel around the body. Sometimes, these cells collect in certain parts of the body.",
"     </p>",
"     <p>",
"      When the bone marrow makes abnormal blood cells, it does not make enough of the normal blood cells a person&rsquo;s body needs. This can cause symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H543324963\">",
"      <span class=\"h1\">",
"       What are the symptoms of hairy cell leukemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some people with hairy cell leukemia have no symptoms, especially when it is in the early stages. People might find out they have it after they have a routine exam or blood test.",
"     </p>",
"     <p>",
"      When hairy cell leukemia causes symptoms, they can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Belly pain (because an organ called the spleen gets very big)",
"       </li>",
"       <li>",
"        Feeling very tired or weak",
"       </li>",
"       <li>",
"        Losing weight without trying to",
"       </li>",
"       <li>",
"        Bleeding or bruising more easily than normal",
"       </li>",
"       <li>",
"        Getting sick from infections more easily than normal",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      These symptoms can also be caused by conditions that are not hairy cell leukemia. But if you have these symptoms, let your doctor or nurse know.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H543324978\">",
"      <span class=\"h1\">",
"       Is there a test for hairy cell leukemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will talk with you, do an exam, and order a few different blood tests. He or she will also order a bone marrow biopsy. For this test, a doctor takes a very small sample of your bone marrow. Then another doctor looks at the cells under a microscope to see if abnormal (cancer) cells are present.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H543324993\">",
"      <span class=\"h1\">",
"       How is hairy cell leukemia treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on whether you have symptoms or not. If you do not have any symptoms, you will not need treatment right away. But your doctor will follow your condition closely by doing exams and blood tests until treatment is needed.",
"     </p>",
"     <p>",
"      When treatment is needed, doctors usually treat hairy cell leukemia with chemotherapy. Chemotherapy is the term doctors use to describe a group of medicines that kill cancer cells. Doctors can use different chemotherapy medicines to treat hairy cell leukemia. Your doctor will work with you to choose the medicine that is right for you.",
"     </p>",
"     <p>",
"      When people have chemotherapy, they can get sick from infections more easily than normal. Because of this, it&rsquo;s important to wash your hands often and stay away from people who are sick. Let your doctor or nurse know right away if you get a fever.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H543325008\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, your doctor will check you every so often to see if your cancer comes back. Follow-ups include talking with your doctor, exams, and blood tests. Sometimes, your doctor will also do a bone marrow biopsy.",
"     </p>",
"     <p>",
"      You should also watch for the symptoms listed above. Having these symptoms again could mean your cancer has come back. Tell the doctor or nurse if you have any symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H543325023\">",
"      <span class=\"h1\">",
"       What happens if the chemotherapy doesn&rsquo;t work or the leukemia comes back?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If the chemotherapy doesn&rsquo;t work or the hairy cell leukemia comes back, your doctor can try other treatments. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        More chemotherapy &ndash; You might get the same chemotherapy medicine you got before, or you might get a different kind.",
"       </li>",
"       <li>",
"        Medicines called &ldquo;immunotherapy&rdquo; &ndash; These medicines kill cancer cells by recognizing proteins on the cancer cells.",
"       </li>",
"       <li>",
"        Surgery to remove the spleen",
"       </li>",
"       <li>",
"        A type of medicine called &ldquo;interferon alpha&rdquo;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H543325038\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It&rsquo;s important to follow all of your doctor&rsquo;s instructions about visits and tests. It&rsquo;s also important to talk to your doctor about any side effects or problems you have during treatment.",
"     </p>",
"     <p>",
"      Getting treated for hairy cell leukemia involves making many choices, such as what treatment to have and when.",
"     </p>",
"     <p>",
"      Always let your doctors and nurses know how you feel about a treatment. Any time you are offered a treatment, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What are the benefits of this treatment? Is it likely to help me live longer? Will it reduce or prevent symptoms?",
"       </li>",
"       <li>",
"        What are the downsides to this treatment?",
"       </li>",
"       <li>",
"        Are there other options besides this treatment?",
"       </li>",
"       <li>",
"        What happens if I do not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H543325053\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/40/24194?source=see_link\">",
"       Patient information: Leukemia in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/39/12914?source=see_link\">",
"       Patient information: Chronic lymphocytic leukemia (CLL) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/21/25939?source=see_link\">",
"       Patient information: Medical care during advanced illness (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=see_link\">",
"       Patient information: What are clinical trials? (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/10/6309?source=see_link\">",
"       Patient information: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?13/12/13506?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83669 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-F1B7A60FFB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_12_13506=[""].join("\n");
var outline_f13_12_13506=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H543324948\">",
"      What is hairy cell leukemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H543324963\">",
"      What are the symptoms of hairy cell leukemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H543324978\">",
"      Is there a test for hairy cell leukemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H543324993\">",
"      How is hairy cell leukemia treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H543325008\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H543325023\">",
"      What happens if the chemotherapy doesn&rsquo;t work or the leukemia comes back?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H543325038\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H543325053\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/39/12914?source=related_link\">",
"      Patient information: Chronic lymphocytic leukemia (CLL) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/10/6309?source=related_link\">",
"      Patient information: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/40/24194?source=related_link\">",
"      Patient information: Leukemia in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/21/25939?source=related_link\">",
"      Patient information: Medical care during advanced illness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=related_link\">",
"      Patient information: What are clinical trials? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_12_13507="Shingles";
var content_f13_12_13507=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Shingles (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?13/12/13507/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/12/13507/contributors\" id=\"au4221\">",
"       Mary A Albrecht, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?13/12/13507/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/12/13507/contributors\" id=\"se636\">",
"       Martin S Hirsch, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?13/12/13507/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/12/13507/contributors\" id=\"de1919\">",
"       Anna R Thorner, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?13/12/13507?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      SHINGLES OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Herpes zoster (shingles) is a painful rash caused by the same virus that causes chickenpox. After an episode of chickenpox, the virus resides in cells of the nervous system. The term \"shingles\" comes from a Latin word, \"cingulum\", which means belt or girdle; the rash of herpes zoster usually appears in a band or beltlike pattern.",
"    </p>",
"    <p>",
"     Shingles can affect people of all ages. It is particularly common in adults over age 50 years. It is also more common in individuals of all ages with conditions that weaken the immune system.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      SHINGLES CAUSE",
"     </span>",
"    </p>",
"    <p>",
"     Shingles is caused by the varicella-zoster virus, the same virus that causes chickenpox. After an episode of chickenpox, the virus retreats to cells of the nervous system, where it can reside quietly for decades. However, later in life, the varicella-zoster virus can become active again. When it reactivates, it causes shingles.",
"    </p>",
"    <p>",
"     The virus belongs to a group of viruses called herpesviruses, which also includes the herpes simplex virus (HSV); HSV-1 causes cold sores and HSV-2 causes genital herpes. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/3/36916?source=see_link\">",
"      \"Patient information: Genital herpes (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      RISK OF SHINGLES",
"     </span>",
"    </p>",
"    <p>",
"     Up to 20 percent of people will develop shingles during their lifetime. The condition only occurs in people who have had chickenpox, although occasionally, chickenpox is mild enough that you may not be aware that you were infected in the past.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Age",
"     </span>",
"     &nbsp;&mdash;&nbsp;Shingles can occur in individuals of all ages, but it is much more common in adults aged 50 years and older.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Immune status",
"     </span>",
"     &nbsp;&mdash;&nbsp;Shingles can occur in healthy adults. However, some people are at a higher risk of developing shingles because of a weakened immune system. The immune system may be weakened by:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Certain cancers or other diseases that interfere with a normal immune response",
"      </li>",
"      <li>",
"       Immune-suppressing medications used to treat certain conditions (eg, rheumatoid arthritis) or to prevent rejection after organ transplantation",
"      </li>",
"      <li>",
"       Chemotherapy for cancer",
"      </li>",
"      <li>",
"       Infection with the human immunodeficiency virus (HIV), the virus that causes AIDS",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      SHINGLES SIGNS AND SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Shingles usually begins with unusual sensations, called parasthesias, such as itching, burning, or tingling in an area of skin on one side of the body. Some people develop a fever, a generalized feeling of being unwell, or a headache. Within one to two days, a rash of blisters appears on one side of the body in a bandlike pattern (",
"     <a class=\"graphic graphic_picture graphicRef50627 graphicRef66249 \" href=\"UTD.htm?30/53/31571\">",
"      picture 1A-B",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     The trunk (chest, upper, or lower back) is usually affected by the shingles rash (",
"     <a class=\"graphic graphic_figure graphicRef74926 \" href=\"UTD.htm?22/21/22868\">",
"      figure 1",
"     </a>",
"     ). The rash can also occur on the face; a rash appearing near the eye can permanently affect vision (see",
"     <a class=\"local\" href=\"#H11\">",
"      'Eye complications'",
"     </a>",
"     below).",
"    </p>",
"    <p>",
"     The pain of shingles can be mild or severe, and usually has a sharp, stabbing, or burning quality. Pain may begin several days before the rash. Pain is limited to the skin affected by the rash, but it can be severe enough to interfere with daily activities and sleep. Pain is often worse in older adults compared to younger individuals.",
"    </p>",
"    <p>",
"     Within three to four days, the shingles blisters can become open sores or \"ulcers\". These ulcers can sometimes become infected with bacteria. In individuals with a healthy immune system, the sores crust over and are no longer infectious by day 7 to 10, and the rash generally disappears within three to four weeks. Scarring and changes in skin color may persist long after shingles has resolved.",
"    </p>",
"    <p>",
"     In most individuals, shingles runs its course without any lasting health problems. However, the condition can be associated with complications.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Is shingles contagious?",
"     </span>",
"     &nbsp;&mdash;&nbsp;It is not possible to catch shingles from another person. However, some people can become infected with the varicella-zoster virus itself:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       If you have",
"       <strong>",
"        never had",
"       </strong>",
"       chickenpox or the chickenpox vaccine, you can develop chickenpox after direct (skin to skin) contact with a shingles blister or by inhaling the varicella-zoster virus in the air. You should take precautions if you are near anyone with shingles. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?2/40/2691?source=see_link\">",
"        \"Patient information: Chickenpox prevention and treatment (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       If you have had chickenpox or the chickenpox vaccine, being near a person with shingles will not cause you to develop shingles.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      SHINGLES COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     Complications of shingles can occur in anyone with the condition, but are more likely in older adults and in those with a weakened immune system. Overall, complications occur in about 12 percent of all individuals with shingles.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Pain",
"     </span>",
"     &nbsp;&mdash;&nbsp;Postherpetic neuralgia (PHN) is the most common complication of shingles. It causes mild to severe pain or unpleasant sensations and is often described as \"burning\". PHN affects 10 to 15 percent of patients, with about half of these cases in individuals older than 60 years.",
"    </p>",
"    <p>",
"     In most patients, the pain of postherpetic neuralgia gradually improves over time. Some patients continue to experience pain for months to years after the rash resolves. This pain can be so severe that it causes difficulty sleeping, weight loss, depression, and interferes with normal daily activities. Several treatments are available to both prevent and treat PHN. (See",
"     <a class=\"local\" href=\"#H19\">",
"      'Treatment of postherpetic neuralgia'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Skin infection",
"     </span>",
"     &nbsp;&mdash;&nbsp;The sores of shingles can become infected with bacteria, and this can delay healing. This complication occurs in about 2 percent of individuals. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/55/15217?source=see_link\">",
"      \"Patient information: Skin and soft tissue infection (cellulitis) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Eye complications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Eye complications occur in about 2 percent of individuals. Eye complications are much more likely to occur when the shingles rash occurs around the eye. These complications are serious and can lead to vision loss.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Eye inflammation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Eye inflammation (called herpes zoster ophthalmicus) typically begins with fever, headache, decreased vision, a droopy eyelid, and a generalized feeling of being unwell. These symptoms are accompanied by pain or extreme sensitivity of the eye, forehead, and top of the head.",
"    </p>",
"    <p>",
"     Early diagnosis and treatment are important in preventing worsening eye inflammation and vision loss. People who have zoster lesions near an eye should be evaluated immediately by an eye specialist. Treatment usually includes oral acyclovir, valacyclovir, or famciclovir plus steroid eye drops to reduce inflammation.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Retinal inflammation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Herpes zoster of the eye can cause inflammation and damage of the retina (called acute retinal necrosis). The retina is in the back of the eye, and is the part of the eye that senses light and enables vision. Retinal inflammation can progress rapidly in individuals with HIV infection.",
"    </p>",
"    <p>",
"     Retinal inflammation usually begins with blurry vision and pain in one eye. In up to 50 percent of individuals, it later affects the other eye. It is treated with intravenous acyclovir, which improves symptoms within 48 to 72 hours.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Ear inflammation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Herpes zoster can cause inflammation of the ear (called herpes zoster oticus or Ramsay Hunt syndrome). Symptoms include weakness of the facial muscles on the affected side. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2378?source=see_link\">",
"      \"Clinical manifestations of varicella-zoster virus infection: Herpes zoster\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Complications due to immune suppression",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with a weakened immune system, including people infected with HIV and transplant recipients, are at substantial risk for severe varicella zoster virus related complications.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      SHINGLES TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Treatment of shingles usually includes a combination of antiviral and pain-relieving medications. The affected areas should be kept clean and dry. Creams or gels might increase the likelihood of a secondary bacterial skin infection and are not recommended.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Antiviral medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Antiviral medications stop the varicella zoster virus from multiplying, speed healing of skin lesions, and reduce the severity and duration of pain.",
"    </p>",
"    <p>",
"     Antiviral treatment is recommended for EVERYONE with shingles, and is most effective when started within 72 hours after the shingles rash appears. After this time, antiviral medications may still be helpful if new blisters are appearing.",
"    </p>",
"    <p>",
"     Three antiviral drugs are used to treat shingles: acyclovir (Zovirax&reg;), famciclovir (Famvir&reg;), and valacyclovir (Valtrex&reg;). Acyclovir is the least expensive treatment but it must be taken more frequently than the other drugs.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Pain medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;The pain of shingles and postherpetic neuralgia can be severe, and prescription medications are frequently needed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Treatment of postherpetic neuralgia",
"     </span>",
"     &nbsp;&mdash;&nbsp;Treatment is available to reduce pain and maintain quality of life in people with postherpetic neuralgia. Treatment generally begins with a low-dose tricyclic antidepressant, and may also include narcotic medications and an anti-seizure medication.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h3\">",
"      Tricyclic antidepressants",
"     </span>",
"     &nbsp;&mdash;&nbsp;Tricyclic antidepressants (TCAs) are commonly used to treat the pain of postherpetic neuralgia. The dose of TCAs is typically much lower than that used for treating depression. It is believed that these drugs reduce pain when used in low doses, but it is not clear how the drug works.",
"    </p>",
"    <p>",
"     TCAs used to treat pain include amitriptyline, desipramine, and nortriptyline. It is common to feel tired when starting a tricyclic antidepressant; this is not always an undesirable side effect since it can help improve sleep when TCAs are taken in the evening. TCAs are generally started in low doses and increased gradually. The pain-relief benefit may not be seen for three or more weeks. Tricyclic antidepressants may not be recommended for older adults with heart problems.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h3\">",
"      Oral pain medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Prescription pain medications may be recommended if tricyclic antidepressants do not provide enough pain relief.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h3\">",
"      Anti-seizure medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Medications that are traditionally used to prevent seizures, called anticonvulsants, can sometimes reduce the pain of postherpetic neuralgia. They may be used instead of or in addition to TCAs. Anticonvulsants commonly used for postherpetic neuralgia include gabapentin (Neurontin&reg;) and pregabalin (Lyrica&reg;).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h3\">",
"      Capsaicin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Capsaicin is a substance derived from chili peppers that can help to treat pain. Capsaicin cream (Zostrix&reg;) may be recommended to treat postherpetic neuralgia. However, the side effects of the cream (including burning, stinging, and skin redness) are intolerable for up to one-third of patients.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h3\">",
"      Topical anesthetics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Lidocaine (Xylocaine) gel is a medicine that you can rub into your skin. A lidocaine patch (Lidoderm&reg;) is also available, which you wear on your skin for 12 hours per day. It delivers a small amount of lidocaine to the most painful or itchy areas. However, the benefit of lidocaine is likely to be moderate at best.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25\">",
"     <span class=\"h3\">",
"      Steroid injections",
"     </span>",
"     &nbsp;&mdash;&nbsp;For people with postherpetic neuralgia who have severe pain despite using the above measures, an injection of steroids directly into the space around the spinal cord may be considered. Steroid injections are not used to treat facial pain.",
"    </p>",
"    <p>",
"     In one study of patients with postherpetic neuralgia for at least one year, steroid injections led to good or excellent pain relief in about 90 percent of individuals [",
"     <a class=\"abstract\" href=\"UTD.htm?13/12/13507/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H26\">",
"     <span class=\"h1\">",
"      RETURN TO WORK",
"     </span>",
"    </p>",
"    <p>",
"     If you have shingles, you may wonder when it is safe to return to work. The answer depends upon where you work and where your blisters are located.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       If the blisters are on your face, do not return to work until the area has crusted over, which generally takes seven to 10 days.",
"      </li>",
"      <li>",
"       If the blisters are in an area that you can cover (eg, with a gauze bandage or clothing), you may return to work when you feel well.",
"      </li>",
"      <li>",
"       If you work in a healthcare facility (hospital, medical office, nursing home), consult your healthcare provider about when it is safe to return to work.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H27\">",
"     <span class=\"h1\">",
"      PREVENTION OF SHINGLES",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H28\">",
"     <span class=\"h2\">",
"      Vaccination",
"     </span>",
"     &nbsp;&mdash;&nbsp;A vaccine is now available to reduce the chance of developing shingles. If you do develop shingles after receiving the vaccine, your infection may be less severe and you are less likely to develop postherpetic neuralgia [",
"     <a class=\"abstract\" href=\"UTD.htm?13/12/13507/abstract/2\">",
"      2",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     The vaccine is recommended for most adults over 60 years. You should get the vaccine even if you are not sure if you had chicken pox or shingles previously. The vaccine is not recommended for people with a weakened immune system, pregnant women, or those with a history of a severe allergic reaction to gelatin or neomycin.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H29\">",
"     <span class=\"h2\">",
"      Natural boost of immunity",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you have had chickenpox previously, you have developed immunity to the virus that causes shingles. However, this immunity declines over time. But, if you are later exposed to a child or adult with chickenpox, your immunity to the virus is \"boosted\". This boost may help to reduce your risk of developing shingles.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H30\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H301\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27351429\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/57/27538?source=see_link\">",
"      Patient information: Chickenpox (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/0/14338?source=see_link\">",
"      Patient information: Shingles (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/42/8867?source=see_link\">",
"      Patient information: Neuropathic pain (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27351444\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/3/36916?source=see_link\">",
"      Patient information: Genital herpes (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/40/2691?source=see_link\">",
"      Patient information: Chickenpox prevention and treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/55/15217?source=see_link\">",
"      Patient information: Skin and soft tissue infection (cellulitis) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H32\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2378?source=see_link\">",
"      Clinical manifestations of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/4/77?source=see_link\">",
"      Diagnosis of varicella-zoster virus infection",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23688?source=see_link\">",
"      Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21608?source=see_link\">",
"      Postherpetic neuralgia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36200?source=see_link\">",
"      Prevention of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33096?source=see_link\">",
"      Treatment of herpes zoster in the immunocompetent host",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33225?source=see_link\">",
"      Varicella-zoster virus infection in pregnancy",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/shingles.html\">",
"      www.nlm.nih.gov/medlineplus/shingles.html",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Centers for Disease Control and Prevention (CDC)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; Phone: (800) 311-3435",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/vaccines/vpd-vac/shingles/dis-faqs.htm\">",
"      www.cdc.gov/vaccines/vpd-vac/shingles/dis-faqs.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Neurological Disorders and Stroke",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.ninds.nih.gov/disorders/shingles/detail_shingles.htm\">",
"      www.ninds.nih.gov/disorders/shingles/detail_shingles.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?13/12/13507/abstract/1-6\">",
"      1-6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 30, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?13/12/13507?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13507/abstract/1\">",
"      Kotani N, Kushikata T, Hashimoto H, et al. Intrathecal methylprednisolone for intractable postherpetic neuralgia. N Engl J Med 2000; 343:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13507/abstract/2\">",
"      Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13507/abstract/3\">",
"      Bowsher D. The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage 1997; 13:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13507/abstract/4\">",
"      Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007; 44 Suppl 1:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13507/abstract/5\">",
"      Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med 2002; 347:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13507/abstract/6\">",
"      Johnson RW, Whitton TL. Management of herpes zoster (shingles) and postherpetic neuralgia. Expert Opin Pharmacother 2004; 5:551.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f13_12_13507=[""].join("\n");
var outline_f13_12_13507=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           SHINGLES OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           SHINGLES CAUSE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           RISK OF SHINGLES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           SHINGLES SIGNS AND SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           SHINGLES COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           SHINGLES TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H26\">",
"           RETURN TO WORK",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H27\">",
"           PREVENTION OF SHINGLES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H30\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/21/22868\" title=\"figure 1\">",
"           Thoracic dermatomes PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/58/12192\" title=\"picture 1A\">",
"           Herpes zoster rash 1 PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/49/10015\" title=\"picture 1B\">",
"           Herpes zoster rash 2 PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f13_12_13508="Hepatic adenoma Light";
var content_f13_12_13508=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51149&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51149&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hepatic adenoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hematoxylin and eosin slide of an hepatic adenoma. Adenoma cells resemble normal hepatocytes but have small regular nuclei and some fat vacuoles and are arranged in thickened trabeculae. There is a characteristic absence of portal tracts.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Sanjiv Chopra, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_12_13508=[""].join("\n");
var outline_f13_12_13508=null;
var title_f13_12_13509="Manometry PSS DM";
var content_f13_12_13509=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Manometry of the stomach and small intestine differentiates neuropathic and myopathic disorders",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Postprandial gastrointestinal motility in a patient with systemic sclerosis (myopathic disorder, left panel) is characterized by low amplitude contractions at all levels compared with controls. By comparison, a neuropathic disorder such as diabetes mellitus (right panel) is characterized by normal contraction amplitude, but abnormal organization of the contractile response. Specifically, there is a lack of distal antral contractions, pyloric tonic, and phasic pressure activity, and persistence of migrating motor complex-like activity postprandially (proximal jejunum rows 2 and 3) despite the ingestion of a solid-liquid meal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Camilleri M. Pract Gastroenterol 1991; 15:10.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_12_13509=[""].join("\n");
var outline_f13_12_13509=null;
var title_f13_12_13510="Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD)";
var content_f13_12_13510=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Patient information: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) (Beyond the Basics)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/12/13510/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/12/13510/contributors\">",
"     Robert F Casper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/12/13510/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/12/13510/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/12/13510/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/12/13510/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/12/13510/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/12/13510/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     PMS AND PMDD OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premenstrual syndrome (PMS) refers to a group of physical and behavioral symptoms that occur in a cyclic pattern during the second half of the menstrual cycle. Premenstrual dysphoric disorder (PMDD) is the severe form of PMS. Common symptoms include anger, irritability, and internal tension that are severe enough to interfere with daily activities.",
"   </p>",
"   <p>",
"    Mild PMS is common, affecting up to 75 percent of women with regular menstrual cycles; PMDD affects only 3 to 8 percent of women. This condition can affect women of any socioeconomic, cultural, or ethnic background.",
"   </p>",
"   <p>",
"    PMDD is usually a chronic condition and can have a serious impact on a woman's quality of life. Fortunately, a variety of treatments and self-care measures can effectively control the symptoms in most women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PMS AND PMDD CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tissues throughout the body are sensitive to hormone levels that change throughout a woman's menstrual cycle (",
"    <a class=\"graphic graphic_figure graphicRef79496 \" href=\"UTD.htm?13/13/13530\">",
"     figure 1",
"    </a>",
"    ). Studies suggest that rising and falling levels of hormones (eg, estrogen and progesterone) may also influence chemicals in the brain, including a substance called serotonin, which affects mood.",
"   </p>",
"   <p>",
"    However, it is not clear why some women develop PMS or PMDD and others do not. Levels of estrogen and progesterone are similar in women with and without these conditions. The most likely explanation, based upon several studies, is that women who develop PMDD are highly sensitive to changes in hormone levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PMS AND PMDD SYMPTOMS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Common symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common symptoms of PMS and PMDD are fatigue, bloating, irritability, and anxiety. Other symptoms include the following (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39751?source=see_link\">",
"     \"Clinical manifestations and diagnosis of premenstrual syndrome and premenstrual dysphoric disorder\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sadness, hopelessness, or feelings of worthlessness",
"     </li>",
"     <li>",
"      Tension, anxiety, or \"edginess\"",
"     </li>",
"     <li>",
"      Variable moods with frequent tearfulness",
"     </li>",
"     <li>",
"      Persistent irritability, anger, and conflict with family, coworkers, or friends",
"     </li>",
"     <li>",
"      Decreased interest in usual activities",
"     </li>",
"     <li>",
"      Difficulty concentrating",
"     </li>",
"     <li>",
"      Fatigue, lethargy, or lack of energy",
"     </li>",
"     <li>",
"      Changes in appetite, which may include binge eating or craving certain foods",
"     </li>",
"     <li>",
"      Excessive sleeping or difficulty sleeping",
"     </li>",
"     <li>",
"      Feelings of being overwhelmed or out of control",
"     </li>",
"     <li>",
"      Breast tenderness or swelling, headaches, joint or muscle pain, weight gain",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Disorders that mimic PMS and PMDD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other conditions have symptoms that are similar to those of PMS and PMDD, including depression, anxiety disorders, and perimenopause (the four- to five-year period before menopause). It is important to distinguish between underlying depression (which often worsens before menses) and true PMS or PMDD because the treatments are quite different.",
"   </p>",
"   <p>",
"    Women with underlying depression often feel better during or after menses, but their symptoms do NOT resolve completely. On the other hand, women with PMS or PMDD have a complete resolution of symptoms when their menses begin. Some women who think they have PMS or PMDD actually have depression or an anxiety disorder. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=see_link\">",
"     \"Patient information: Depression in adults (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are other medical disorders that worsen before or during menstruation, such as migraines, chronic fatigue syndrome, pelvic and bladder pain, or irritable bowel syndrome. A careful medical history should be able to distinguish among these disorders. It is also possible for a woman to have PMDD in addition to another medical condition. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?15/51/16179?source=see_link\">",
"     \"Patient information: Headache causes and diagnosis in adults (Beyond the Basics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?3/53/3926?source=see_link\">",
"     \"Patient information: Irritable bowel syndrome (Beyond the Basics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?30/48/31490?source=see_link\">",
"     \"Patient information: Diagnosis of interstitial cystitis/bladder pain syndrome (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PMS AND PMDD DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no single test that can diagnose PMS or PMDD. The symptoms must occur only during the second half (luteal phase) of the menstrual cycle, most often during the five to seven days before the menstrual period, and there must be physical as well as behavioral symptoms. In women with PMS or PMDD, these symptoms should not be present between days 4 through 12 of a 28-day menstrual cycle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Blood tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood tests are not necessary to diagnose PMS or PMDD. A blood count may be recommended to screen for other medical conditions that cause fatigue, such as anemia. Thyroid function tests can detect hypothyroidism (an underactive thyroid gland) or hyperthyroidism (an overactive thyroid gland), both of which have similar signs and symptoms to PMS and PMDD. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15203?source=see_link\">",
"     \"Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=see_link\">",
"     \"Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Recording symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a woman's symptoms may suggest PMDD, a clinician may request that she carefully record her symptoms on a daily basis for two full menstrual cycles (",
"    <a class=\"graphic graphic_table graphicRef86743 \" href=\"UTD.htm?31/14/31978\">",
"     table 1",
"    </a>",
"    ). Using this calendar, a woman can rate the severity of 10 physical symptoms and 12 behavioral symptoms on a four-point scale.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PMS AND PMDD TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Conservative treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conservative treatments for PMS may be recommended first, including regular exercise, relaxation techniques, and vitamin and mineral supplementation. These therapies relieve symptoms in some women and have few or no side effects. If these therapies do not bring sufficient relief, prescription medication can be considered as a second option.",
"   </p>",
"   <p>",
"    Conservative treatments are also recommended for women with PMDD, along with a prescription medication.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exercise &mdash; Exercise can help to reduce stress, tension, anxiety, and depression. (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/42/7844?source=see_link\">",
"       \"Patient information: Exercise (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Relaxation&nbsp;therapy &mdash; PMS and PMDD can be worsened by stress, anxiety, depression, and other psychological conditions. Furthermore, living with PMS or PMDD can cause difficulties in interpersonal relationships, at work or school, and with general day-to-day living. Relaxation therapy can help to ease the stress and anxiety of daily life and may include techniques such as meditation, progressive muscle relaxation, self-hypnosis, or biofeedback.",
"     </li>",
"     <li>",
"      Vitamin and mineral supplements &mdash; Vitamin B6 (up to 100",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      might have a small benefit for women with mild PMS. No more than 100 mg of vitamin B6 should be taken per day. The most effective medications are described in the next section.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Selective serotonin reuptake inhibitors (SSRIs)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective serotonin reuptake inhibitors (SSRIs) are a highly effective treatment for the symptoms of PMS and PMDD. The SSRIs include",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?29/58/30630?source=see_link\">",
"     fluoxetine",
"    </a>",
"    (Prozac&reg; and Sarafem&reg;),",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?22/43/23222?source=see_link\">",
"     sertraline",
"    </a>",
"    (Zoloft&reg;),",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?11/49/12054?source=see_link\">",
"     citalopram",
"    </a>",
"    (Celexa&reg;), and",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?17/12/17606?source=see_link\">",
"     paroxetine",
"    </a>",
"    (Paxil&reg;). Studies showed that SSRIs reduced the symptoms of PMDD significantly compared with placebo; between 60 and 75 percent of women with PMDD improve with an SSRI. It may not be necessary to take the medication every day. Taking the SSRI only during the second half of the menstrual cycle may be sufficient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3241?source=see_link\">",
"     \"Treatment of premenstrual syndrome and premenstrual dysphoric disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some women have sexual side effects with SSRIs. The most common sexual side effect is difficulty having an orgasm. If this occurs, using a lower dose or trying an alternative drug in the same drug class is recommended.",
"   </p>",
"   <p>",
"    SSRIs should be taken for at least two menstrual cycles to measure their benefit. About 15 percent of women do not experience relief with these drugs after two cycles, in which case an alternative treatment is recommended.",
"   </p>",
"   <p>",
"    Other antidepressants that are effective are",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?19/43/20150?source=see_link\">",
"     venlafaxine",
"    </a>",
"    (Effexor&reg;) and",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?43/1/44053?source=see_link\">",
"     escitalopram",
"    </a>",
"    (Lexapro&reg;).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H232259005\">",
"    <span class=\"h2\">",
"     Birth control pills",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some women with PMS or PMDD get relief from their symptoms when they take a birth control pill.",
"   </p>",
"   <p>",
"    The pill can be taken continuously to avoid having a menstrual period. To do this, the woman takes all of the active pills in a pack and then opens a new pack; the placebo pills are discarded. In theory, taking the pill continuously prevents the usual cyclical hormone changes that could affect mood.",
"   </p>",
"   <p>",
"    In the United States, one birth control pill (Yaz&reg;) is approved for the treatment of PMDD. Yaz&reg; contains 24 tablets of 20 mcg ethinyl estradiol and 3 mg drospirenone. It is thought that mood symptoms are improved with a shorter pill-free interval (number of placebo days). Yaz has only four days, instead of the typical seven days. However, there are some concerns that women who start Yaz might be at higher risk for blood clots in the legs and lungs (but the absolute risk of having a blood clot is very, very low).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Gonadotropin-releasing hormone agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gonadotropin-releasing hormone (GnRH) agonists (eg,",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?0/48/774?source=see_link\">",
"     leuprolide",
"    </a>",
"    acetate or Lupron&reg;) are a type of medication that causes the ovaries to temporarily stop making estrogen and progesterone. This causes a temporary menopause and improves the physical symptoms (eg, bloating) and irritability caused by PMS and PMDD. However, the medication results in extremely low estrogen levels, which causes severe hot flashes and bone loss over time. Therefore, in addition to the GnRH medicine, women are treated with low doses of estrogen and progesterone to treat the hot flashes, and to prevent bone loss. Although this treatment is very effective, it is complicated and expensive, and is only used if other treatments do not work.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Ineffective treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several treatments are of no proven benefit in relieving the symptoms of PMS. These treatments include progesterone, other antidepressant drugs (tricyclic antidepressants and monoamine oxidase inhibitors), and",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?27/29/28117?source=see_link\">",
"     lithium",
"    </a>",
"    . There is also no proven benefit of several popular dietary supplements, including evening primrose oil, essential free fatty acids, and ginkgo biloba.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Premenstrual syndrome (PMS) causes symptoms one to two weeks before a woman's menstrual period. Common symptoms include fatigue, bloating, irritability, and anxiety.",
"     </li>",
"     <li>",
"      Premenstrual dysphoric disorder (PMDD) is the severe form of PMS. PMDD can cause a woman to feel very sad or nervous, to have trouble with friends or family (eg, disagreements with husband or children), and can cause difficulty paying attention to work or school (see",
"      <a class=\"local\" href=\"#H3\">",
"       'PMS and PMDD symptoms'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      The cause of PMS and PMDD is not known. Some women may be very sensitive to changes in hormone levels. Hormone levels normally change before and during the menstrual period (see",
"      <a class=\"local\" href=\"#H2\">",
"       'PMS and PMDD causes'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Other problems, such as depression and anxiety disorder, are similar to PMS and PMDD. The main difference is that the symptoms of PMS and PMDD occur only in the days preceding a woman's period. Depression and anxiety are usually noticeable all the time. The treatments of PMDD and depression are quite different.",
"     </li>",
"     <li>",
"      There is no test for PMS or PMDD. To be diagnosed with PMS or PMDD, a woman must have physical symptoms (eg, breast tenderness, muscle pain) and mood changes (eg, sadness, crying). These symptoms must occur before her menstrual period (not during or after). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'PMS and PMDD diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some women are asked to keep a record of their feelings every day for two full menstrual cycles before PMS or PMDD is diagnosed (",
"      <a class=\"graphic graphic_table graphicRef86743 \" href=\"UTD.htm?31/14/31978\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A medication is usually the best treatment for women with PMDD (see",
"      <a class=\"local\" href=\"#H9\">",
"       'PMS and PMDD treatment'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      The best medications for PMS or PMDD are the SSRIs (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Selective serotonin reuptake inhibitors (SSRIs)'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     WHERE TO GET MORE INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"   </p>",
"   <p>",
"    This article will be updated as needed on our web site (",
"    <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"     www.uptodate.com/patients",
"    </a>",
"    ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181\">",
"    <span class=\"h2\">",
"     Patient level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15454083\">",
"    <span class=\"h3\">",
"     The Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?41/10/42146?source=see_link\">",
"     Patient information: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?11/57/12179?source=see_link\">",
"     Patient information: Depression (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?20/42/21155?source=see_link\">",
"     Patient information: Swelling (The Basics)",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15454091\">",
"    <span class=\"h3\">",
"     Beyond the Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=see_link\">",
"     Patient information: Depression in adults (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=see_link\">",
"     Patient information: Depression treatment options for adults (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?15/51/16179?source=see_link\">",
"     Patient information: Headache causes and diagnosis in adults (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?3/53/3926?source=see_link\">",
"     Patient information: Irritable bowel syndrome (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?30/48/31490?source=see_link\">",
"     Patient information: Diagnosis of interstitial cystitis/bladder pain syndrome (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15203?source=see_link\">",
"     Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=see_link\">",
"     Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?7/42/7844?source=see_link\">",
"     Patient information: Exercise (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?24/49/25366?source=see_link\">",
"     Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"    </a>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Professional level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39751?source=see_link\">",
"     Clinical manifestations and diagnosis of premenstrual syndrome and premenstrual dysphoric disorder",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28935?source=see_link\">",
"     Epidemiology and pathogenesis of premenstrual syndrome and premenstrual dysphoric disorder",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3241?source=see_link\">",
"     Treatment of premenstrual syndrome and premenstrual dysphoric disorder",
"    </a>",
"    <br/>",
"    <br/>",
"    The following organizations also provide reliable health information:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hormone Health Network",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.hormone.org/\">",
"     www.hormone.org",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Institutes of Health",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"     www.nlm.nih.gov/medlineplus/healthtopics.html",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Mayo Clinic",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.mayoclinic.com/\">",
"     www.mayoclinic.com",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13510/abstract/1-9\">",
"     1-9",
"    </a>",
"    ]",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13510/abstract/1\">",
"      Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ 2001; 322:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13510/abstract/2\">",
"      Thys-Jacobs S, Starkey P, Bernstein D, Tian J. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group. Am J Obstet Gynecol 1998; 179:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13510/abstract/3\">",
"      Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005; 72:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13510/abstract/4\">",
"      Fontana AM, Palfai TG. Psychosocial factors in premenstrual dysphoria: stressors, appraisal, and coping processes. J Psychosom Res 1994; 38:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13510/abstract/5\">",
"      Ling FW. Recognizing and treating premenstrual dysphoric disorder in the obstetric, gynecologic, and primary care practices. J Clin Psychiatry 2000; 61 Suppl 12:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13510/abstract/6\">",
"      Bailey JW, Cohen LS. Prevalence of mood and anxiety disorders in women who seek treatment for premenstrual syndrome. J Womens Health Gend Based Med 1999; 8:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13510/abstract/7\">",
"      Wyatt KM, Dimmock PW, O'Brien PM. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev 2002; :CD001396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13510/abstract/8\">",
"      Bedaiwy MA, Casper RF. Treatment with leuprolide acetate and hormonal add-back for up to 10 years in stage IV endometriosis patients with chronic pelvic pain. Fertil Steril 2006; 86:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13510/abstract/9\">",
"      Mitwally MF, Gotlieb L, Casper RF. Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome. Menopause 2002; 9:236.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2159 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-125.39.66.150-851E2265C2-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_12_13510=[""].join("\n");
var outline_f13_12_13510=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      PMS AND PMDD OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PMS AND PMDD CAUSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PMS AND PMDD SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Common symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Disorders that mimic PMS and PMDD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PMS AND PMDD DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Blood tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Recording symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PMS AND PMDD TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Conservative treatments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Selective serotonin reuptake inhibitors (SSRIs)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H232259005\">",
"      Birth control pills",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Gonadotropin-releasing hormone agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Ineffective treatments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      WHERE TO GET MORE INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H181\">",
"      Patient level information",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15454083\">",
"      - The Basics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15454091\">",
"      - Beyond the Basics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Professional level information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/2159\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PI/2159|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/13/13530\" title=\"figure 1\">",
"      Menstrual cycle PI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PI/2159|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/14/31978\" title=\"table 1\">",
"      DRSP form",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39751?source=related_link\">",
"      Clinical manifestations and diagnosis of premenstrual syndrome and premenstrual dysphoric disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28935?source=related_link\">",
"      Epidemiology and pathogenesis of premenstrual syndrome and premenstrual dysphoric disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/57/12179?source=related_link\">",
"      Patient information: Depression (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=related_link\">",
"      Patient information: Depression in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/24/21894?source=related_link\">",
"      Patient information: Depression treatment options for adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/48/31490?source=related_link\">",
"      Patient information: Diagnosis of interstitial cystitis/bladder pain syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/42/7844?source=related_link\">",
"      Patient information: Exercise (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/51/16179?source=related_link\">",
"      Patient information: Headache causes and diagnosis in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15203?source=related_link\">",
"      Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/53/3926?source=related_link\">",
"      Patient information: Irritable bowel syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/49/25366?source=related_link\">",
"      Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/10/42146?source=related_link\">",
"      Patient information: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/42/21155?source=related_link\">",
"      Patient information: Swelling (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/10/3241?source=related_link\">",
"      Treatment of premenstrual syndrome and premenstrual dysphoric disorder",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_12_13511="Intravascular large cell lymphoma";
var content_f13_12_13511=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intravascular large cell lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/12/13511/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/12/13511/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/12/13511/contributors\">",
"     Jon C Aster, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/12/13511/contributors\">",
"     Almut B&ouml;er-Auer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/12/13511/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/12/13511/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/12/13511/contributors\">",
"     John A Zic, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/12/13511/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/12/13511/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/12/13511/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravascular large cell lymphoma (ILCL) is a rare subtype of large cell lymphoma that is characterized by the proliferation of lymphoma cells within the lumina of small blood vessels, particularly capillaries and post-capillary venules, without an obvious extravascular tumor mass or detectable circulating lymphoma cells in the peripheral blood.",
"   </p>",
"   <p>",
"    This type of lymphoma has also been described as intravascular lymphomatosis, angiotropic large cell lymphoma, and malignant angioendotheliomatosis. The clinical presentation is varied and often includes symptoms related to organ dysfunction caused by occlusion of blood vessels. Particularly in the past, the diagnosis was usually only recognized at autopsy. In recent years, the heightened awareness of ILCL with appropriate investigations has resulted in more patients being diagnosed during life, thereby allowing for treatment.",
"   </p>",
"   <p>",
"    Most information on ILCL comes from case reports and small case series of patients. In addition, an expert panel of pathologists and clinicians, convened under the sponsorship of the International Extranodal Lymphoma Study Group, has proposed practical guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13511/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical presentation, diagnosis, and treatment of intravascular large cell lymphoma will be discussed here. Other types of large cell lymphoma are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=see_link\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;ILCL is a rare subtype of large cell lymphoma; the true incidence is unknown. Median age at diagnosis is in the sixth to seventh decades; there is no sex predilection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13511/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients can present with a bewildering variety of symptoms caused by the occlusion of small vessels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Constitutional B symptoms (ie, fever, night sweats, and weight loss) are seen in the majority of patients (55 to 85 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13511/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. The clinical presentation appears to differ by country of origin, although individual presentations vary tremendously and virtually any organ can be involved:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In Western countries, patients most commonly present with symptoms related to involvement of the central nervous system (39 percent) and skin (39 percent). Fever, skin lesions, and prominent, rapidly progressive neurologic signs (eg, dementia, progressive cerebral vascular accident, peripheral neuropathy) are frequent [",
"      <a class=\"abstract\" href=\"UTD.htm?13/12/13511/abstract/2,5,6\">",
"       2,5,6",
"      </a>",
"      ]. Less commonly involved tissues include the bone marrow (32 percent), spleen (26 percent), and liver (26 percent).",
"     </li>",
"     <li>",
"      In Asia, neurological symptoms (27 percent) and cutaneous lesions (15 percent) are less common than in Western countries [",
"      <a class=\"abstract\" href=\"UTD.htm?13/12/13511/abstract/7\">",
"       7",
"      </a>",
"      ]. Patients frequently present with involvement of the bone marrow (75 percent), spleen (67 percent), and liver (55 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/12/13511/abstract/3,8-10\">",
"       3,8-10",
"      </a>",
"      ]. Hemophagocytic syndrome, an aggressive proliferation of normal histiocytes and T-lymphocytes resulting in the hemophagocytosis of red cells, white blood cells, or platelets, can be seen [",
"      <a class=\"abstract\" href=\"UTD.htm?13/12/13511/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=see_link\">",
"       \"Hemophagocytic lymphohistiocytosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is a cutaneous variant of ILCL that presents with symptoms limited to the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13511/abstract/2\">",
"     2",
"    </a>",
"    ]. This variant is seen more frequently in Western Countries (24 percent) and is rare in Asia (3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13511/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients are mostly younger females with good performance status [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13511/abstract/2\">",
"     2",
"    </a>",
"    ]. Skin lesions are most commonly nodules, plaques, or macules of red to livid (grayish-blue) color on the leg (35 percent), thigh (41 percent), and trunk (31 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13511/abstract/11\">",
"     11",
"    </a>",
"    ]. Telangiectases, edema, and pain are often accompanying, making it difficult to differentiate cutaneous ILCL from inflammatory skin diseases such as thrombophlebitis or erythema nodosum. To date, no criteria enable clinical distinction between skin lesions of ILCL restricted to the skin and skin lesions concurrent with ILCL in other organs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;While not specific for ILCL, patients often present with the following laboratory abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13511/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased serum levels of lactate dehydrogenase (LDH) and beta 2-microglobulin &mdash; 80 to 90 percent",
"     </li>",
"     <li>",
"      Anemia &mdash; 65 percent",
"     </li>",
"     <li>",
"      Elevated sedimentation rate &mdash; 43 percent",
"     </li>",
"     <li>",
"      Altered hepatic, renal, or thyroid function &mdash; 15 to 20 percent",
"     </li>",
"     <li>",
"      Presence of a serum monoclonal protein &mdash; 14 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, patients from Western countries and Asian countries differ in their rates of thrombocytopenia (29 versus 76 percent) and hypoalbuminemia (18 versus 84 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involved tissues demonstrate neoplastic lymphoid cells lodged in the capillaries and post-capillary venules (",
"    <a class=\"graphic graphic_picture graphicRef62103 \" href=\"UTD.htm?4/41/4757\">",
"     picture 1",
"    </a>",
"    ). Malignant cells are rarely found in cerebrospinal fluid or peripheral blood; bone marrow involvement varies with geographic location [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13511/abstract/12\">",
"     12",
"    </a>",
"    ]. Like large cell lymphomas elsewhere, the morphology varies; most often the lymphoid cells are large in size, have vesicular, nuclei and prominent nucleoli (",
"    <a class=\"graphic graphic_picture graphicRef81094 \" href=\"UTD.htm?33/11/33973\">",
"     picture 2",
"    </a>",
"    ). Frequent mitotic figures are seen. Ki-67 demonstrates a high proliferative activity. The immunophenotype usually identifies the cells as being mature B cells (ILBL); such cases can be considered an intravascular variant of diffuse large B-cell lymphoma. Rare cases of ILCL are of T cell or NK cell origin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13511/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. A subset of the cases associated with hemophagocytic syndrome is positive for Epstein Barr virus (EBV) infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\", section on 'Pathology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the skin, intravascular neoplastic lymphoid cells may be accompanied by reactive perivascular infiltrates of small lymphocytes and plasma cells (",
"    <a class=\"graphic graphic_picture graphicRef81381 \" href=\"UTD.htm?19/21/19799\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13511/abstract/11\">",
"     11",
"    </a>",
"    ]. Vessels housing lymphoma cells may be very few and can be found at any level of the skin and subcutaneous tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of intravascular large cell lymphoma (ILCL) is made by demonstrating large lymphoma cells within small to medium blood vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13511/abstract/1\">",
"     1",
"    </a>",
"    ]. If the diagnosis is considered, biopsies of lesional skin or random biopsies of \"normal\" skin without any obvious abnormality may be diagnostic [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13511/abstract/15-21\">",
"     15-21",
"    </a>",
"    ]. It is essential to perform deep skin biopsies including the subcutis because vessels involved in ILCL may be located mainly in the subcutaneous fat [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13511/abstract/11\">",
"     11",
"    </a>",
"    ]. If this does not yield a diagnosis, biopsy of other sites of suspected involvement may be undertaken in the appropriate clinical setting. As examples, biopsies of the liver (eg, in the setting of unexplained abnormal liver function tests), lung (eg, unexplained pulmonary symptoms), and brain (eg, unexplained dementia) have been diagnostic in case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13511/abstract/1,15,19,22\">",
"     1,15,19,22",
"    </a>",
"    ]. Immunophenotyping of intravascular lymphoid cells is required in order to differentiate intravascular large B-cell lymphoma (ILBL) from rare types of ILCL with T- or NK-differentiation.",
"   </p>",
"   <p>",
"    Although commonly involved in other subtypes of lymphoma, the bone marrow, lymph nodes, peripheral blood, and cerebrospinal fluid are often uninvolved in ILCL [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13511/abstract/23\">",
"     23",
"    </a>",
"    ]. Involvement of these sites can be very subtle, and stains for lymphoid markers, such as CD20, may bring out the presence of single tumor cells within small vessels that are missed by morphology alone. As discussed above, bone marrow involvement is more frequent in the so-called Asian variant of ILCL. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Symptoms'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;On occasion, clusters of activated lymphocytes may be observed within the post-capillary venules of tissues involved in inflammatory or immune reactions, particularly the lymph nodes. On purely morphologic grounds, these may be difficult to distinguish from focal involvement by ILCL. As noted above, however, most patients with ILCL have systemic constitutional symptoms, laboratory abnormalities, and evidence of organ dysfunction, all typically associated with extensive intravascular disease in extranodal organs, allowing for the diagnosis to be established on clinicopathologic grounds.",
"   </p>",
"   <p>",
"    Intralymphatic histiocytosis, a reactive condition associated with rheumatoid arthritis, may present with clinical lesions similar to those of ILCL and with intravascular proliferations of large cells, but can be differentiated on histopathology by CD68 positivity of intravascular proliferations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13511/abstract/24\">",
"     24",
"    </a>",
"    ]. Vessels involved are lymphatics, which stain positive with podoplanin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13511/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pretreatment evaluation both determines the extent of the disease and provides information about the individual's comorbidities that are likely to have impact on treatment options. In general, the pretreatment evaluation is the same as that performed for patients with diffuse large B-cell lymphoma. This is presented in detail separately. Of note, patients with intravascular large B-cell lymphoma have a high rate of central nervous system (CNS) involvement. As such, we typically evaluate the CNS with a lumbar puncture and magnetic resonance imaging (MRI) of the brain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link&amp;anchor=H2#H2\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\", section on 'Pretreatment evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of patients with ILCL includes both systemic therapy and therapy directed at the central nervous system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Systemic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the presence of lymphoma cells within the blood vessels, all cases of ILCL are considered disseminated and are therefore treated as advanced disease. Only case reports and retrospective analyses have been reported on the treatment of ILCL. Most patients diagnosed with intravascular large B-cell lymphoma (ILBL) are treated with regimens used for the treatment of diffuse large B-cell lymphoma. Specifically, a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    with the recombinant anti-CD20 antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (R-CHOP) is the most commonly employed treatment (",
"    <a class=\"graphic graphic_table graphicRef63586 \" href=\"UTD.htm?22/2/22574\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Support for the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    plus anthracycline-based chemotherapy comes from case reports and retrospective studies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13511/abstract/1,2,4,17,25-28\">",
"     1,2,4,17,25-28",
"    </a>",
"    ]. The largest retrospective analysis of treatment included 106 patients with newly diagnosed ILBL treated either with chemotherapy alone (57 patients) or chemotherapy plus rituximab (49 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13511/abstract/4\">",
"     4",
"    </a>",
"    ]. Approximately 83 percent of the patients received CHOP or CHOP-like chemotherapy with or without rituximab. There was no difference in the rate of treatment-related deaths. At a median follow-up of 18 months, patients treated with chemotherapy plus rituximab had significantly higher rates:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete response (82 versus 51 percent).",
"     </li>",
"     <li>",
"      Two-year progression free survival (56 versus 27 percent)",
"     </li>",
"     <li>",
"      Two-year overall survival (66 versus 46 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If a timely diagnosis is made and anthracycline-based chemotherapy (eg, CHOP, CHOP-R) instituted, many patients achieve complete remission, with a 60 percent response rate and an estimated 3-year overall survival greater than 30 percent; long-term survival appears to be possible [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13511/abstract/1,2,4,17,25-28\">",
"     1,2,4,17,25-28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     CNS directed therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central nervous system (CNS) involvement is seen in 30 to 40 percent of patients with ILBL at diagnosis and occurs in another 25 percent of patients during follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13511/abstract/7\">",
"     7",
"    </a>",
"    ]. Systemic therapy with R-CHOP does not sufficiently penetrate the CNS, therefore patients with ILBL also require therapies directed towards the CNS, either as prophylaxis for or treatment of CNS involvement. As mentioned above, the pretreatment evaluation includes a lumbar puncture and magnetic resonance imaging (MRI) of the brain. CNS directed therapy is determined based upon the results of these tests:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients without tumor cells in the cerebrospinal fluid (CSF) and normal imaging by MRI, we administer CNS prophylaxis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=see_link&amp;anchor=H23#H23\">",
"       \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\", section on 'Prophylaxis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with secondary involvement of the brain or spinal cord at the time of diagnosis, we administer specific treatment targeting these areas. Such treatment varies based upon the exact disease site, but can include intrathecal chemotherapy, systemic high dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiation to the sites of involvement. The treatment of CNS involvement is presented in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=see_link\">",
"       \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with neurologic compromise from spinal cord compression require urgent therapy, often with neurosurgical intervention. The timing of chemotherapy and radiation therapy is controversial; however, many patients are treated with radiation therapy prior to receiving systemic therapy. The benefit of intrathecal therapy, particularly in the presence of a normal spinal fluid evaluation, is unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26970?source=see_link\">",
"     \"Treatment and prognosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     EVALUATION OF RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;One month following the completion of planned therapy (or sooner if the outcome is unfavorable), the response to treatment should be documented by history, physical examination, and laboratory studies (complete blood count, lactate dehydrogenase, and biochemical profile).",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    should be obtained six to eight weeks after completion of chemotherapy and 12 weeks after the completion of radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13511/abstract/29-31\">",
"     29-31",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    imaging obtained earlier than this is likely to demonstrate increased uptake due to an inflammatory reaction to treatment.",
"   </p>",
"   <p>",
"    Given its unusual initial presentation and location of disease, the response criteria used for other types of non-Hodgkin lymphoma may not apply. Instead, prospective studies have used the following criteria for response [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13511/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete response - Disappearance of all clinical symptoms and radiographic or laboratory abnormalities, including bone marrow involvement, observed at diagnosis and the absence of any new abnormalities.",
"     </li>",
"     <li>",
"      Progressive disease - Appearance of new abnormalities associated with the disease or evident deterioration of the initial abnormalities associated with the disease.",
"     </li>",
"     <li>",
"      Stable disease - Failure to achieve a complete response and lack of progressive disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Relapsed disease occurs when there is progression of the disease after an initial complete response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PATIENT FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although follow-up data are scarce, relapses may be more common in those with CNS involvement and less common in those with cutaneous involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13511/abstract/1\">",
"     1",
"    </a>",
"    ]. When the disease is restricted to the skin, the prognosis seems to be favorable [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13511/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following the completion of therapy, restaging, and documentation of complete remission, patients are seen at periodic intervals to monitor for treatment complications and assess for possible relapse. The frequency and extent of these visits depends upon the comfort of both the patient and physician. There have been no prospective, randomized trials comparing various schedules of follow-up. When planning the post-treatment surveillance strategy, care should be taken to limit the number of CT scans, particularly in younger individuals, given concerns about radiation exposure and the risk for second malignancies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our approach to patient surveillance is to schedule patient visits every three months during the first year, every three to six months during the second year, and every six months starting two years after complete response. At these visits we perform a history and physical examination, complete blood count, chemistries, and LDH. We do perform CT scans at months 6, 12, 18, 24, 30 or 36, and then yearly until five years after attainment of a complete remission. No more imaging is performed after five years unless an abnormality suggests the possibility relapse or the patient requests it.",
"   </p>",
"   <p>",
"    Relapsed disease can be suggested by changes on imaging studies but can only be confirmed by biopsy. As such, a biopsy should always be obtained to document relapsed disease before proceeding to salvage therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33178?source=see_link\">",
"     \"Treatment of relapsed or refractory diffuse large B cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravascular large cell lymphoma (ILCL) is a rare subtype of large cell lymphoma that is characterized by the proliferation of lymphoma cells within the lumina of small blood vessels, particularly capillaries and post-capillary venules, without an obvious extravascular tumor mass or detectable circulating tumor cells in the peripheral blood.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients present with a bewildering variety of symptoms caused by the occlusion of small vessels. These include constitutional B symptoms (ie, fever, night sweats, and weight loss), rapidly progressive neurologic signs (eg, dementia, progressive cerebral vascular accident, peripheral neuropathy), and skin lesions imitating inflammatory skin conditions such as thrombophlebitis and erythema nodosum. Laboratory abnormalities increased lactate dehydrogenase (LDH) and beta 2-microglobulin, anemia, and an elevated sedimentation rate. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of ILCL is made by demonstrating large lymphoma cells within small to medium blood vessels. If the diagnosis is considered, deep biopsies of lesional skin or random biopsies of \"normal\" skin without any obvious abnormality may be diagnostic. If this does not yield a diagnosis, biopsy of other sites of suspected involvement may be undertaken in the appropriate clinical setting. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pathology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of patients with intravascular large B cell lymphoma (ILBL) includes both systemic therapy and therapy directed at the central nervous system. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with ILBL, we suggest initial treatment with a combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      with the recombinant anti-CD20 antibody",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (R-CHOP) (",
"      <a class=\"graphic graphic_table graphicRef63586 \" href=\"UTD.htm?22/2/22574\">",
"       table 1",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link\">",
"       \"Initial treatment of advanced stage diffuse large B cell lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients without tumor cells in the cerebrospinal fluid (CSF) and normal imaging by MRI, we generally recommend CNS prophylaxis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=see_link&amp;anchor=H23#H23\">",
"       \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\", section on 'Prophylaxis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with secondary involvement of the brain or spinal cord at the time of diagnosis, we administer specific treatment targeting these areas. Such treatment varies based upon the exact disease site, but can include intrathecal chemotherapy, systemic high dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiation to the sites of involvement. The treatment of CNS involvement is presented in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=see_link\">",
"       \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13511/abstract/1\">",
"      Ponzoni M, Ferreri AJ, Campo E, et al. Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting. J Clin Oncol 2007; 25:3168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13511/abstract/2\">",
"      Ferreri AJ, Campo E, Seymour JF, et al. Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'. Br J Haematol 2004; 127:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13511/abstract/3\">",
"      Murase T, Yamaguchi M, Suzuki R, et al. Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood 2007; 109:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13511/abstract/4\">",
"      Shimada K, Matsue K, Yamamoto K, et al. Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. J Clin Oncol 2008; 26:3189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13511/abstract/5\">",
"      Chapin JE, Davis LE, Kornfeld M, Mandler RN. Neurologic manifestations of intravascular lymphomatosis. Acta Neurol Scand 1995; 91:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13511/abstract/6\">",
"      Detsky ME, Chiu L, Shandling MR, et al. Clinical problem-solving. Heading down the wrong path. N Engl J Med 2006; 355:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13511/abstract/7\">",
"      Shimada K, Murase T, Matsue K, et al. Central nervous system involvement in intravascular large B-cell lymphoma: a retrospective analysis of 109 patients. Cancer Sci 2010; 101:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13511/abstract/8\">",
"      Murase T, Nakamura S, Kawauchi K, et al. An Asian variant of intravascular large B-cell lymphoma: clinical, pathological and cytogenetic approaches to diffuse large B-cell lymphoma associated with haemophagocytic syndrome. Br J Haematol 2000; 111:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13511/abstract/9\">",
"      Kojima K, Kaneda K, Yasukawa M, et al. Specificity of polymerase chain reaction-based clonality analysis of immunoglobulin heavy chain gene rearrangement for the detection of bone marrow infiltrate in B-cell lymphoma-associated haemophagocytic syndrome. Br J Haematol 2002; 119:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13511/abstract/10\">",
"      Narimatsu H, Morishita Y, Saito S, et al. Usefulness of bone marrow aspiration for definite diagnosis of Asian variant of intravascular lymphoma: four autopsied cases. Leuk Lymphoma 2004; 45:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13511/abstract/11\">",
"      R&ouml;glin J, B&ouml;er A. Skin manifestations of intravascular lymphoma mimic inflammatory diseases of the skin. Br J Dermatol 2007; 157:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13511/abstract/12\">",
"      Cobcroft R. Images in haematology. Diagnosis of angiotropic large B-cell lymphoma from a peripheral blood film. Br J Haematol 1999; 104:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13511/abstract/13\">",
"      Williams G, Foyle A, White D, et al. Intravascular T-cell lymphoma with bowel involvement: case report and literature review. Am J Hematol 2005; 78:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13511/abstract/14\">",
"      Song DE, Lee MW, Ryu MH, et al. Intravascular large cell lymphoma of the natural killer cell type. J Clin Oncol 2007; 25:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13511/abstract/15\">",
"      Ganguly S. Acute intracerebral hemorrhage in intravascular lymphoma: a serious infusion related adverse event of rituximab. Am J Clin Oncol 2007; 30:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13511/abstract/16\">",
"      Kiyohara T, Kumakiri M, Kobayashi H, et al. A case of intravascular large B-cell lymphoma mimicking erythema nodosum: the importance of multiple skin biopsies. J Cutan Pathol 2000; 27:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13511/abstract/17\">",
"      Gill S, Melosky B, Haley L, ChanYan C. Use of random skin biopsy to diagnose intravascular lymphoma presenting as fever of unknown origin. Am J Med 2003; 114:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13511/abstract/18\">",
"      Odawara J, Asada N, Aoki T, et al. 18F-Fluorodeoxyglucose positron emission tomography for evaluation of intravascular large B-cell lymphoma. Br J Haematol 2007; 136:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13511/abstract/19\">",
"      Martusewicz-Boros M, Wiatr E, Radzikowska E, et al. Pulmonary intravascular large B-cell lymphoma as a cause of severe hypoxemia. J Clin Oncol 2007; 25:2137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13511/abstract/20\">",
"      Asada N, Odawara J, Kimura S, et al. Use of random skin biopsy for diagnosis of intravascular large B-cell lymphoma. Mayo Clin Proc 2007; 82:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13511/abstract/21\">",
"      Le EN, Gerstenblith MR, Gelber AC, et al. The use of blind skin biopsy in the diagnosis of intravascular B-cell lymphoma. J Am Acad Dermatol 2008; 59:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13511/abstract/22\">",
"      Yamada S, Nishii R, Oka S, et al. FDG-PET a pivotal imaging modality for diagnosis of stroke-onset intravascular lymphoma. Arch Neurol 2010; 67:366.",
"     </a>",
"    </li>",
"    <li>",
"     Gatter KC, Warnke RA. Intravascular large B-cell lymphoma. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, Jaffe ES, Harris NL, Stein H, Vardiman JW (Eds), IARC Press, Lyon 2001. p.177.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13511/abstract/24\">",
"      Requena L, El-Shabrawi-Caelen L, Walsh SN, et al. Intralymphatic histiocytosis. A clinicopathologic study of 16 cases. Am J Dermatopathol 2009; 31:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13511/abstract/25\">",
"      Tsukadaira A, Okubo Y, Ogasawara H, et al. Chromosomal aberrations in intravascular lymphomatosis. Am J Clin Oncol 2002; 25:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13511/abstract/26\">",
"      Bouzani M, Karmiris T, Rontogianni D, et al. Disseminated intravascular B-cell lymphoma: clinicopathological features and outcome of three cases treated with anthracycline-based immunochemotherapy. Oncologist 2006; 11:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13511/abstract/27\">",
"      Koizumi M, Nishimura M, Yokota A, et al. Successful treatment of intravascular malignant lymphomatosis with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2001; 27:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13511/abstract/28\">",
"      Ferreri AJ, Dognini GP, Govi S, et al. Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma? J Clin Oncol 2008; 26:5134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13511/abstract/29\">",
"      Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13511/abstract/30\">",
"      Shimada K, Kosugi H, Shimada S, et al. Evaluation of organ involvement in intravascular large B-cell lymphoma by 18F-fluorodeoxyglucose positron emission tomography. Int J Hematol 2008; 88:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13511/abstract/31\">",
"      Hoshino A, Kawada E, Ukita T, et al. Usefulness of FDG-PET to diagnose intravascular lymphomatosis presenting as fever of unknown origin. Am J Hematol 2004; 76:236.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4738 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.97.94.19-A044F949FA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_12_13511=[""].join("\n");
var outline_f13_12_13511=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CNS directed therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      EVALUATION OF RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PATIENT FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4738\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4738|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/41/4757\" title=\"picture 1\">",
"      Intravascular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/11/33973\" title=\"picture 2\">",
"      Intravascular lymphoma brain biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/21/19799\" title=\"picture 3\">",
"      Cutaneous involvement ILCL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4738|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/2/22574\" title=\"table 1\">",
"      R-CHOP21 regimen for non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24282?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=related_link\">",
"      Hemophagocytic lymphohistiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=related_link\">",
"      Initial treatment of advanced stage diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=related_link\">",
"      Secondary involvement of the central nervous system by non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26970?source=related_link\">",
"      Treatment and prognosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33178?source=related_link\">",
"      Treatment of relapsed or refractory diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_12_13512="Overview of the treatment of classical Hodgkin lymphoma in adults";
var content_f13_12_13512=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the treatment of classical Hodgkin lymphoma in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/12/13512/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/12/13512/contributors\">",
"     Peter M Mauch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/12/13512/contributors\">",
"     George P Canellos, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/12/13512/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/12/13512/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/12/13512/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/12/13512/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/12/13512/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H740942\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of patients with Hodgkin lymphoma (formerly called Hodgkin's disease) is primarily guided by the clinical stage of disease as determined by the Cotswolds classification (",
"    <a class=\"graphic graphic_table graphicRef66651 \" href=\"UTD.htm?19/23/19836\">",
"     table 1",
"    </a>",
"    ). This staging system is important in determining not only prognosis and treatment, but is also important for the comparison of results obtained with different types of treatment in different studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=see_link\">",
"     \"Staging and prognosis of Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will provide a brief review of the selection of treatment based upon disease stage. The initial evaluation, diagnosis, and staging of patients with Hodgkin lymphoma are discussed separately, as is a more detailed description of treatment selection for patients with early or advanced stage Hodgkin lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29206?source=see_link\">",
"     \"Initial evaluation and diagnosis of Hodgkin lymphoma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=see_link\">",
"     \"Staging and prognosis of Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15578?source=see_link\">",
"     \"Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF SELECTION OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over the past century, Hodgkin lymphoma has been converted from a uniformly fatal disease to one that is curable in approximately 75 percent of patients worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13512/abstract/1\">",
"     1",
"    </a>",
"    ]. While the majority of patients will be cured of their lymphoma, treatment-related toxicities have become a competing cause of late mortality. As such, the selection of therapy must balance the desire to maintain a high rate of cure and the need to minimize long-term complications. Treatment has evolved such that patients with early stage disease can achieve long term remission with less intensive therapy, while more intensive therapy is reserved for patients with advanced stage disease. Despite agreement that therapy should be tailored to the stage of disease, there is some disagreement regarding what should constitute intensive and less intensive therapy.",
"   </p>",
"   <p>",
"    The successful management of patients with Hodgkin lymphoma requires close attention to details of the staging and treatment protocols to achieve these results, while minimizing the potential serious toxicities of therapy. Some of the serious effects of therapy, such as secondary malignancy and heart disease, are not evident until years after treatment is completed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30007?source=see_link\">",
"     \"Monitoring of the patient with classical Hodgkin lymphoma during and after treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3079?source=see_link\">",
"     \"Long-term follow-up of the patient with classical Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35242?source=see_link\">",
"     \"Second malignancies after treatment of classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In an attempt to minimize late complications, there has been a gradual change in treatment regimens, including a decrease in radiation doses and volumes, the use of multiagent chemotherapy in combination with radiation (permitting the administration of fewer cycles of less toxic drugs), and the use of multiagent chemotherapy alone, especially in those patients who have a high risk of late effects from the radiation exposure (ie, young women and breast cancer risk).",
"   </p>",
"   <p>",
"    Patients with Hodgkin lymphoma have a significant likelihood of being cured of disease even after recurrence or relapse following initial treatment. Therefore, consideration for the long term complications of successful primary and secondary therapy is warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13512/abstract/2\">",
"     2",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    Recurrence after initial chemotherapy is usually treated with conventional or high dose chemotherapy. Patients may also achieve prolonged control of their disease after two or more recurrences by means of intensive therapy supported by autologous hematopoietic cell transplantation regimens. When patients are not cured (cure is less likely with each recurrence) and have exhausted standard treatment programs, they should be managed with palliation as the goal or be considered for experimental programs. Some patients with persistent Hodgkin lymphoma, despite multiple courses of treatment, tolerate their disease relatively well for prolonged periods. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/17/37145?source=see_link\">",
"     \"Treatment of relapse of classical Hodgkin lymphoma after initial chemotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38009?source=see_link\">",
"     \"Second and third line chemotherapy regimens and biologic therapy for relapsing or resistant classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Treatment selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selection of initial treatment for Hodgkin lymphoma is usually based upon presenting stage and prognostic factors (",
"    <a class=\"graphic graphic_table graphicRef66651 \" href=\"UTD.htm?19/23/19836\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13512/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The definitions used for radiation fields in the treatment of Hodgkin lymphoma are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef78652 \" href=\"UTD.htm?27/6/27756\">",
"     table 2",
"    </a>",
"    ). An important issue during any form of therapy is monitoring for extent of disease. CT scan is usually performed, but if residual abnormalities are present, this modality cannot distinguish between necrosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fibrosis and active disease.",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scanning and, if necessary, tissue biopsy are used to establish the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30007?source=see_link\">",
"     \"Monitoring of the patient with classical Hodgkin lymphoma during and after treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Early stage Hodgkin lymphoma (Stage I-II)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In this discussion, patients with stage I or stage II disease are considered to have &ldquo;early stage&rdquo; Hodgkin lymphoma (",
"    <a class=\"graphic graphic_table graphicRef66651 \" href=\"UTD.htm?19/23/19836\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage I &mdash; Involvement of a single lymph node region (I) or of a single extralymphatic organ or site (Ie)",
"     </li>",
"     <li>",
"      Stage II &mdash; Involvement of two or more lymph node regions on the same side of the diaphragm alone (II) or with involvement of limited, contiguous extralymphatic organ or tissue (IIe).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among patients with early disease, there is subsequent stratification into favorable and unfavorable prognosis disease based upon the presence or absence of certain clinical features, such as age, B symptoms, and large mediastinal adenopathy. Cooperative research groups have used varying definitions of favorable and unfavorable prognosis disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10711?source=see_link\">",
"     \"Definition of favorable and unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11770?source=see_link&amp;anchor=H1#H1\">",
"     \"Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The two most commonly used definitions of favorable disease are those proposed by the European Organization for the Research and Treatment of Cancer (EORTC) and the German Hodgkin Study Group (GHSG):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The EORTC defines the limited stage favorable prognostic group as patients age 50 or under; without large mediastinal adenopathy; with an ESR of less than",
"      <span class=\"nowrap\">",
"       50/h",
"      </span>",
"      and no B symptoms (or with an ESR of less than 30",
"      <span class=\"nowrap\">",
"       mm/h",
"      </span>",
"      in those who have B symptoms); and disease limited to three or fewer regions of involvement [",
"      <a class=\"abstract\" href=\"UTD.htm?13/12/13512/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The GHSG defines the limited stage favorable prognostic group as patients with no more than two sites of disease; no extranodal extension; no mediastinal mass measuring one-third the maximum thoracic diameter or greater; and ESR less than 50",
"      <span class=\"nowrap\">",
"       mm/h",
"      </span>",
"      (less than 30",
"      <span class=\"nowrap\">",
"       mm/h",
"      </span>",
"      if B symptoms present) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/12/13512/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who do not fall into these categories are considered to have unfavorable prognosis early stage Hodgkin lymphoma. Patients with favorable prognosis disease may have acceptable outcomes with less intensive therapy than that required for those with unfavorable prognosis early stage or advanced stage disease.",
"   </p>",
"   <p>",
"    Patients with early stage disease are treated with a combination of chemotherapy plus radiation therapy. The amount of chemotherapy and dose of radiation differs for patients with favorable and unfavorable prognosis disease. While treatment with initial radiotherapy had resulted in high cure rates among patients with early stage disease, toxicity was substantially reduced and long-term disease control was improved when chemotherapy was added. As such, radiotherapy is rarely, if ever, used currently as the sole treatment of Hodgkin lymphoma. Patients who relapse after initial treatment with radiotherapy alone can be successfully treated with combination chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13512/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7784?source=see_link\">",
"     \"Relapse of classical Hodgkin lymphoma after initial radiotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the increasing availability of guidelines for the treatment of Hodgkin lymphoma, there must remain room for individualization of treatment. In particular, patient preference must be considered with different treatment options, some of which result in a higher recurrence risk at the gain of less toxic initial treatment (without any difference in long-term survival). Treatment should also be individualized when a particular approach might result in a higher risk of a serious late complication (eg, the use of large radiation fields and the risk of late breast cancer in young females and of lung cancer in smokers). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35242?source=see_link\">",
"     \"Second malignancies after treatment of classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h4\">",
"     Favorable prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, cooperative research groups have used varying definitions of favorable prognosis early stage disease. The following treatment options are generally used in patients with favorable prognosis stage I-II disease. There are differences in relapse rates and toxicity between treatment approaches. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11770?source=see_link\">",
"     \"Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ABVD (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      ) for three to four cycles, followed by involved field irradiation to 30 to 36 Gy with fields encompassing the initially involved lymph node site. This approach has the lowest relapse rate.",
"     </li>",
"     <li>",
"      ABVD for two cycles, followed by involved field irradiation with 20 Gy may be sufficient treatment for patients with favorable disease as defined by the GHSG. This regimen has lower toxicity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2792?source=see_link&amp;anchor=H9#H9\">",
"       \"Clinical trials of specific regimens in favorable prognosis early (stage I-II) classical Hodgkin lymphoma\", section on 'Modified chemotherapy and involved field irradiation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      ABVD for four to six cycles without radiation therapy. This is an emerging option for patients at risk of long-term complications from radiotherapy. However, this option is associated with higher recurrence rates compared with combined modality therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11770?source=see_link&amp;anchor=H5#H5\">",
"       \"Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma\", section on 'Is there a role for chemotherapy alone?'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Experts disagree regarding the best choice among these treatment approaches. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11770?source=see_link\">",
"     \"Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h4\">",
"     Unfavorable prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with unfavorable prognosis stage I-II Hodgkin lymphoma are treated with chemotherapy followed by involved field radiotherapy in a combined modality program. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27496?source=see_link\">",
"     \"Treatment of unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ABVD (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    ) remains the \"gold standard\" chemotherapy for these patients (",
"    <a class=\"graphic graphic_table graphicRef68131 \" href=\"UTD.htm?0/59/958\">",
"     table 3",
"    </a>",
"    ). ABVD cycles are administered every 28 days until maximal tumor response, as judged by computed tomography (CT) scan and positron emission tomographic (PET) imaging. After maximal tumor response has been achieved, two additional cycles of consolidation chemotherapy with ABVD are often given. Chemotherapy is followed by radiation therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30007?source=see_link\">",
"     \"Monitoring of the patient with classical Hodgkin lymphoma during and after treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Four to six monthly cycles of ABVD are usually required for patients with bulky disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13512/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Patients considered to have unfavorable disease without large mediastinal adenopathy may be treated adequately with as few as three or four months of ABVD followed by radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13512/abstract/11\">",
"     11",
"    </a>",
"    ], but four months of ABVD is the general minimum for patients with bulky disease.",
"   </p>",
"   <p>",
"    Radiation fields can be safely limited to involved regions as determined by CT scan and PET imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13512/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. It is important to take advantage of tumor regression secondary to chemotherapy and to design treatment fields that conform to the width of the residual disease and not to the initial tumor volume. Restricting fields reduces the risk of pulmonary complications related to the radiation, while treatment of the original tumor volume is associated with enhanced risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27496?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma\", section on 'Radiation field size'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Advanced stage Hodgkin lymphoma (Stage III-IV)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In this discussion, advanced stage Hodgkin lymphoma refers to clinical stage (CS) III and IV disease, although many experts and clinical trials include patients with stage II plus bulky nodal disease (CS IIA or IIB). CS III describes involvement of lymph nodes or lymphoid structures on both sides of the diaphragm. CS IV refers to diffuse or disseminated involvement of one or more extranodal organs or tissues, with or without lymph node disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=see_link\">",
"     \"Staging and prognosis of Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Combination chemotherapy is the main treatment for patients with advanced stage Hodgkin lymphoma. Radiation therapy may be used for select patients as consolidation. The three treatment regimens widely used for advanced stage Hodgkin lymphoma include (",
"    <a class=\"graphic graphic_table graphicRef74186 \" href=\"UTD.htm?7/60/8142\">",
"     table 4",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ABVD (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"       dacarbazine",
"      </a>",
"      ) has been the standard regimen for several decades. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39786?source=see_link&amp;anchor=H7#H7\">",
"       \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\", section on 'ABVD chemotherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Escalated BEACOPP (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) programs incorporate radiation therapy for most patients and have shown advantages in freedom from progression when compared with ABVD and overall survival when compared with",
"      <span class=\"nowrap\">",
"       COPP/ABVD.",
"      </span>",
"      These advantages are most marked among patients with higher risk international prognostic score (IPS) and this more intense regimen is a reasonable alternative to ABVD for these patients with the highest risk of relapse (",
"      <a class=\"graphic graphic_table graphicRef76219 \" href=\"UTD.htm?11/50/12077\">",
"       table 5",
"      </a>",
"      ). Toxicities associated with the administration of escalated BEACOPP in the elderly make it inappropriate for this population. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39786?source=see_link&amp;anchor=H10#H10\">",
"       \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\", section on 'BEACOPP chemotherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Stanford V (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/57/40853?source=see_link\">",
"       mechlorethamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ) incorporates radiation therapy for all patients and may be preferred in some settings because of its short administration schedule (12 versus 24 to 32 weeks) and decreased pulmonary toxicity. It may have advantages for certain patients, particularly those for whom radiation will be part of their planned therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39786?source=see_link&amp;anchor=H14#H14\">",
"       \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\", section on 'Stanford V'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A choice among these regimens must take into consideration the response rates, relapse rates, toxicity, and patient preference. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39786?source=see_link&amp;anchor=H6#H6\">",
"     \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of consolidation radiotherapy after chemotherapy induction for advanced stage Hodgkin lymphoma is controversial. Consolidation radiation therapy appears to improve freedom from progression but not overall survival. Its use depends primarily upon the initial chemotherapy administered and the patient's response to that chemotherapy. Radiation therapy is an essential component of the Stanford V protocol. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39786?source=see_link&amp;anchor=H22#H22\">",
"     \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\", section on 'General'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39786?source=see_link&amp;anchor=H24#H24\">",
"     \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\", section on 'With Stanford V'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Primary refractory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary refractory (resistant) disease refers to patients who do not attain a complete remission after initial therapy. The incidence of primary refractory disease varies depending upon the stage of disease at diagnosis and the treatment regimen used. Durable responses and remissions may be achieved in approximately one-half of these patients with second line chemotherapy that incorporates drugs not used in initial treatment followed by high dose chemotherapy and autologous hematopoietic cell rescue. Patients with a second relapse or progressive, resistant disease are candidates for high dose chemotherapy and autologous hematopoietic cell transplantation as well. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21274?source=see_link\">",
"     \"Hematopoietic cell transplantation in classical Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38009?source=see_link&amp;anchor=H2#H2\">",
"     \"Second and third line chemotherapy regimens and biologic therapy for relapsing or resistant classical Hodgkin lymphoma\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112049114\">",
"    <span class=\"h3\">",
"     Relapsed disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Hodgkin lymphoma relapsing after prior treatment with chemotherapy are generally treated with either conventional chemotherapy combined with radiation therapy or high dose chemotherapy and autologous hematopoietic cell transplantation (HCT) given with or without radiation therapy. The choice of therapy is usually based upon prognostic features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a localized, asymptomatic relapse occurring more than 12 months after initial treatment are usually treated with conventional salvage chemotherapy, often combined with radiation therapy with or without high dose chemotherapy and autologous HCT. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/17/37145?source=see_link&amp;anchor=H7#H7\">",
"       \"Treatment of relapse of classical Hodgkin lymphoma after initial chemotherapy\", section on 'Late first relapse'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      High dose chemotherapy and autologous HCT should be considered as the treatment of choice for the following subsets of patients:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Early relapse (less than 12 months after treatment) or induction failure.",
"     </li>",
"     <li>",
"      Second relapse after conventional treatment for first relapse.",
"     </li>",
"     <li>",
"      Generalized systemic relapse even beyond 12 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, patients with relapsed disease are treated with a chemotherapy regimen that is different from the one used for initial treatment. Details on these regimens are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/17/37145?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of relapse of classical Hodgkin lymphoma after initial chemotherapy\", section on 'Choice of regimen'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38009?source=see_link\">",
"     \"Second and third line chemotherapy regimens and biologic therapy for relapsing or resistant classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiation therapy is indicated for patients with localized residual disease after salvage chemotherapy. In addition, patients with a localized late relapse (&gt;12 months) may achieve long-term remission with chemotherapy followed by involved-field radiation therapy (IF-RT) rather than chemotherapy followed by HCT. The role of IF-RT in the treatment of patients who achieve a complete response to chemotherapy and plan to proceed with HCT is less clear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/17/37145?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of relapse of classical Hodgkin lymphoma after initial chemotherapy\", section on 'Radiation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107010540\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112049302\">",
"    <span class=\"h2\">",
"     Early stage disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with early stage (stage I-II) Hodgkin lymphoma have a high likelihood of achieving long-term complete remission. As described above, treatment selection of these patients is largely determined based upon other prognostic factors that allow the discrimination of patients with &ldquo;favorable prognosis&rdquo; early stage Hodgkin lymphoma and those with &ldquo;unfavorable prognosis&rdquo; early stage Hodgkin lymphoma. These factors are presented in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10711?source=see_link\">",
"     \"Definition of favorable and unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112049651\">",
"    <span class=\"h2\">",
"     International prognostic score",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with advanced stage (stage",
"    <span class=\"nowrap\">",
"     III/IV)",
"    </span>",
"    Hodgkin disease, prognosis is largely determined by the International Prognostic Score (IPS). The IPS was created by the International Prognostic Factor Project on Advanced Hodgkin's Disease based upon the total number of seven potential unfavorable features at diagnosis: serum albumin less than 4",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (40",
"    <span class=\"nowrap\">",
"     g/L),",
"    </span>",
"    hemoglobin less than 10.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (105",
"    <span class=\"nowrap\">",
"     g/L),",
"    </span>",
"    male gender, age over 45 years, stage IV disease, white blood cell count",
"    <span class=\"nowrap\">",
"     &ge;15,000/microL,",
"    </span>",
"    and lymphocyte count less than",
"    <span class=\"nowrap\">",
"     600/microL",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    less than 8 percent of the white blood cell count (",
"    <a class=\"graphic graphic_table graphicRef76219 \" href=\"UTD.htm?11/50/12077\">",
"     table 5",
"    </a>",
"    ) (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?4/32/4609?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13512/abstract/14\">",
"     14",
"    </a>",
"    ]. This analysis showed a spread in freedom from progression at five years, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No factors &mdash; 84 percent (7 percent of patients)",
"     </li>",
"     <li>",
"      One factor &mdash; 77 percent (22 percent of patients)",
"     </li>",
"     <li>",
"      Two factors &mdash; 67 percent (29 percent of patients)",
"     </li>",
"     <li>",
"      Three factors &mdash; 60 percent (23 percent of patients)",
"     </li>",
"     <li>",
"      Four factors &mdash; 51 percent (12 percent of patients)",
"     </li>",
"     <li>",
"      Five or more factors &mdash; 42 percent (7 percent of patients)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MINIMIZING LONG-TERM COMPLICATIONS OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hodgkin lymphoma survivors are at risk of developing therapy-related complications that may present years after treatment (eg, second malignancies, cardiac disease, radiation-induced hypothyroidism). These complications have surfaced as significant causes of increased mortality among survivors. Screening for some of these entities is advised in the hope that early detection may lead to better management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3079?source=see_link&amp;anchor=H1167672644#H1167672644\">",
"     \"Long-term follow-up of the patient with classical Hodgkin lymphoma\", section on 'Follow-up for long-term complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, measures can be taken at the time of diagnosis to minimize the potential of some long-term complications of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Fertility preservation",
"    </span>",
"    &nbsp;&mdash;&nbsp;An overall discussion of fertility issues should be undertaken in patients of childbearing age prior to the initiation of treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=see_link\">",
"     \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Smoking cessation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of chest irradiation and smoking can dramatically increase a patient's risk for lung cancer. We recommend smoking cessation for all patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/34997?source=see_link\">",
"     \"Patterns of tobacco use\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/10/23714?source=see_link\">",
"       \"Patient information: Hodgkin lymphoma in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/37/13908?source=see_link\">",
"       \"Patient information: Hodgkin lymphoma in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107010793\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The treatment of patients with Hodgkin lymphoma (formerly called Hodgkin's disease) is primarily guided by the clinical stage of disease as determined by the Cotswolds classification (",
"      <a class=\"graphic graphic_table graphicRef66651 \" href=\"UTD.htm?19/23/19836\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=see_link\">",
"       \"Staging and prognosis of Hodgkin lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      While the majority of patients will be cured of their lymphoma, treatment-related toxicities have become a competing cause of late mortality. As such, the selection of therapy must balance the desire to maintain a high rate of cure and the need to minimize long-term complications. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview of selection of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with early stage disease (stage I-II) are treated with a combination of chemotherapy plus radiation therapy. The amount of chemotherapy and dose of radiation differs for patients with favorable and unfavorable prognosis disease. While treatment with initial radiotherapy had resulted in high cure rates among patients with early stage disease, toxicity was substantially reduced and long-term disease control was improved when chemotherapy was added. As such, radiotherapy is rarely, if ever, used currently as the sole treatment of Hodgkin lymphoma. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Early stage Hodgkin lymphoma (Stage I-II)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Combination chemotherapy is the main treatment for patients with advanced stage (stage III-IV) Hodgkin lymphoma. Radiation therapy may be used for select patients as consolidation. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Advanced stage Hodgkin lymphoma (Stage III-IV)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with primary refractory (resistant) disease may attain durable responses and remissions with second line chemotherapy that incorporates drugs not used in initial treatment followed by high dose chemotherapy and autologous hematopoietic cell rescue. Patients with a second relapse or progressive, resistant disease are candidates for high dose chemotherapy and autologous hematopoietic cell transplantation as well. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21274?source=see_link\">",
"       \"Hematopoietic cell transplantation in classical Hodgkin lymphoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38009?source=see_link&amp;anchor=H2#H2\">",
"       \"Second and third line chemotherapy regimens and biologic therapy for relapsing or resistant classical Hodgkin lymphoma\", section on 'Overview'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with early stage (stage I-II) Hodgkin lymphoma have a high likelihood of achieving long-term complete remission. A variety of prognostic factors allow for the discrimination of patients with &ldquo;favorable prognosis&rdquo; early stage Hodgkin lymphoma and those with &ldquo;unfavorable prognosis&rdquo; early stage Hodgkin lymphoma. These factors are presented in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10711?source=see_link\">",
"       \"Definition of favorable and unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among patients with advanced stage (stage",
"      <span class=\"nowrap\">",
"       III/IV)",
"      </span>",
"      Hodgkin disease, prognosis is largely determined by the International Prognostic Score (IPS) (",
"      <a class=\"graphic graphic_table graphicRef76219 \" href=\"UTD.htm?11/50/12077\">",
"       table 5",
"      </a>",
"      ) (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?4/32/4609?source=see_link\">",
"       calculator 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Hodgkin lymphoma survivors are at risk of developing therapy-related complications that may present years after treatment (eg, second malignancies, cardiac disease, radiation-induced hypothyroidism). Measures to minimize the incidence of these complications and to screening for them after therapy is complete are part of the management of this disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3079?source=see_link&amp;anchor=H1167672644#H1167672644\">",
"       \"Long-term follow-up of the patient with classical Hodgkin lymphoma\", section on 'Follow-up for long-term complications'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H13\">",
"       'Minimizing long-term complications of therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13512/abstract/1\">",
"      DeVita VT Jr. A selective history of the therapy of Hodgkin's disease. Br J Haematol 2003; 122:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13512/abstract/2\">",
"      Connors JM. State-of-the-art therapeutics: Hodgkin's lymphoma. J Clin Oncol 2005; 23:6400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13512/abstract/3\">",
"      Diehl V, Thomas RK, Re D. Part II: Hodgkin's lymphoma--diagnosis and treatment. Lancet Oncol 2004; 5:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13512/abstract/4\">",
"      Cosset JM, Henry-Amar M, Meerwaldt JH, et al. The EORTC trials for limited stage Hodgkin's disease. The EORTC Lymphoma Cooperative Group. Eur J Cancer 1992; 28A:1847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13512/abstract/5\">",
"      Engert A, Pl&uuml;tschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010; 363:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13512/abstract/6\">",
"      Bonfante V, Santoro A, Viviani S, et al. ABVD in the treatment of Hodgkin's disease. Semin Oncol 1992; 19:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13512/abstract/7\">",
"      Santoro A, Viviani S, Villarreal CJ, et al. Salvage chemotherapy in Hodgkin's disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP. Cancer Treat Rep 1986; 70:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13512/abstract/8\">",
"      Brusamolino E, Lazzarino M, Orlandi E, et al. Early-stage Hodgkin's disease: long-term results with radiotherapy alone or combined radiotherapy and chemotherapy. Ann Oncol 1994; 5 Suppl 2:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13512/abstract/9\">",
"      Colonna P, Jais JP, Desablens B, et al. Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients. J Clin Oncol 1996; 14:1928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13512/abstract/10\">",
"      Andrieu JM, Bayle-Weisgerber C, Boiron M, et al. The chemotherapy--radiotherapy sequence in the management of Hodgkin's disease. Results of a clinical trial. Eur J Cancer 1979; 15:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13512/abstract/11\">",
"      Colonna P, Andrieu JM, Ghouadni R, et al. Hodgkin's disease, clinical stages IA to IIIB: combined modality therapy (3 MOPP followed by curative and prophylactic radiotherapy including the spleen). Six-year results. Eur J Haematol 1987; 39:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13512/abstract/12\">",
"      Zittoun R, Audebert A, Hoerni B, et al. Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin's disease. J Clin Oncol 1985; 3:207.",
"     </a>",
"    </li>",
"    <li>",
"     Santoro A. Annual Conference of ECCO, Hamburg, Germany 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13512/abstract/14\">",
"      Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339:1506.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4761 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-168C04E0CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_12_13512=[""].join("\n");
var outline_f13_12_13512=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H107010793\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H740942\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF SELECTION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Treatment selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Early stage Hodgkin lymphoma (Stage I-II)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Favorable prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Unfavorable prognosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Advanced stage Hodgkin lymphoma (Stage III-IV)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Primary refractory disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H112049114\">",
"      - Relapsed disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H107010540\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H112049302\">",
"      Early stage disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H112049651\">",
"      International prognostic score",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MINIMIZING LONG-TERM COMPLICATIONS OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Fertility preservation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H107010793\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4761\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4761|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/23/19836\" title=\"table 1\">",
"      Cotswolds system in HL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/6/27756\" title=\"table 2\">",
"      Radiation fields in HL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/59/958\" title=\"table 3\">",
"      ABVD chemotherapy for Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/60/8142\" title=\"table 4\">",
"      Comb chemo reg HL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/50/12077\" title=\"table 5\">",
"      IPS Hodgkin lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?4/32/4609?source=related_link\" title=\"calculator 1\">",
"      Calculator: International Prognostic Score in Hodgkin Lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2792?source=related_link\">",
"      Clinical trials of specific regimens in favorable prognosis early (stage I-II) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10711?source=related_link\">",
"      Definition of favorable and unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15578?source=related_link\">",
"      Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=related_link\">",
"      Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21274?source=related_link\">",
"      Hematopoietic cell transplantation in classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29206?source=related_link\">",
"      Initial evaluation and diagnosis of Hodgkin lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39786?source=related_link\">",
"      Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3079?source=related_link\">",
"      Long-term follow-up of the patient with classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30007?source=related_link\">",
"      Monitoring of the patient with classical Hodgkin lymphoma during and after treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/37/13908?source=related_link\">",
"      Patient information: Hodgkin lymphoma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/10/23714?source=related_link\">",
"      Patient information: Hodgkin lymphoma in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/34997?source=related_link\">",
"      Patterns of tobacco use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7784?source=related_link\">",
"      Relapse of classical Hodgkin lymphoma after initial radiotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38009?source=related_link\">",
"      Second and third line chemotherapy regimens and biologic therapy for relapsing or resistant classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35242?source=related_link\">",
"      Second malignancies after treatment of classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=related_link\">",
"      Staging and prognosis of Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11770?source=related_link\">",
"      Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/17/37145?source=related_link\">",
"      Treatment of relapse of classical Hodgkin lymphoma after initial chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27496?source=related_link\">",
"      Treatment of unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_12_13513="Molecular pathogenesis of exocrine pancreatic cancer";
var content_f13_12_13513=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Molecular pathogenesis of exocrine pancreatic cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/12/13513/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/12/13513/contributors\">",
"     Ralph H Hruban, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/12/13513/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/12/13513/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/12/13513/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/12/13513/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/12/13513/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carcinoma of the exocrine pancreas is a genetic disease which is caused by inherited and acquired mutations in specific cancer-associated genes. The sequencing of the protein-coding exons from 20,661 genes in 24 advanced ductal adenocarcinomas of the pancreas provided the foundation for a more complete understanding of the key signaling pathways that are dysregulated in pancreatic tumorigenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/1\">",
"     1",
"    </a>",
"    ]. Progress in our understanding of the genes involved in the molecular pathogenesis of pancreatic cancer has provided insight into the familial aggregation of the disease, the progression of normal pancreatic ductal cells to noninvasive precursor lesions and to invasive carcinoma, and led to a new classification system of pancreatic neoplasms that encompasses both morphology and genetics [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/2-5\">",
"     2-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a general rule, multiple combinations of genetic mutations are commonly found in pancreatic adenocarcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/6\">",
"     6",
"    </a>",
"    ]. These can be divided into three broad categories [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mutational activation of oncogenes such as K-ras",
"     </li>",
"     <li>",
"      Inactivation of tumor suppressor genes such as TP53,",
"      <span class=\"nowrap\">",
"       p16/CDKN2A,",
"      </span>",
"      and SMAD4",
"     </li>",
"     <li>",
"      Inactivation of genome maintenance genes, such as hMLH1 and MSH2, which control the repair of DNA damage",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although most of these genetic aberrations represent somatic mutations, others are present in the germline of kindreds who carry a familial predisposition to pancreatic cancer (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Familial pancreatic cancer'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SPECIFIC GENE ABNORMALITIES INVOLVED IN MOLECULAR PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following sections will provide a brief overview of the current understanding of the molecular events that underlie pancreatic carcinogenesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     K-ras mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The K-ras gene, located on chromosome 12p, is one of the most frequently mutated genes in pancreatic cancer. This gene is the human homolog of a transforming gene isolated from the Kirsten rat sarcoma virus, hence the name, K-ras. As noted earlier, K-ras is an oncogene. Mutations in this gene, the vast majority of which are at codon 12, are activating, leading to activation of the protein product of the gene [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Over 90 percent of pancreatic cancers harbor a K-ras gene mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/1,9,10\">",
"     1,9,10",
"    </a>",
"    ]. Furthermore, these mutations appear to occur very early in pancreatic carcinogenesis, as indicated by their presence in noninvasive precursors. K-ras gene mutations have been identified in noninvasive intraductal papillary mucinous neoplasms (IPMNs), in pancreatic intraepithelial neoplasia (PanIN) and in noninvasive mucinous cystic neoplasms (MCNs), and the prevalence of mutations increases with increasing degrees of dysplasia in these noninvasive precursor lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. Mouse studies provide compelling evidence that oncogenic K-ras is required for the formation of PanIN, the most common precursor lesion to pancreatic cancer, as well as for the initiation and maintenance of invasive pancreatic cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44472?source=see_link\">",
"     \"Pathology of exocrine pancreatic neoplasms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33288?source=see_link\">",
"     \"Pathophysiology and clinical manifestations of intraductal papillary mucinous neoplasm of the pancreas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since mutations are both common and early events in pancreatic neoplasia, the K-ras gene is an attractive target for the development of an early detection test (see",
"    <a class=\"local\" href=\"#H20\">",
"     'Molecular screening and early detection'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Tumor suppressor genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loss of function of several postulated tumor suppressor genes has been documented in pancreatic carcinomas. In order to abrogate gene function, both copies (both the maternal and paternal alleles) of the gene need to be inactivated. This can occur by one of three mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inactivation of one copy of the gene by an intragenic mutation coupled with loss of the second allele (called loss of heterozygosity)",
"     </li>",
"     <li>",
"      Homozygous deletion (deletion of both copies of the gene)",
"     </li>",
"     <li>",
"      Hypermethylation of the promoter of the gene",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tumor suppressor genes that are inactivated in more than one-half of all pancreatic cancers are",
"    <span class=\"nowrap\">",
"     p16/CDKN2A,",
"    </span>",
"    TP53 and SMAD4 (previously known as DPC4) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     p16/CDKN2A",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     p16/CDKN2A",
"    </span>",
"    gene on chromosome 9p is somatically inactivated in almost all pancreatic cancers (approximately 95 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Most of these inactivating mutations lead to loss of function of p16, the protein product of CDKN2A. In 40 percent of the cancers, the gene is inactivated by homozygous deletion, in 40 percent, there is an intragenic mutation coupled with deletion of the second allele, and in 15 percent, gene inactivation is through hypermethylation of the",
"    <span class=\"nowrap\">",
"     p16/CDKN2A",
"    </span>",
"    gene promoter.",
"   </p>",
"   <p>",
"    Inactivation of the",
"    <span class=\"nowrap\">",
"     p16/CDKN2A",
"    </span>",
"    gene in pancreatic cancer is important for several reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Loss of gene function abrogates an important control of the cell cycle in these tumors.",
"     </li>",
"     <li>",
"      Inherited mutations in the",
"      <span class=\"nowrap\">",
"       p16/CDKN2A",
"      </span>",
"      gene are one of the causes of the Familial Atypical Multiple Mole Melanoma (FAMMM) syndrome. &nbsp;Patients with the FAMMM syndrome have an increased risk of developing melanoma and a 20 to 34-fold increased risk of developing pancreatic cancer. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6569?source=see_link\">",
"       \"Inherited susceptibility to melanoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The homozygous deletions that inactivate the",
"      <span class=\"nowrap\">",
"       p16/CDKN2A",
"      </span>",
"      gene frequently also inactivate an adjacent gene, the methylthioadenosine phosphorylase (MTAP) gene [",
"      <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. Data from cell lines suggests that inactivation of the MTAP gene in some pancreatic cancers could be exploited therapeutically [",
"      <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     TP53",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TP53 gene on chromosome 17p is one of the most frequently targeted genes in human cancer, including pancreatic cancer. The TP53 gene is inactivated in 75 to 85 percent of pancreatic cancers, almost always by an intragenic mutation (which is most often somatically acquired) coupled with loss of the second allele [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/1,23\">",
"     1,23",
"    </a>",
"    ]. Genetic inactivation of TP53 abrogates two important cell functions: regulation of cellular proliferation and cell death (apoptosis) in response to DNA damage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     SMAD4",
"    </span>",
"    &nbsp;&mdash;&nbsp;The SMAD4 gene (formerly known as DPC4), located on chromosome 18q, is inactivated in approximately 60 percent of pancreatic cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/1,24\">",
"     1,24",
"    </a>",
"    ]. In 30 percent of tumors, the gene is inactivated by homozygous deletion, and in another 30 percent of cases, there is an intragenic mutation coupled with loss of the second allele.",
"   </p>",
"   <p>",
"    The protein product of the SMAD4 gene functions in the transmission of intracellular signals from transforming growth factor beta (TGFb) receptors within the cell membrane to the nucleus [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/25\">",
"     25",
"    </a>",
"    ]. Mutations in other components of the TGF beta signaling pathway, such as SMAD3, TGFbR1 and TGFbR2, have also been reported in pancreatic cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/1,26\">",
"     1,26",
"    </a>",
"    ], underscoring the importance of this signaling pathway to the development of pancreatic cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/1,26\">",
"     1,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The inactivation of SMAD4 in pancreatic cancer is important for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An immunostain for the Smad4 protein has been developed, and the results of immunohistochemical staining (IHC) of tissue sections using this antibody strongly correlate with SMAD4 gene status [",
"      <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/27\">",
"       27",
"      </a>",
"      ]. This means that IHC for the presence of absence of Smad4 protein can be used diagnostically, as an adjunct to the interpretation of difficult tissue biopsies and to suggest the pancreas as a possible primary in patients with metastatic adenocarcinoma of unknown primary site [",
"      <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/27,28\">",
"       27,28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an example, if a patient had a pancreatic cancer in which SMAD4 is genetically inactivated and later developed an adenocarcinoma in the lung, which showed intact Smad4 expression, it could be deduced that the tumor in the lung was a separate primary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28121?source=see_link\">",
"     \"Adenocarcinoma of unknown primary site\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pancreatic cancers with loss of SMAD4 expression have higher rates of distant metastases and a poorer prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. While further studies are needed, these data suggest that SMAD4 gene status may some day be useful for prognostic stratification and therapeutic decision-making.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     BRCA2",
"    </span>",
"    &nbsp;&mdash;&nbsp;The BRCA2 gene on chromosome 13q is inactivated in fewer than 10 percent of pancreatic cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/31\">",
"     31",
"    </a>",
"    ]. The gene is almost always inactivated by a germline (inherited) mutation coupled with somatic loss of the second allele [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Germline mutations in BRCA2 (one of the causes of the hereditary breast and ovarian cancer syndrome) are associated with an increased risk of pancreatic cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/8,34,35\">",
"     8,34,35",
"    </a>",
"    ]. This constitutes one of the most important causes of familial aggregation of pancreatic cancer. BRCA2 mutations are found in up to 17 percent of patients with familial pancreatic cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/13/27866?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology and risk factors for exocrine pancreatic cancer\", section on 'Inherited cancer susceptibility syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The protein product of the BRCA2 gene functions in the Fanconi anemia pathway, and it plays an important role in the repair of DNA cross-linking damage [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=see_link&amp;anchor=H4#H4\">",
"     \"Inherited aplastic anemia in children\", section on 'Fanconi anemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=see_link&amp;anchor=H3#H3\">",
"     \"Genetic testing for hereditary breast and ovarian cancer syndrome\", section on 'Gene function'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been suggested that this function of BRCA2 can be exploited therapeutically. In vitro studies suggest that pancreatic cancers with genetically inactivated BRCA2 are significantly more susceptible to DNA cross-linking agents then are pancreatic cancers with a genetically intact BRCA2 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/36\">",
"     36",
"    </a>",
"    ]. While it is possible that patients whose cancers have inactivated BRCA2 would be more susceptible to DNA cross-linking agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , or to poly ADP-ribose polymerase (PARP) inhibitors, this hypothesis has yet to be validated prospectively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     PALB2",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PALB2 gene on chromosome 16p encodes for a BRCA2 binding protein [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/38\">",
"     38",
"    </a>",
"    ]. Germline mutations in PALB2 are known to increase the risk of breast cancer, and germline truncating mutations in the PALB2 gene have been identified in approximately 3 percent of individuals with familial pancreatic cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     STK11",
"    </span>",
"    &nbsp;&mdash;&nbsp;The STK11 gene on chromosome 19p encodes for a",
"    <span class=\"nowrap\">",
"     serine/threonine",
"    </span>",
"    kinase which regulates cell polarity and functions as a tumor suppressor gene [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/41\">",
"     41",
"    </a>",
"    ]. Germline mutations in the STK11 gene are associated with Peutz-Jeghers syndrome (PJS), an autosomal dominant disorder in which affected individuals develop hamartomatous polyps of the gastrointestinal tract, pigmented macules on the lips and buccal mucosa, and a variety of gastrointestinal malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. Patients with the PJS have a dramatically increased risk of developing pancreatic cancer, with a lifetime risk of 36 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37990?source=see_link\">",
"     \"Overview of Peutz-Jeghers syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, somatic STK11 mutations have been observed in a small fraction (approximately 4 percent) of pancreatic cancers, particularly those that arise in association with an IPMN [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/42,44\">",
"     42,44",
"    </a>",
"    ]. LOH for STK11 is reported in 25 percent of patients with IPMN from patients lacking features of PJS [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/44\">",
"     44",
"    </a>",
"    ]. Thus, inactivation of the STK11 gene appears to play a role in both hereditary and sporadic pancreatic cancers.",
"   </p>",
"   <p>",
"    Screening of individuals with PJS and other high-risk hereditary conditions using endoscopic ultrasound (EUS) and CT can detect asymptomatic early pancreatic neoplasms, including IPMNs at a time when they are potentially curable [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/9/3224?source=see_link&amp;anchor=H21759646#H21759646\">",
"     \"Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families\", section on 'Peutz-Jeghers syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     DNA mismatch repair genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;DNA mismatch repair genes such as hMLH1 and hMSH2 are well known for their important role in the pathogenesis of colorectal cancer, particularly in HNPCC (Hereditary Non-polyposis Colorectal Cancer Syndrome, Lynch syndrome). Patients with HNPCC have inherited (germline) mutations in DNA repair genes and an elevated risk of several gastrointestinal cancers, including pancreatic cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30234?source=see_link\">",
"     \"Molecular genetics of colorectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    DNA mismatch repair genes are mutated in approximately 4 percent of pancreatic cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Because of their distinctive \"medullary\" histologic appearance, pancreatic cancers with defects in DNA mismatch repair gene can sometimes be recognized histologically at the diagnostic microscope [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44472?source=see_link\">",
"     \"Pathology of exocrine pancreatic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These tumors are important to recognize for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As is true in the colorectum, the inactivation of a DNA repair gene in a patient with pancreatic cancer suggests the possibility of a germline mutation and the HNPCC syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/48-51\">",
"       48-51",
"      </a>",
"      ]. These patients (and their family members) are at risk for a variety of gastrointestinal neoplasms. There are published screening guidelines. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=see_link\">",
"       \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/9/3224?source=see_link&amp;anchor=H21759690#H21759690\">",
"       \"Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families\", section on 'Pancreatic cancer'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pancreatic cancers with microsatellite instability (MSI), the hallmark of an inactivated DNA mismatch repair gene, appear to have a somewhat better prognosis than standard ductal adenocarcinomas [",
"      <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pancreatic cancers with MSI also may be less responsive to chemotherapeutic agents such as 5-fluorouracil (5-FU) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/53\">",
"       53",
"      </a>",
"      ]. However, in contrast to the situation with early colon cancer, there are no widely accepted clinical scenarios in which the selection of chemotherapy treatment for pancreatic cancer is influenced by the presence or absence of MSI. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/55/30586?source=see_link&amp;anchor=H589530415#H589530415\">",
"       \"Adjuvant chemotherapy for resected stage II colon cancer\", section on 'Molecular prognostic and predictive factors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other lower frequency genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other genes have been identified that are only rarely mutated in pancreatic cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/1\">",
"     1",
"    </a>",
"    ], and they are of generally less importance than K-ras,",
"    <span class=\"nowrap\">",
"     p16/CDKN2A,",
"    </span>",
"    TP53 and SMAD4. Among the genes that are mutated at low frequency are EP300, SMARCA4, CDH1, EPHA3, FBXW7, MLL3, DPP6, BAI3, GPR133, GUCY1A2, PRKCG, ARID1A, and TGF beta R2 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/1,54\">",
"     1,54",
"    </a>",
"    ]. In addition, inactivating mutations in the ring finger protein 43[RNF43] gene, a component of ubiquitin-dependent pathways, and the GNAS complex locus, which encodes the alpha subunit of guanine nucleotide binding protein, have also been identified in cystic neoplasms of the pancreas [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/14,55\">",
"     14,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While this list is long, many of these genes are involved in common signaling pathways, and the complexity of the mutational spectrum in pancreatic cancer can be simplified by thinking of the cellular pathways targeted by these genetic alterations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/1\">",
"     1",
"    </a>",
"    ]. For example, in one study, cellular pathways regulating apoptosis, the",
"    <span class=\"nowrap\">",
"     G1/S",
"    </span>",
"    phase transition, hedgehog signaling, KRAS signaling, TGF beta signaling and",
"    <span class=\"nowrap\">",
"     Wnt/Notch",
"    </span>",
"    signaling were all found to be mutated in all of the 24 pancreatic cancers that were completely sequenced [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Methylation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to mutational inactivation, the expression of a number of genes in pancreatic cancer can be silenced by aberrant promoter methylation, an epigenetic method of gene silencing [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. Among the genes that can be silenced in this manner in pancreatic cancer are UCHL1, NPTX2, SARP2, CLDN5, reprimo, LHX1, WNT7A, FOXE1, TJP2, CDH3, ST14 and",
"    <span class=\"nowrap\">",
"     p16/CDKN2A",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conversely, some of the genes that are overexpressed in pancreatic cancer are hypomethylated [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/57\">",
"     57",
"    </a>",
"    ]. A number of investigators are working to exploit the differences in methylation patterns between pancreatic neoplasms and normal cells to develop early detection tests and novel approaches to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/56-60\">",
"     56-60",
"    </a>",
"    ]. Additional work is needed before any of these approaches can be adopted for routine clinical use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Mitochondrial mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations most often target nuclear DNA, but mitochondrial DNA can also be somatically mutated in pancreatic cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. It is unclear if any of these mutations play a role in tumorigenesis.",
"   </p>",
"   <p>",
"    However, some have suggested that mitochondrial mutations could be exploited for the development of early detection tests. Mitochondrial mutations are a particularly attractive target for early detection, as cells contain thousands of mitochondria, and a clonal mutation in mitochondria should therefore be easier to detect than a clonal mutation in nuclear DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     MicroRNA expression",
"    </span>",
"    &nbsp;&mdash;&nbsp;MicroRNAs are short, non-coding segments of RNA that regulate the expression of other genes. A number of microRNAs appear to be differentially expressed in pancreatic cancer and in the precursor lesions that give rise to pancreatic cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/63-67\">",
"     63-67",
"    </a>",
"    ]. For example, miR-34a is often deleted in pancreatic cancer, and miR-34a appears to play a role in TP53-related gene expression [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Genetic progression model",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful genetic analyses of small intraductal lesions in the pancreas have helped to establish that \"pancreatic intraepithelial neoplasia (PanIN)\" can be a precursor to invasive ductal adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44472?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathology of exocrine pancreatic neoplasms\", section on 'Pancreatic intraepithelial neoplasia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PanIN lesions harbor many of the same mutations as are found in invasive ductal adenocarcinomas, and increasing numbers of mutations are associated with increasing degrees of dysplasia in PanIN [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/5\">",
"     5",
"    </a>",
"    ]. K-ras gene mutations appear to occur first, in the lowest grade of PanIN, called PanIN-1.",
"    <span class=\"nowrap\">",
"     p16/CDKN2A",
"    </span>",
"    gene mutations start to appear in PanIN-2 lesions, and SMAD4 and TP53 inactivation do not appear until the highest grade of PanIN, the PanIN-3 lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/5\">",
"     5",
"    </a>",
"    ]. The exact molecular events that underlie the progression from intraductal to invasive neoplasia are not yet understood.",
"   </p>",
"   <p>",
"    The development of a progression model of pancreatic tumorigenesis has important implications for the development of chemoprevention and early detection strategies. As an example, very early molecular events may be appropriate targets for chemoprevention, while later events may be useful for early detection strategies for pancreatic neoplasia. This model was also critical to the development of genetically-engineered animal models of pancreatic cancer. The recognition that K-ras gene mutations are one of the earliest events in pancreatic tumorigenesis led investigators to introduce mutant K-ras into the pancreatic glands of mice, and these mice developed pancreatic tumors that appear to accurately mimic human disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/15,68\">",
"     15,68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CLINICAL IMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Molecular classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patterns of genetic alterations identified in neoplasms of the pancreas are beginning to be integrated with tumor morphology and patient prognosis, and a new \"molecular classification\" of pancreatic neoplasia is slowly emerging [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/4\">",
"     4",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Almost all solid-pseudopapillary neoplasms of the pancreas harbor a beta-catenin gene mutation, and these mutations may explain the poor cohesion that is so characteristic of the neoplastic cells in this tumor type [",
"      <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/14,69,70\">",
"       14,69,70",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44472?source=see_link&amp;anchor=H19#H19\">",
"       \"Pathology of exocrine pancreatic neoplasms\", section on 'Solid pseudopapillary neoplasm'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The vast majority of undifferentiated carcinomas of the pancreas show a loss of e-cadherin expression, and the loss of e-cadherin may correlate with the invasive phenotype and poor prognosis associated with these neoplasms [",
"      <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Most pancreatoblastomas arise in childhood, and the majority of these distinctive neoplasms have lost the maternal copy of chromosome 11p [",
"      <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/72\">",
"       72",
"      </a>",
"      ]. This molecular finding unites this disease with other primitive tumors of childhood such as the nephroblastoma (Wilms' tumor) and hepatoblastoma, which also have typically lost the maternal copy of chromosome 11p. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44472?source=see_link&amp;anchor=H21#H21\">",
"       \"Pathology of exocrine pancreatic neoplasms\", section on 'Pancreatoblastoma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pancreatic neoplasms with prominent osteoclast-like giant cells have been recognized for decades, but their fundamental direction of differentiation was not clear. However, it is now apparent that the undifferentiated pleomorphic cells that are between the osteoclast-like giant cells are the cells that harbor genetic alterations and that these genetic alterations are identical to the mutations found in adjacent epithelial precursors [",
"      <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/73\">",
"       73",
"      </a>",
"      ]. These observations helped to establish that these distinctive neoplasms are, in fact, carcinomas, and the name of these tumors was therefore changed to undifferentiated carcinomas with osteoclast-like giant cells [",
"      <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Familial pancreatic cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most significant benefits from the improved understanding of the molecular genetics of pancreatic cancer has been the discovery of some of the genes that are responsible for the familial aggregation of pancreatic cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/8,74\">",
"     8,74",
"    </a>",
"    ]. Between 3 and 16 percent of pancreatic cancers are either syndromic or familial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/13/27866?source=see_link\">",
"     \"Epidemiology and risk factors for exocrine pancreatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As discussed in detail in the sections above, the genes which, when mutated in the germline, increase the risk of pancreatic cancer include [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/74\">",
"     74",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      BRCA2 &mdash; breast and ovarian cancer and pancreatic cancer",
"     </li>",
"     <li>",
"      PALB2 - breast and pancreatic cancer",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       p16/CDKN2A",
"      </span>",
"      &mdash; melanoma and pancreatic cancer",
"     </li>",
"     <li>",
"      STK11 &mdash; Peutz-Jeghers syndrome and pancreatic cancer",
"     </li>",
"     <li>",
"      PRSS1 (serine protease 1) &mdash; familial pancreatitis and pancreatic cancer",
"     </li>",
"     <li>",
"      Mismatch repair genes hMLH1 and MSH2 &mdash; HNPCC and pancreatic cancer",
"     </li>",
"     <li>",
"      ATM &mdash; ataxia telangiectasia mutated gene [",
"      <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/75\">",
"       75",
"      </a>",
"      ] &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Improved understanding of the genetic basis for the development of pancreatic cancer has had a significant impact on individuals with an inherited predisposition. Selected individuals from these kindreds can now be tested for inherited germline mutations in genes (eg, CDKN2A or BRCA2) that are known to predispose carriers to pancreatic cancer. Individuals found to carry a mutation associated with an increased risk of developing pancreatic cancer may choose a surveillance strategy with periodic screening or even prophylactic surgery. As noted above, screening of individuals with high-risk hereditary conditions using EUS",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CT can detect predominantly asymptomatic early pancreatic neoplasms, including IPMNs and PanIN, at a time when they are potentially curable [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/45-47,76\">",
"     45-47,76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/13/27866?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology and risk factors for exocrine pancreatic cancer\", section on 'Hereditary risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/9/3224?source=see_link&amp;anchor=H21759646#H21759646\">",
"     \"Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families\", section on 'Peutz-Jeghers syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Individuals carrying one of these inherited mutations may also benefit from screening for extra-pancreatic neoplasms. For example, patients with FAMMM should be screened for melanocytic lesions and individuals with inherited BRCA2 gene mutations for breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6569?source=see_link\">",
"     \"Inherited susceptibility to melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, the discovery of familial syndromes with an increased risk of pancreatic cancer forms the basis for the design and implementation of early detection tests for this disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Molecular screening and early detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of patients with pancreatic cancer are not diagnosed until after their cancer has metastasized. However, even when diagnosed at a time when it is potentially resectable, the prognosis of invasive pancreatic cancer is poor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/34/8746?source=see_link&amp;anchor=H18#H18\">",
"     \"Surgery in the treatment of exocrine pancreatic cancer and prognosis\", section on 'Prognosis and prognostic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given these facts, an accurate and sensitive test for the diagnosis of early, potentially curable noninvasive pancreatic neoplasia is urgently needed. Several techniques can detect rare mutant genes even when they are admixed with thousands of normal copies of the gene. Acquired genetic mutations that are associated with particular cancers can provide new targets for the development of sensitive screening tests for that disease. Genetic alterations are attractive targets for such early detection tests because, as has been discussed above, many of these alterations are specific for the cancer (they do not occur in normal cells and thus are highly specific), and many occur in the vast majority of the cancers (they have the potential of being very sensitive).",
"   </p>",
"   <p>",
"    As an example, K-ras gene mutations can be detected in duodenal juice and even in the stool of patients with pancreatic cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/77-79\">",
"     77-79",
"    </a>",
"    ]. However, questions remain as to the ability of K-ras mutations to differentiate between pancreatic neoplasms and chronic pancreatitis. Further work is needed before any molecular diagnostic test can be used in routine clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carcinoma of the exocrine pancreas is a genetic disease that is caused by inherited and acquired mutations in specific cancer-associated genes. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Specific gene abnormalities involved in molecular pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The patterns of genetic alterations identified in neoplasms of the pancreas are beginning to be integrated with tumor morphology and patient prognosis, and a new \"molecular classification\" of pancreatic neoplasia is slowly emerging [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13513/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Molecular classification'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Progress in our understanding of the genes involved in pancreatic carcinogenesis has also provided insight into the familial aggregation of the disease and the progression of normal pancreatic ductal cells to noninvasive precursor lesions and to invasive carcinoma. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Familial pancreatic cancer'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H16\">",
"     'Genetic progression model'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Acquired genetic mutations may represent new targets for the development of sensitive screening tests for early diagnosis of pancreatic cancer, particularly before it becomes invasive. However, this work is in its infancy, and additional study is needed before any molecular screening test can be recommended for routine clinical practice. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Molecular screening and early detection'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/1\">",
"      Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/2\">",
"      Hruban RH, Canto MI, Griffin C, et al. Treatment of familial pancreatic cancer and its precursors. Curr Treat Options Gastroenterol 2005; 8:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/3\">",
"      Hruban RH, Adsay NV, Albores-Saavedra J, et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001; 25:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/4\">",
"      Shi C, Daniels JA, Hruban RH. Molecular characterization of pancreatic neoplasms. Adv Anat Pathol 2008; 15:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/5\">",
"      Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin Cancer Res 2000; 6:2969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/6\">",
"      Wilentz RE, Iacobuzio-Donahue CA, Argani P, et al. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000; 60:2002.",
"     </a>",
"    </li>",
"    <li>",
"     Hruban RH, Yeo CJ, and Kern SE. Pancreatic Cancer. In: The Genetic Basis of Human Cancer, Vogelstein B, Kinzler KW (Eds), McGraw-Hill, New York 1998. p.659.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/8\">",
"      Lal G, Liu G, Schmocker B, et al. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res 2000; 60:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/9\">",
"      Hruban RH, van Mansfeld AD, Offerhaus GJ, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993; 143:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/10\">",
"      Almoguera C, Shibata D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/11\">",
"      Moskaluk CA, Hruban RH, Kern SE. p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res 1997; 57:2140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/12\">",
"      Jimenez RE, Warshaw AL, Z'graggen K, et al. Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy. Ann Surg 1999; 230:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/13\">",
"      Z'graggen K, Rivera JA, Compton CC, et al. Prevalence of activating K-ras mutations in the evolutionary stages of neoplasia in intraductal papillary mucinous tumors of the pancreas. Ann Surg 1997; 226:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/14\">",
"      Wu J, Jiao Y, Dal Molin M, et al. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A 2011; 108:21188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/15\">",
"      Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003; 4:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/16\">",
"      Collins MA, Bednar F, Zhang Y, et al. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest 2012; 122:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/17\">",
"      Aguirre AJ, Bardeesy N, Sinha M, et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 2003; 17:3112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/18\">",
"      Rozenblum E, Schutte M, Goggins M, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997; 57:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/19\">",
"      Caldas C, Hahn SA, da Costa LT, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994; 8:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/20\">",
"      Schutte M, Hruban RH, Geradts J, et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997; 57:3126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/21\">",
"      Hustinx SR, Hruban RH, Leoni LM, et al. Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in periampullary cancer: a potential new target for therapy. Cancer Biol Ther 2005; 4:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/22\">",
"      Subhi AL, Tang B, Balsara BR, et al. Loss of methylthioadenosine phosphorylase and elevated ornithine decarboxylase is common in pancreatic cancer. Clin Cancer Res 2004; 10:7290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/23\">",
"      Redston MS, Caldas C, Seymour AB, et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994; 54:3025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/24\">",
"      Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/25\">",
"      Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003; 425:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/26\">",
"      Goggins M, Shekher M, Turnacioglu K, et al. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res 1998; 58:5329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/27\">",
"      Wilentz RE, Su GH, Dai JL, et al. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation. Am J Pathol 2000; 156:37.",
"     </a>",
"    </li>",
"    <li>",
"     Hruban RH, Pitman MB, Klimstra DS. Tumors of the pancreas. In: Atlas of tumor pathology, American Registry of Pathology and Armed Forces Institute of Pathology, Washington, DC 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/29\">",
"      Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009; 27:1806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/30\">",
"      Blackford A, Serrano OK, Wolfgang CL, et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res 2009; 15:4674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/31\">",
"      Goggins M, Schutte M, Lu J, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996; 56:5360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/32\">",
"      van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 2005; 42:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/33\">",
"      Hahn SA, Greenhalf B, Ellis I, et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 2003; 95:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/34\">",
"      Phelan CM, Lancaster JM, Tonin P, et al. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet 1996; 13:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/35\">",
"      Murphy KM, Brune KA, Griffin C, et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 2002; 62:3789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/36\">",
"      van der Heijden MS, Brody JR, Dezentje DA, et al. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res 2005; 11:7508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/37\">",
"      Yuan SS, Lee SY, Chen G, et al. BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. Cancer Res 1999; 59:3547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/38\">",
"      Xia B, Sheng Q, Nakanishi K, et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 2006; 22:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/39\">",
"      Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009; 324:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/40\">",
"      Slater EP, Langer P, Niemczyk E, et al. PALB2 mutations in European familial pancreatic cancer families. Clin Genet 2010; 78:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/41\">",
"      Jenne DE, Reimann H, Nezu J, et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 1998; 18:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/42\">",
"      Su GH, Hruban RH, Bansal RK, et al. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol 1999; 154:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/43\">",
"      Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000; 119:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/44\">",
"      Sato N, Rosty C, Jansen M, et al. STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. Am J Pathol 2001; 159:2017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/45\">",
"      Canto MI, Goggins M, Hruban RH, et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 2006; 4:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/46\">",
"      Canto MI, Goggins M, Yeo CJ, et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2004; 2:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/47\">",
"      Larghi A, Verna EC, Lecca PG, Costamagna G. Screening for pancreatic cancer in high-risk individuals: a call for endoscopic ultrasound. Clin Cancer Res 2009; 15:1907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/48\">",
"      Goggins M, Offerhaus GJ, Hilgers W, et al. Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am J Pathol 1998; 152:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/49\">",
"      Wilentz RE, Goggins M, Redston M, et al. Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: A newly described and characterized entity. Am J Pathol 2000; 156:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/50\">",
"      Kastrinos F, Mukherjee B, Tayob N, et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA 2009; 302:1790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/51\">",
"      Win AK, Young JP, Lindor NM, et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol 2012; 30:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/52\">",
"      Nakata B, Wang YQ, Yashiro M, et al. Prognostic value of microsatellite instability in resectable pancreatic cancer. Clin Cancer Res 2002; 8:2536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/53\">",
"      Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/54\">",
"      Jones S, Li M, Parsons DW, et al. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat 2012; 33:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/55\">",
"      Wu J, Matthaei H, Maitra A, et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med 2011; 3:92ra66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/56\">",
"      Omura N, Li CP, Li A, et al. Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma. Cancer Biol Ther 2008; 7:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/57\">",
"      Sato N, Maitra A, Fukushima N, et al. Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res 2003; 63:4158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/58\">",
"      Sato N, Fukushima N, Maitra A, et al. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 2003; 63:3735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/59\">",
"      Parsi MA, Li A, Li CP, Goggins M. DNA methylation alterations in endoscopic retrograde cholangiopancreatography brush samples of patients with suspected pancreaticobiliary disease. Clin Gastroenterol Hepatol 2008; 6:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/60\">",
"      Hong SM, Kelly D, Griffith M, et al. Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas. Mod Pathol 2008; 21:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/61\">",
"      Jones JB, Song JJ, Hempen PM, et al. Detection of mitochondrial DNA mutations in pancreatic cancer offers a \"mass\"-ive advantage over detection of nuclear DNA mutations. Cancer Res 2001; 61:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/62\">",
"      Maitra A, Cohen Y, Gillespie SE, et al. The Human MitoChip: a high-throughput sequencing microarray for mitochondrial mutation detection. Genome Res 2004; 14:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/63\">",
"      Habbe N, Koorstra JB, Mendell JT, et al. MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Ther 2009; 8:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/64\">",
"      Szafranska AE, Davison TS, John J, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007; 26:4442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/65\">",
"      Bloomston M, Frankel WL, Petrocca F, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007; 297:1901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/66\">",
"      Chang TC, Wentzel EA, Kent OA, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007; 26:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/67\">",
"      Ryu JK, Hong SM, Karikari CA, et al. Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. Pancreatology 2010; 10:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/68\">",
"      Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005; 7:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/69\">",
"      Tanaka Y, Kato K, Notohara K, et al. Frequent beta-catenin mutation and cytoplasmic/nuclear accumulation in pancreatic solid-pseudopapillary neoplasm. Cancer Res 2001; 61:8401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/70\">",
"      Abraham SC, Klimstra DS, Wilentz RE, et al. Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. Am J Pathol 2002; 160:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/71\">",
"      Winter JM, Ting AH, Vilardell F, et al. Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer. Clin Cancer Res 2008; 14:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/72\">",
"      Abraham SC, Wu TT, Klimstra DS, et al. Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposis-associated pancreatoblastomas : frequent alterations in the APC/beta-catenin pathway and chromosome 11p. Am J Pathol 2001; 159:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/73\">",
"      Westra WH, Sturm P, Drillenburg P, et al. K-ras oncogene mutations in osteoclast-like giant cell tumors of the pancreas and liver: genetic evidence to support origin from the duct epithelium. Am J Surg Pathol 1998; 22:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/74\">",
"      Klein AP, Hruban RH, Brune KA, et al. Familial pancreatic cancer. Cancer J 2001; 7:266.",
"     </a>",
"    </li>",
"    <li>",
"     Roberts NJ, Jiao Y, Yu, et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discovery 2012; 2:41. file://cancerdiscovery.aacrjournals.org/content/2/1/41.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/76\">",
"      Canto MI, Hruban RH, Fishman EK, et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 2012; 142:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/77\">",
"      Shi C, Fukushima N, Abe T, et al. Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection. Cancer Biol Ther 2008; 7:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/78\">",
"      Kondo H, Sugano K, Fukayama N, et al. Detection of K-ras gene mutations at codon 12 in the pancreatic juice of patients with intraductal papillary mucinous tumors of the pancreas. Cancer 1997; 79:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13513/abstract/79\">",
"      Caldas C, Hahn SA, Hruban RH, et al. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994; 54:3568.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2492 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-210.101.131.232-3CA5444EA1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_12_13513=[""].join("\n");
var outline_f13_12_13513=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SPECIFIC GENE ABNORMALITIES INVOLVED IN MOLECULAR PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      K-ras mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Tumor suppressor genes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - p16/CDKN2A",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - TP53",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - SMAD4",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - BRCA2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - PALB2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - STK11",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DNA mismatch repair genes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other lower frequency genes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Methylation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Mitochondrial mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MicroRNA expression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Genetic progression model",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CLINICAL IMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Molecular classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Familial pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Molecular screening and early detection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28121?source=related_link\">",
"      Adenocarcinoma of unknown primary site",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/55/30586?source=related_link\">",
"      Adjuvant chemotherapy for resected stage II colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=related_link\">",
"      Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/13/27866?source=related_link\">",
"      Epidemiology and risk factors for exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=related_link\">",
"      Genetic testing for hereditary breast and ovarian cancer syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=related_link\">",
"      Inherited aplastic anemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6569?source=related_link\">",
"      Inherited susceptibility to melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30234?source=related_link\">",
"      Molecular genetics of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37990?source=related_link\">",
"      Overview of Peutz-Jeghers syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44472?source=related_link\">",
"      Pathology of exocrine pancreatic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33288?source=related_link\">",
"      Pathophysiology and clinical manifestations of intraductal papillary mucinous neoplasm of the pancreas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/9/3224?source=related_link\">",
"      Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/34/8746?source=related_link\">",
"      Surgery in the treatment of exocrine pancreatic cancer and prognosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_12_13514="Liquid and foam sclerotherapy techniques for the treatment of lower extremity veins";
var content_f13_12_13514=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Liquid and foam sclerotherapy techniques for the treatment of lower extremity veins",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/12/13514/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/12/13514/contributors\">",
"     Deborah L Greenberg, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/12/13514/contributors\">",
"     Sherry Scovell, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/12/13514/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/12/13514/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/12/13514/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/12/13514/contributors\">",
"     Jeffrey S Dover, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/12/13514/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/12/13514/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/12/13514/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sclerotherapy is a minimally invasive percutaneous technique using chemical irritants to close unwanted veins [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Sclerotherapy is used primarily in the treatment of telangiectasias, reticular veins, and small varicose veins, which can be symptomatic and a source of significant distress to some patients even in the absence of symptoms. Saphenous and perforator reflux can also be treated with sclerotherapy techniques.",
"   </p>",
"   <p>",
"    The treatment of telangiectasias, reticular veins, and varicose veins, and underlying perforator or saphenous reflux with liquid and foam sclerotherapy will be reviewed here.",
"   </p>",
"   <p>",
"    Alternative approaches to treatment of chronic venous disease using cutaneous laser, endovenous ablation devices, and open surgical management are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34521?source=see_link\">",
"     \"Overview and management of lower extremity chronic venous disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17031?source=see_link\">",
"     \"Laser and light therapy of lower extremity telangiectasias, reticular veins and small varicose veins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30809?source=see_link\">",
"     \"Radiofrequency ablation for the treatment of lower extremity chronic venous disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major superficial veins of the lower extremity include the great and small saphenous veins (",
"    <a class=\"graphic graphic_figure graphicRef55019 graphicRef52340 \" href=\"UTD.htm?5/25/5527\">",
"     figure 1A-B",
"    </a>",
"    ). Additionally, other superficial veins are present in the lower extremity, many of which have variable anatomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/29/11735?source=see_link&amp;anchor=H22#H22\">",
"     \"Classification of lower extremity chronic venous disorders\", section on 'Superficial venous system (As)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The deep veins of the lower extremity are contained within the deep muscle compartments bounded by the muscle fascia (",
"    <a class=\"graphic graphic_figure graphicRef75219 \" href=\"UTD.htm?42/56/43906\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/29/11735?source=see_link&amp;anchor=H24#H24\">",
"     \"Classification of lower extremity chronic venous disorders\", section on 'Deep venous system (Ad)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Perforating veins are those veins that traverse the muscular fascia to connect superficial veins with the deep veins. They are located anteriorly, posteriorly, laterally, and medially in both the thigh and calf.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Telangiectasias, reticular veins, and varicose veins are the visible signs of venous disease and can occur in the presence or absence of either symptoms or an underlying functional venous disorder (ie, reflux) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/2\">",
"     2",
"    </a>",
"    ]. Candidates for sclerotherapy are patients with persistent symptoms (eg, pain, aching, swelling) and signs (eg, telangiectasias, reticular veins, varicose veins, pigmentary changes, and ulceration) of venous disease after six months of medical therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34521?source=see_link\">",
"     \"Overview and management of lower extremity chronic venous disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32410?source=see_link\">",
"     \"Medical management of lower extremity chronic venous disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sclerotherapy may be used to treat superficial telangiectasias, reticular veins, and varicose veins. Sclerotherapy techniques to achieve perforator and saphenous closure are also available for patients with documented reflux (ie, retrograde flow &gt;0.5 seconds duration) as a source of their symptoms. For patients with ulceration who are refractory to medical management, or have recurrent ulceration, ultrasound-guided sclerotherapy (UGS) of perforators can lead to significant reduction of symptoms and signs. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Perforator ablation'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H16\">",
"     'Saphenous ablation'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H32\">",
"     'Clinical outcomes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    While telangiectasias and reticular veins may be symptomatic, most are asymptomatic, and patients often find the cosmetic appearance of their veins distressing. Sclerotherapy can be performed following physical examination without further diagnostic studies, as these patients are not as likely as symptomatic patients to have underlying venous reflux [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Patient counseling'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with complaints of recurrent bleeding and stigmata of recent venous hemorrhage may benefit from sclerotherapy of that vein site [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Sclerotherapy is often successful even in the presence of venous insufficiency. [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/4\">",
"     4",
"    </a>",
"    ]. Duplex examination can be performed either before (if time permits) or after attempted control of bleeding. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Perforator ablation'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/29/21977?source=see_link\">",
"     \"Open surgical techniques for lower extremity vein ablation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sclerotherapy should not be performed in patients who have signs of acute",
"    <span class=\"nowrap\">",
"     thrombosis/phlebitis,",
"    </span>",
"    due to the increased risk of deep venous thrombosis. Pregnant patients should defer treatment until after delivery.",
"   </p>",
"   <p>",
"    Diabetes and peripheral arterial occlusive disease (ankle-brachial index &lt;0.9) are relative contraindications to a risk for wound complications, but this depends upon the nature and extent of sclerotherapy being considered.",
"   </p>",
"   <p>",
"    A history of migraine headache and patent foramen ovale are relative contraindications to sclerotherapy due to a risk for microembolism [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/6-11\">",
"     6-11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Visual and other neurologic disturbances'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATIENT COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to offer sclerotherapy depends upon symptoms, response to conservative therapy, extent of lower extremity disease, patient expectations, and likelihood of providing a durable benefit either with respect to appearance or improvement in symptoms.",
"   </p>",
"   <p>",
"    Patients treated for cosmetic purposes need to be counseled carefully prior to treatment. Patients are informed that veins will lighten and become less noticeable but may not completely disappear, that hyperpigmentation is a relatively common complication, and that multiple treatments are typically required to achieve the desired effect.",
"   </p>",
"   <p>",
"    For all patients, it is important to address patient expectations, potential adverse effects, potential failure of treatment, and the complications of treatment. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients must understand that the results of sclerotherapy are unpredictable despite expert technique, and some patients with favorable conditions (skin type I and II, ideal injections) may have unsatisfactory results. It is important to document veins photographically prior to each treatment and to review these photographs with the patient periodically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SCLEROTHERAPY AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common agents used in the treatment of lower extremity telangiectasias, reticular veins, and small varicose veins are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1603?source=see_link\">",
"     sodium tetradecyl",
"    </a>",
"    sulfate,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/6/110?source=see_link\">",
"     polidocanol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/32/14852?source=see_link\">",
"     glycerin",
"    </a>",
"    , and hypertonic saline (",
"    <a class=\"graphic graphic_table graphicRef70171 \" href=\"UTD.htm?5/63/6142\">",
"     table 1",
"    </a>",
"    ). These substances cause endothelial damage by their actions as either osmotic or detergent agents. Osmotic agents achieve their effect by dehydrating endothelial cells through osmosis. Detergents are surface active agents which damage the endothelium by interfering with cell membrane lipids [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/12\">",
"     12",
"    </a>",
"    ]. In vitro, the detergent agents also exhibit procoagulant activity at lower concentrations, and anticoagulant activity in higher concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systematic reviews of randomized trials of injection sclerotherapy for telangiectasia or varicosities found no evidence to support the use of one sclerosant over another in the short-term success of sclerotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Sodium tetradecyl sulfate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1603?source=see_link\">",
"     Sodium tetradecyl",
"    </a>",
"    sulfate is the most commonly studied sclerosant [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/14\">",
"     14",
"    </a>",
"    ]. The maximum recommended dosage is 10 mL of a 3% solution in the United States and Canada; the volume used varies worldwide depending on formulation. Dilutions between 0.1% and 3.0% are used depending upon the size of the vein treated; narrower diameter veins are treated with lower concentrations (",
"    <a class=\"graphic graphic_table graphicRef70171 \" href=\"UTD.htm?5/63/6142\">",
"     table 1",
"    </a>",
"    ). As an example, in small diameter veins, a systematic review comparing various sclerotherapy agents for the treatment of telangiectasias found that sodium tetradecyl sulfate (STS) was more likely to cause adverse reactions at a concentration of 1% compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/6/110?source=see_link\">",
"     polidocanol",
"    </a>",
"    at 0.5% [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Polidocanol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/6/110?source=see_link\">",
"     Polidocanol",
"    </a>",
"    , also known as aethoxysklerol, is also a detergent. The maximum dosage is dependent upon the weight of the patient. Dilutions between 0.25% and 5% are used depending on the size of the vein treated (",
"    <a class=\"graphic graphic_table graphicRef70171 \" href=\"UTD.htm?5/63/6142\">",
"     table 1",
"    </a>",
"    ). Polidocanol is now available for commercial use in the United States (ie, Asclera&reg;). In a systematic review comparing various sclerotherapy agents for the treatment of telangiectasias, polidocanol was no more painful than placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hypertonic saline",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertonic saline is the most commonly used osmotic agent for lower extremity sclerotherapy. The dilution used to treat lower extremity vessels ranges from 11.7% to 23.4% (",
"    <a class=\"graphic graphic_table graphicRef70171 \" href=\"UTD.htm?5/63/6142\">",
"     table 1",
"    </a>",
"    ). Hypertonic saline (20%) mixed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    100",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    constitutes Heparsal. Hypertonic saline is frequently mixed with local anesthetic to reduce the pain associated with injection (eg, 20% saline plus 2%",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H168866740\">",
"    <span class=\"h2\">",
"     Glycerin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chromated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/32/14852?source=see_link\">",
"     glycerin",
"    </a>",
"    (eg, Chromex&reg;, Skermo&reg;) is a potent osmotic with dilutions that range from 25% to 72%. The maximum recommended amount per session is 10 mL [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/16\">",
"     16",
"    </a>",
"    ]. While very popular worldwide, it is not commercially available in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PREPARATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Liquid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liquid sclerotherapy can be used to treat telangiectasias, reticular veins, small non-saphenous varicose veins (&lt;5 mm), residual or recurrent varicosities following endovenous ablation or surgery, and perforator veins [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/14,17\">",
"     14,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Liquid injection sclerotherapy is the gold standard for the treatment of the majority of lower extremity telangiectasias and reticular veins. When vessels are treated sequentially from deep to superficial and from larger to smaller veins, over 90 percent of vessels can be successfully treated. The results of sclerotherapy are usually, but are not always, superior to those of cutaneous",
"    <span class=\"nowrap\">",
"     laser/light",
"    </span>",
"    therapy.",
"   </p>",
"   <p>",
"    Due to the risk of longstanding hypopigmentation from laser and light treatments, liquid sclerotherapy is a more appropriate choice for patients with Fitzpatrick skin types IV, V, and VI.",
"    <span class=\"nowrap\">",
"     Laser/light",
"    </span>",
"    treatments are recommended for patients who have failed sclerotherapy, those with veins too small to access (&lt;0.3 millimeters) or poor outcome, patients with post-sclerotherapy matting, needle-phobic patients, and patients allergic to sclerosant agents.",
"    <span class=\"nowrap\">",
"     Laser/light",
"    </span>",
"    treatment is also preferred for vessels located at or below the ankle regions, which are more prone to ulceration with sclerotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17031?source=see_link\">",
"     \"Laser and light therapy of lower extremity telangiectasias, reticular veins and small varicose veins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Foam",
"    </span>",
"    &nbsp;&mdash;&nbsp;Foam preparations are becoming increasingly popular [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/18\">",
"     18",
"    </a>",
"    ]. Sclerosant foam was developed from the detergent sclerosant agents to increase the surface area of exposure, and is more commonly used for the treatment of larger veins. The foam is produced just prior to injection by the Tessari method (",
"    <a class=\"graphic graphic_figure graphicRef79497 \" href=\"UTD.htm?35/14/36065\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/19\">",
"     19",
"    </a>",
"    ]. Foam prepared according to the Tessari technique has a half-life of approximately 90 seconds. Thus, the procedure should be completed within 1 minute, before the foam separates. Sclerosant foam is echogenic due to the tiny air bubbles in the foam, which are easily seen with duplex ultrasound. The expanded volume of the foam compared with liquid agents provides more surface contact, a more uniform vessel closure and use of smaller volumes of sclerosant. In principle, all vein calibers are suitable for foam sclerotherapy; however, a minority of practitioners would use it for treatment of telangiectasias or reticular veins because there is no significant advantage over liquid sclerotherapy in small vessels and, therefore, ultrasound-guided foam sclerotherapy (UGFS) is predominantly applied to the treatment of saphenous incompetence (great or small) and incompetent perforating veins [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus on specific aspects of sclerotherapy technique including: type of sclerosing agent, use of local anesthetic, use or type of local compression pad, and use or duration of compression dressing (bandage or elastic). Serial injections are often needed to address the veins of interest. Typical sessions last from 15 to 60 minutes.",
"   </p>",
"   <p>",
"    In general, a sclerosant liquid or foam (with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    ) is mixed into a syringe at the appropriate concentration for the vein to be treated (",
"    <a class=\"graphic graphic_table graphicRef70171 \" href=\"UTD.htm?5/63/6142\">",
"     table 1",
"    </a>",
"    ). The syringe is attached to a 27 or 30 gauge needle (or butterfly), which is angled to assist its introduction into the vessel. The patient is placed in Trendelenburg position during injection to discourage refilling of the injected veins. Following the application of alcohol to clean the area, the needle is introduced into the vein, and blood aspirated to ensure an intraluminal needle position; the sclerosant is then injected.",
"   </p>",
"   <p>",
"    The procedure is terminated when either the maximum volume of sclerosant has been injected (",
"    <a class=\"graphic graphic_table graphicRef70171 \" href=\"UTD.htm?5/63/6142\">",
"     table 1",
"    </a>",
"    ) or all the veins of interest have been treated. A light dressing and graduated compression stockings (",
"    <a class=\"graphic graphic_table graphicRef74574 \" href=\"UTD.htm?36/42/37547\">",
"     table 2",
"    </a>",
"    ), or bandages (Coban&trade;, Elastocrepe&trade;, Ace&trade;) are applied.",
"   </p>",
"   <p>",
"    The patient is discharged, providing they have experienced no adverse reactions. The patient is counseled to ambulate normally and may return to work. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Telangiectasias, reticular veins, varicose veins",
"    </span>",
"    &nbsp;&mdash;&nbsp;A fixed amount of sclerosant is injected depending on the size of the vein being treated (",
"    <a class=\"graphic graphic_table graphicRef70171 \" href=\"UTD.htm?5/63/6142\">",
"     table 1",
"    </a>",
"    ). When larger underlying reticular veins are identified, these are obliterated prior to addressing more superficial telangiectasias. A vein light (fiberoptic illuminator) is helpful in identifying reticular veins.",
"   </p>",
"   <p>",
"    The needle is withdrawn and local compression and massage are applied to keep blood out of the lumen of the vessel and to help disperse the sclerosant. Local compression pads (eg, mole foam, sorbo pads, dental bumpers) are placed and fixed with tape to maintain compression while moving on to the next vein.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Saphenous ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Foam sclerotherapy to treat reflux of the great saphenous vein is performed with ultrasound guidance. The saphenous vein is cannulated in the mid to distal thigh with the needle directed toward the foot. The extremity is elevated and sclerosant foam injected until it is visualized approaching the saphenofemoral junction, whereupon the injection is discontinued. The syringe is aspirated, and if blood is returned the procedure is repeated until the aspirate becomes white, indicating that the saphenous vein is filled with foam. Compression at the level of the groin can be performed. A study that evaluated a small number of patients for whom ultrasound-guided sclerotherapy was performed in combination with compression of the saphenofemoral junction found that this practice reduced but did not completely prevent migration of the foam [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/20\">",
"     20",
"    </a>",
"    ]. Some postulate that release of compression could promote microembolization. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Perforator ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injection of the sclerosant solution at the level of a refluxing perforator vein can be used to ablate the perforator or to treat associated interconnected superficial veins (Fegan's technique) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/21\">",
"     21",
"    </a>",
"    ]. This technique has been used with good long-term results and without significant complications, but requires an experienced practitioner [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following UGS of perforator veins, duplex ultrasound should be performed (three to six weeks after sclerotherapy) for surveillance to identify recurrent perforator veins which can lead to venous ulcer recurrence. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Clinical outcomes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     FOLLOW UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;We advise our patients to wear compression stockings continuously for 48 hours after treatment, after which time they may be worn during the day (off at night and to bathe) for the next two weeks. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Compression therapy following sclerotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Exercise is avoided for two weeks and treated areas should not be exposed to the sun during this time period. Alternatively, sunscreen with a high sun protection factor (&ge;SPF 30) may be applied to the treated areas. The patient should contact the physician immediately if they are experiencing increasing pain or if any ulcers are observed at the injection sites.",
"   </p>",
"   <p>",
"    Repeat injections, which are frequently needed, are not performed for at least six weeks.",
"   </p>",
"   <p>",
"    Patients are instructed to call their physician if they experience any visual, sensory, or motor disturbances. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Visual and other neurologic disturbances'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ADVERSE REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of adverse reaction following sclerotherapy depends upon the sclerosing agent used (",
"    <a class=\"graphic graphic_table graphicRef70171 \" href=\"UTD.htm?5/63/6142\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/14\">",
"     14",
"    </a>",
"    ]. Common local adverse reactions to sclerosing agents include pain, ulceration, urticaria, hyperpigmentation, and telangiectatic matting (",
"    <a class=\"graphic graphic_table graphicRef70171 \" href=\"UTD.htm?5/63/6142\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/23\">",
"     23",
"    </a>",
"    ]. Most local reactions are transient and resolve within months following the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/24\">",
"     24",
"    </a>",
"    ]. Vasovagal reactions have also been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Minor pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain is common at the sclerotherapy injection site. Significant pain during injection may be an indication that the sclerosing agent has extravasated into the tissue around the vein.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/6/110?source=see_link\">",
"     Polidocanol",
"    </a>",
"    is associated with the least amount of pain upon injection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/14\">",
"     14",
"    </a>",
"    ], whereas hypertonic saline and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/32/14852?source=see_link\">",
"     glycerin",
"    </a>",
"    are the most painful, especially when used without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Ulceration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ulcers may occur when the sclerosing agent extravasates from the vein into the subcutaneous tissue. The reported incidence is 1 to 5 percent of patients treated (",
"    <a class=\"graphic graphic_picture graphicRef54891 \" href=\"UTD.htm?1/46/1761\">",
"     picture 1A",
"    </a>",
"    ). Care must be taken to ensure that the needle is intraluminal before injection is performed. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Techniques'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    When ulcers occur, they are usually small and most often heal with local care in four to six weeks. However, they may result in scarring.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/6/110?source=see_link\">",
"     Polidocanol",
"    </a>",
"    is rarely associated with skin ulceration or necrosis because it is non-toxic to tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Skin breakdown may also occur in response to excessive pressure from tape or compression garments [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Larger areas of skin necrosis may be related to retrograde flow of the sclerosant through an unexpected cutaneous arteriovenous malformation or the inadvertent injection of a small arteriole. This type of skin necrosis is rare and is independent of the type of sclerosant used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Thrombus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombus forms within the vessel if blood comes into contact with the sclerosing agent. The resulting mild inflammatory reaction is a source of post-treatment pain and is more common with treatment of reticular veins and small varicose veins than telangiectasias.",
"   </p>",
"   <p>",
"    Micro-thrombectomy, which removes clot, significantly reduces post-sclerotherapy pain and inflammation and, in one multicenter randomized trial, reduced hyperpigmentation in vessels smaller than one millimeter [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/26\">",
"     26",
"    </a>",
"    ]. Micro-thrombectomy is typically performed within three weeks following treatment by making stab incisions (18 to 22 gauge needle or No. 65 Beaver blade) along the length of the thrombosed vein with aseptic technique. Thrombus is extruded by rolling a cotton-tipped applicator along the course of the vein, and the area is cleansed and dressed with sterile bandages. Topical local anesthesia is not usually necessary but may be helpful in some individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Telangiectatic matting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Telangiectatic matting consists of multiple, fine dilated vessels in the area of the injection site (",
"    <a class=\"graphic graphic_picture graphicRef74776 \" href=\"UTD.htm?13/16/13568\">",
"     picture 2",
"    </a>",
"    ). It is relatively common, occurring in 15 to 24 percent of patients and usually resolves within 3 to 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/27\">",
"     27",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1603?source=see_link\">",
"     Sodium tetradecyl",
"    </a>",
"    sulfate is associated with a lower incidence of telangiectatic matting [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one retrospective review of 2120 patients, significantly more patients in the matting group were overweight, on female hormones (estrogen, progesterone) during sclerotherapy treatment, and had both a family history and a longer duration of abnormal veins compared with the non-matting group [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a feeding reticular vein can be identified, repeat sclerotherapy can be attempted; otherwise, the area can be treated with cutaneous laser [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17031?source=see_link\">",
"     \"Laser and light therapy of lower extremity telangiectasias, reticular veins and small varicose veins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Hyperpigmentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperpigmentation occurs in up to 30 percent of patients following sclerotherapy (",
"    <a class=\"graphic graphic_picture graphicRef54891 graphicRef55318 \" href=\"UTD.htm?38/57/39830\">",
"     picture 1A-B",
"    </a>",
"    ). It is caused by deposition of hemosiderin in the skin as a result of extravasation of red blood cells. It usually becomes noticeable within a month following sclerotherapy and resolves spontaneously in 80 percent of patients within two years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/29\">",
"     29",
"    </a>",
"    ]. It occurs more commonly with treatment of veins greater than one millimeter in diameter, and in patients with darker hair and Fitzpatrick skin types III through VI (",
"    <a class=\"graphic graphic_table graphicRef60541 \" href=\"UTD.htm?15/37/15963\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyperpigmentation is less frequent with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1603?source=see_link\">",
"     sodium tetradecyl",
"    </a>",
"    sulfate, and this agent is also associated with less bruising [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/14\">",
"     14",
"    </a>",
"    ]. Treatment of telangiectasias with lower concentrations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/6/110?source=see_link\">",
"     polidocanol",
"    </a>",
"    (0.5 versus 1.0 percent) reduced the incidence of hyperpigmentation with this agent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Follow up care'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    It is important for patients who experience hyperpigmentation to avoid sun exposure to the treated areas.",
"    <span class=\"nowrap\">",
"     Laser/light",
"    </span>",
"    therapy may be tried in the treatment of post-sclerotherapy hyperpigmentation, but the results are unpredictable and occasionally pigmentation is worsened [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/28,31\">",
"     28,31",
"    </a>",
"    ]. The treatment of cutaneous hyperpigmentation is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/9/9370?source=see_link\">",
"     \"Laser and light therapy for cutaneous hyperpigmentation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mild inflammatory reaction is expected within the treated veins; however, intense superficial thrombophlebitis can occur and deep venous thrombosis, while uncommon, has been reported. Other complications include: microembolic events (ie, coughing, migraine-like headache, visual disturbances, paresthesias, stroke) and anaphylaxis.",
"   </p>",
"   <p>",
"    For patients with severe venous disease, UGS appears to be associated with less skin and wound healing complications and is an attractive alternative to open interruption or subfascial endoscopic perforator vein ligation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/32\">",
"     32",
"    </a>",
"    ]. Other complications are uncommon with this technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Superficial thrombophlebitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mild inflammatory response is expected after sclerotherapy and some patients may have urticaria at the site of injection. A more intense superficial thrombophlebitis with erythema, warmth, and pain can extend to veins neighboring the injection site. The diagnosis and treatment of superficial phlebitis is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/25/43417?source=see_link\">",
"     \"Superficial thrombophlebitis of the lower extremity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Deep vein thrombophlebitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Telangiectasias can communicate with the deep venous system. Contrast media directly injected into a telangiectasia entered the deep venous system in 2 of 15 patients in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/33\">",
"     33",
"    </a>",
"    ]. A systematic review of foam sclerotherapy reported deep vein thrombosis occurring in 0.02 to 5.7 percent in the included studies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/34\">",
"     34",
"    </a>",
"    ]. Although deep venous thrombosis can occur after sclerotherapy of telangiectasias, it is more likely to occur after sclerotherapy of the saphenous veins [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/35\">",
"     35",
"    </a>",
"    ]. Popliteal vein thrombosis has been reported with foam sclerotherapy of the small saphenous vein [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/36\">",
"     36",
"    </a>",
"    ]. Patients are diagnosed and treated for deep venous thrombosis following standard protocols. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=see_link\">",
"     \"Approach to the diagnosis and therapy of lower extremity deep vein thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Visual and other neurologic disturbances",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visual or neurologic disturbance is uncommon during or following sclerotherapy. These disturbances occur in less than 1 percent of patients and are usually transient; permanent deficits are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/6,7,34,37\">",
"     6,7,34,37",
"    </a>",
"    ]. Symptoms include visual disturbance (scotoma), migraine-like headache, and neurologic deficits.",
"   </p>",
"   <p>",
"    Visual disturbances reported following sclerotherapy of telangiectasias and reticular veins are strongly associated with the use of air-block and foam techniques, suggesting that the etiology is air microembolization. Most visual disturbances occur during or immediately after the procedure when the patient ambulates, possibly due to rising microbubbles in the bloodstream. In one study, 20 of 12,173 patients (0.16 percent) treated with sclerotherapy experienced visual disturbances, 70 percent of which were following sclerotherapy of telangiectasias or reticular veins [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/35\">",
"     35",
"    </a>",
"    ]. Visual disturbances were associated with nausea, headache, or vasovagal fainting; all cases regressed spontaneously.",
"   </p>",
"   <p>",
"    During foam sclerotherapy of the great saphenous vein, microbubbles can be detected in the right heart and pulmonary circulation, and in patients with a patent foramen ovale (PFO), in the left heart as well [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/10,38\">",
"     10,38",
"    </a>",
"    ]. Coughing following foam sclerotherapy has been attributed to air microembolization into the pulmonary circulation. In a prospective study of 33 patients, cardiac echo was performed during foam sclerotherapy with cardiac microemboli detected in every patient studied. Microemboli were also seen in the left ventricle of five patients, and each was subsequently found to have a patent foramen ovale; however, none of these patients experienced neurologic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/10\">",
"     10",
"    </a>",
"    ]. Given the significant prevalence (25 to 30 percent) of patent foramen ovale in the general population, it is apparent that the incidence of significant neurologic sequelae following foam sclerotherapy is low. Nevertheless, caution needs to be exercised when performing foam sclerotherapy in any patient known to have a PFO. Patients who develop neurologic symptoms following foam sclerotherapy should be referred for further cardiac evaluation and are advised to avoid future sclerotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3593?source=see_link\">",
"     \"Patent foramen ovale\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=see_link\">",
"     \"Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because visual and neurologic disturbances have been reported with non-foamed (ie, liquid) sclerosant solutions, and have occurred in the absence of a PFO, an alternative theory has been proposed. It proposes that visual and neurologic symptoms related to sclerotherapy are due to the release of endothelin, a potent vasoconstrictor. One group found increased concentrations of endothelin in the blood following injection with various sclerosing agents, first in an animal model and then in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis can occur with any of the sclerosing agents with the exception of hypertonic saline. A test dose of the sclerosing agent is recommended (",
"    <a class=\"graphic graphic_table graphicRef70171 \" href=\"UTD.htm?5/63/6142\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     COMPRESSION THERAPY FOLLOWING SCLEROTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meta-analysis of randomized trials of injection sclerotherapy for varying sizes of varicose veins identified no differences in sclerotherapy success related to method of compression therapy (elastic versus conventional bandaging) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/14\">",
"     14",
"    </a>",
"    ]. Long-term bandaging did not have any advantages over short-term bandaging for cosmetic appearance, incidence of superficial phlebitis or recurrent varicose veins. Short-term bandaging was better tolerated.",
"   </p>",
"   <p>",
"    Most trials have evaluated compression bandaging schemes for liquid sclerotherapy, but it appears that short-term compression therapy for foam sclerotherapy is also favored. One trial randomly assigned 128 patients with varicosities to 24 hours of compression bandaging followed by anti-embolism stockings, or to five days of bandaging [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/41\">",
"     41",
"    </a>",
"    ]. No significant differences were found in phlebitis scores or pain scores at two weeks follow-up. At six weeks, vein occlusion rates, skin changes and venous severity measures were also no different. Another trial randomly assigned 60 patients undergoing foam sclerotherapy of the saphenous vein, to compression stockings or no compression and found no significant differences in vein closure rates, side effects or patient satisfaction between the groups at 14 days and one month follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, the benefit of compression stockings following sclerotherapy for telangiectasias and reticular veins has been documented in numerous studies. Three trials suggested improved cosmetic outcomes with three weeks of compression rather than shorter or no compression following sclerotherapy of telangiectasias [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/43-45\">",
"     43-45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one of these studies, there was a correlation between the duration of compression and degree of improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/44\">",
"     44",
"    </a>",
"    ]. A total of 40 patients with telangiectasias",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reticular veins were treated with sclerotherapy. Ten control patients did not receive compression therapy while 30 patients in three groups of 10 received compression for 3 days, 1 week, or 3 weeks. There was a correlation between the length of time compression was applied and degree of improvement at 6 weeks, 12 weeks, and 24 weeks. Patients treated with compression for three days or one week had significantly more improvement than control patients, while patients treated for three weeks of continuous compression had the most improvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     VEIN CLEARANCE AND CLOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clearance of 60 to 80 percent of treated telangiectasias, reticular veins and small varicose veins can be expected [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/34,46-51\">",
"     34,46-51",
"    </a>",
"    ]. Vein clearance rates and overall patient satisfaction favor sclerotherapy over cutaneous laser [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/46,47,52\">",
"     46,47,52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34521?source=see_link\">",
"     \"Overview and management of lower extremity chronic venous disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rates of saphenous closure with ultrasound-guided foam sclerotherapy (UGFS) appear to be lower compared with endovenous methods [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. In a prospective study, significantly higher rates of great saphenous occlusion were seen in patients treated with endovenous laser compared with foam sclerotherapy (93.4 versus 77.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/53\">",
"     53",
"    </a>",
"    ]. Other studies have reported higher long-term success with one or more treatment sessions [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. In one of these studies, 90 percent of great saphenous veins were free of recanalization with two sessions over a mean 39 months of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/56\">",
"     56",
"    </a>",
"    ]. For the small saphenous vein, closure rates of 91 percent at 12 months follow up were reported in one moderately-sized study (86 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ultrasound-guided sclerotherapy of perforators is an effective and durable method of eliminating reflux in perforator veins. In one observational study, 98 percent of incompetent perforators were successfully obliterated at the time of treatment; 75 percent of limbs showed persistent occlusion of perforators up to five years following treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     CLINICAL OUTCOMES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Venous clinical severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sclerotherapy of telangiectasias, reticular veins and varicose veins is effective in relieving pain in the treated veins with high rates of patient satisfaction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/14,22,59\">",
"     14,22,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a method of eliminating incompetent perforator veins, ultrasound-guided sclerotherapy results in significant reduction of symptoms and signs as determined by venous clinical scores [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/32\">",
"     32",
"    </a>",
"    ]. Clinical improvement was sustained with a mean follow up of 20.1 months in the only available long-term patient series.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Vein recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrence of telangiectasias and reticular veins is uncommon and most often attributable to inadequate technique [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/22\">",
"     22",
"    </a>",
"    ]. The development of new veins (ie, neovascularization) and telangiectatic matting are more typical [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Adverse reactions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Randomized trials suggest that sclerotherapy is less effective than surgery for larger veins [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/61-64\">",
"     61-64",
"    </a>",
"    ]. Recurrence rates following saphenous vein sclerotherapy are significant are related to saphenous recanalization. Foam sclerotherapy is associated with lower rates of recanalization compared with liquid sclerotherapy. A systematic review identified a median recurrence rate of 8.1 percent in 69 studies of foam sclerotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For either liquid or foam sclerotherapy, the recurrence of clinical symptoms may be lower than vein recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/14,65,66\">",
"     14,65,66",
"    </a>",
"    ]. In one prospective trial, saphenous vein recanalization occurred in 27 and 64 percent of patients treated at one and five years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/65\">",
"     65",
"    </a>",
"    ]. However, 70 percent of patients did not have worsened clinical symptoms. Repeat UGFS treatment was performed in 16.5 percent of patients between one and two years, and fewer than 10 percent in subsequent years (up to five years).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Venous ulcer healing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical trials demonstrated reduced ulcer recurrence rates with saphenous stripping [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. Successful application of other methods of saphenous ablation may also be beneficial (eg, sclerotherapy, endovenous ablation); however, there are no randomized trials comparing techniques.",
"   </p>",
"   <p>",
"    Healing rates following ultrasound-guided foam sclerotherapy for venous ulcers appear to be comparable to those reported after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/70\">",
"     70",
"    </a>",
"    ]. In a small observational study, ultrasound-guided foam sclerotherapy (UGS) of the saphenous vein resulted in healing of 79 and 96 percent of ulcers at one and three months, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/71\">",
"     71",
"    </a>",
"    ]. In another study, 79 percent of active ulcers healed following ultrasound-guided foam sclerotherapy of associated varicose veins [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/50\">",
"     50",
"    </a>",
"    ]. A small randomized trial found healing of venous ulcers in",
"    <span class=\"nowrap\">",
"     17/22",
"    </span>",
"    patients treated with four-layer compression bandages alone and",
"    <span class=\"nowrap\">",
"     12/13",
"    </span>",
"    patients treated with compression bandaging plus foam sclerotherapy to incompetent truncal veins; the difference was not significant [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrence of reflux in perforator veins following saphenous ablation is known to be a risk factor for venous ulcer nonhealing or recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/48,67\">",
"     48,67",
"    </a>",
"    ]. UGS of perforating veins is associated with fewer complications compared with surgical management of perforators (ie, SEPS) and is clinically appealing for this indication; however, few clinical studies have been performed.",
"   </p>",
"   <p>",
"    In an observational study evaluating ulcer healing with UGS, ulcer healing was ultimately observed in 32 of 37 limbs treated by ultrasound-guided perforator sclerotherapy. This group of patients did not have concomitant axial vein reflux. More than one treatment session due to the development of recurrent perforators was required in 12 of 37 limbs treated [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     COST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sclerotherapy of telangiectasias and reticular veins is generally considered a cosmetic treatment and is not typically covered by insurance, though occasionally it will be reimbursed when treating veins which have hemorrhaged. The average cost of a sclerotherapy session in the US in 2007 was $342 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/12/13514/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/32/30210?source=see_link\">",
"       \"Patient information: Vein ablation (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dilated veins can occur in the presence or absence of either symptoms or an underlying functional venous disorder. Telangiectasias, reticular veins, and varicose veins can cause symptoms, and are often a source of significant distress to the patient even in the absence of symptoms. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of lower extremity telangiectasias, reticular veins, or varicose veins may indicate an underlying functional venous disorder, especially when associated with symptoms (aching, swelling, heaviness). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/29/11735?source=see_link\">",
"       \"Classification of lower extremity chronic venous disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Symptomatic patients should undergo further evaluation with venous duplex to identify the presence of superficial or deep venous insufficiency, which alters treatment options. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Common local adverse reactions to sclerotherapy include pain, ulceration, telangiectatic matting, and hyperpigmentation and are dependent upon the agent used (",
"      <a class=\"graphic graphic_table graphicRef70171 \" href=\"UTD.htm?5/63/6142\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Adverse reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cosmetic measures of sclerotherapy success are similar regardless of the agent used (ie,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1603?source=see_link\">",
"       sodium tetradecyl",
"      </a>",
"      sulfate,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/6/110?source=see_link\">",
"       polidocanol",
"      </a>",
"      , hypertonic saline). (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Clinical outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For lower extremity telangiectasias, reticular veins, and small varicose veins large enough to admit a 27 or 30 gauge needle, sclerotherapy is the treatment of choice. Sclerotherapy results in improved clearance of treated veins compared with other forms of treatment (eg, laser).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/1\">",
"      Ekl&ouml;f B, Rutherford RB, Bergan JJ, et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg 2004; 40:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/2\">",
"      Langer RD, Ho E, Denenberg JO, et al. Relationships between symptoms and venous disease: the San Diego population study. Arch Intern Med 2005; 165:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/3\">",
"      Criqui MH, Jamosmos M, Fronek A, et al. Chronic venous disease in an ethnically diverse population: the San Diego Population Study. Am J Epidemiol 2003; 158:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/4\">",
"      Labas P, Cambal M. Profuse bleeding in patients with chronic venous insufficiency. Int Angiol 2007; 26:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/5\">",
"      Hamahata A, Yamaki T, Osada A, et al. Foam sclerotherapy for spouting haemorrhage in patients with varicose veins. Eur J Vasc Endovasc Surg 2011; 41:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/6\">",
"      Forlee MV, Grouden M, Moore DJ, Shanik G. Stroke after varicose vein foam injection sclerotherapy. J Vasc Surg 2006; 43:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/7\">",
"      Gillet JL, Guedes JM, Guex JJ, et al. Side-effects and complications of foam sclerotherapy of the great and small saphenous veins: a controlled multicentre prospective study including 1,025 patients. Phlebology 2009; 24:131.",
"     </a>",
"    </li>",
"    <li>",
"     Hartmann, K. Reversible neurologic deficit after foam sclerotherapy. Eur J Vasc Endovasc Surg 2009; Epub ahead of print.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/9\">",
"      Raymond-Martimbeau P. Transient adverse events positively associated with patent foramen ovale after ultrasound-guided foam sclerotherapy. Phlebology 2009; 24:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/10\">",
"      Ceulen RP, Sommer A, Vernooy K. Microembolism during foam sclerotherapy of varicose veins. N Engl J Med 2008; 358:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/11\">",
"      Hanisch F, M&uuml;ller T, Krivokuca M, Winterholler M. Stroke following variceal sclerotherapy. Eur J Med Res 2004; 9:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/12\">",
"      Goldman MP. Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxyskerol and sotradecol. Dermatol Surg 2002; 28:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/13\">",
"      Parsi K, Exner T, Connor DE, et al. In vitro effects of detergent sclerosants on coagulation, platelets and microparticles. Eur J Vasc Endovasc Surg 2007; 34:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/14\">",
"      Tisi PV, Beverley C, Rees A. Injection sclerotherapy for varicose veins. Cochrane Database Syst Rev 2006; :CD001732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/15\">",
"      Schwartz L, Maxwell H. Sclerotherapy for lower limb telangiectasias. Cochrane Database Syst Rev 2011; :CD008826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/16\">",
"      Leach BC, Goldman MP. Comparative trial between sodium tetradecyl sulfate and glycerin in the treatment of telangiectatic leg veins. Dermatol Surg 2003; 29:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/17\">",
"      Galland RB, Magee TR, Lewis MH. A survey of current attitudes of British and Irish vascular surgeons to venous sclerotherapy. Eur J Vasc Endovasc Surg 1998; 16:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/18\">",
"      Breu FX, Guggenbichler S. European Consensus Meeting on Foam Sclerotherapy, April, 4-6, 2003, Tegernsee, Germany. Dermatol Surg 2004; 30:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/19\">",
"      Tessari L, Cavezzi A, Frullini A. Preliminary experience with a new sclerosing foam in the treatment of varicose veins. Dermatol Surg 2001; 27:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/20\">",
"      Ceulen RP, Jagtman EA, Sommer A, et al. Blocking the saphenofemoral junction during ultrasound-guided foam sclerotherapy-- assessment of a presumed safety-measure procedure. Eur J Vasc Endovasc Surg 2010; 40:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/21\">",
"      FEGAN WG. Continuous compression technique of injecting varicose veins. Lancet 1963; 2:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/22\">",
"      Labas P, Ohradka B, Cambal M, et al. Long term results of compression sclerotherapy. Bratisl Lek Listy 2003; 104:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/23\">",
"      Munavalli GS, Weiss RA. Complications of sclerotherapy. Semin Cutan Med Surg 2007; 26:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/24\">",
"      Weiss RA, Weiss MA. Incidence of side effects in the treatment of telangiectasias by compression sclerotherapy: hypertonic saline vs. polidocanol. J Dermatol Surg Oncol 1990; 16:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/25\">",
"      Bukhari RH, Lohr JM, Paget DS, et al. Evaluation of lidocaine as an analgesic when added to hypertonic saline for sclerotherapy. J Vasc Surg 1999; 29:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/26\">",
"      Scultetus AH, Villavicencio JL, Kao TC, et al. Microthrombectomy reduces postsclerotherapy pigmentation: multicenter randomized trial. J Vasc Surg 2003; 38:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/27\">",
"      Davis LT, Duffy DM. Determination of incidence and risk factors for postsclerotherapy telangiectatic matting of the lower extremity: a retrospective analysis. J Dermatol Surg Oncol 1990; 16:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/28\">",
"      Bernstein EF. Clinical characteristics of 500 consecutive patients presenting for laser removal of lower extremity spider veins. Dermatol Surg 2001; 27:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/29\">",
"      Goldman MP, Kaplan RP, Duffy DM. Postsclerotherapy hyperpigmentation: a histologic evaluation. J Dermatol Surg Oncol 1987; 13:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/30\">",
"      Norris MJ, Carlin MC, Ratz JL. Treatment of essential telangiectasia: effects of increasing concentrations of polidocanol. J Am Acad Dermatol 1989; 20:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/31\">",
"      Glaich AS, Goldberg LH, Dai T, Friedman PM. Fractional photothermolysis for the treatment of telangiectatic matting: a case report. J Cosmet Laser Ther 2007; 9:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/32\">",
"      Masuda EM, Kessler DM, Lurie F, et al. The effect of ultrasound-guided sclerotherapy of incompetent perforator veins on venous clinical severity and disability scores. J Vasc Surg 2006; 43:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/33\">",
"      B&ouml;hler-Sommeregger K, Karnel F, Schuller-Petrovic S, Santler R. Do telangiectases communicate with the deep venous system? J Dermatol Surg Oncol 1992; 18:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/34\">",
"      Jia X, Mowatt G, Burr JM, et al. Systematic review of foam sclerotherapy for varicose veins. Br J Surg 2007; 94:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/35\">",
"      Guex JJ, Allaert FA, Gillet JL, Chleir F. Immediate and midterm complications of sclerotherapy: report of a prospective multicenter registry of 12,173 sclerotherapy sessions. Dermatol Surg 2005; 31:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/36\">",
"      Darvall KA, Bate GR, Silverman SH, et al. Medium-term results of ultrasound-guided foam sclerotherapy for small saphenous varicose veins. Br J Surg 2009; 96:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/37\">",
"      Sarvananthan T, Shepherd AC, Willenberg T, Davies AH. Neurological complications of sclerotherapy for varicose veins. J Vasc Surg 2012; 55:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/38\">",
"      Hansen, K, et al. Transthoracic echocardiogram and transcranial doppler detection of emboli after foam sclerotherapy of leg veins. J Vasc Ultrasound 2007; 31:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/39\">",
"      Frullini A, Felice F, Burchielli S, Di Stefano R. High production of endothelin after foam sclerotherapy: a new pathogenetic hypothesis for neurological and visual disturbances after sclerotherapy. Phlebology 2011; 26:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/40\">",
"      Frullini A, Barsotti MC, Santoni T, et al. Significant endothelin release in patients treated with foam sclerotherapy. Dermatol Surg 2012; 38:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/41\">",
"      O'Hare JL, Stephens J, Parkin D, Earnshaw JJ. Randomized clinical trial of different bandage regimens after foam sclerotherapy for varicose veins. Br J Surg 2010; 97:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/42\">",
"      Hamel-Desnos CM, Guias BJ, Desnos PR, Mesgard A. Foam sclerotherapy of the saphenous veins: randomised controlled trial with or without compression. Eur J Vasc Endovasc Surg 2010; 39:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/43\">",
"      Kern P, Ramelet AA, W&uuml;tschert R, Hayoz D. Compression after sclerotherapy for telangiectasias and reticular leg veins: a randomized controlled study. J Vasc Surg 2007; 45:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/44\">",
"      Weiss RA, Sadick NS, Goldman MP, Weiss MA. Post-sclerotherapy compression: controlled comparative study of duration of compression and its effects on clinical outcome. Dermatol Surg 1999; 25:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/45\">",
"      Nootheti PK, Cadag KM, Magpantay A, Goldman MP. Efficacy of graduated compression stockings for an additional 3 weeks after sclerotherapy treatment of reticular and telangiectatic leg veins. Dermatol Surg 2009; 35:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/46\">",
"      Lupton JR, Alster TS, Romero P. Clinical comparison of sclerotherapy versus long-pulsed Nd:YAG laser treatment for lower extremity telangiectases. Dermatol Surg 2002; 28:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/47\">",
"      Coles CM, Werner RS, Zelickson BD. Comparative pilot study evaluating the treatment of leg veins with a long pulse ND:YAG laser and sclerotherapy. Lasers Surg Med 2002; 30:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/48\">",
"      Tenbrook JA Jr, Iafrati MD, O'donnell TF Jr, et al. Systematic review of outcomes after surgical management of venous disease incorporating subfascial endoscopic perforator surgery. J Vasc Surg 2004; 39:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/49\">",
"      Thomasset SC, Butt Z, Liptrot S, et al. Ultrasound guided foam sclerotherapy: factors associated with outcomes and complications. Eur J Vasc Endovasc Surg 2010; 40:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/50\">",
"      Nael R, Rathbun S. Effectiveness of foam sclerotherapy for the treatment of varicose veins. Vasc Med 2010; 15:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/51\">",
"      Hamahata A, Yamaki T, Sakurai H. Outcomes of ultrasound-guided foam sclerotherapy for varicose veins of the lower extremities: a single center experience. Dermatol Surg 2011; 37:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/52\">",
"      Levy JL, Berwald C. Treatment of vascular abnormalities with a long-pulse diode at 980 nm. J Cosmet Laser Ther 2004; 6:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/53\">",
"      Gonzalez-Zeh R, Armisen R, Barahona S. Endovenous laser and echo-guided foam ablation in great saphenous vein reflux: one-year follow-up results. J Vasc Surg 2008; 48:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/54\">",
"      Weiss RA, Munavalli G. Endovenous ablation of truncal veins. Semin Cutan Med Surg 2005; 24:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/55\">",
"      Goldman MP. Intravascular lasers in the treatment of varicose veins. J Cosmet Dermatol 2004; 3:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/56\">",
"      Chen CH, Chiu CS, Yang CH. Ultrasound-guided foam sclerotherapy for treating incompetent great saphenous veins--results of 5 years of analysis and morphologic evolvement study. Dermatol Surg 2012; 38:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/57\">",
"      Barrett JM, Allen B, Ockelford A, Goldman MP. Microfoam ultrasound-guided sclerotherapy of varicose veins in 100 legs. Dermatol Surg 2004; 30:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/58\">",
"      Darvall KA, Bate GR, Adam DJ, et al. Duplex ultrasound outcomes following ultrasound-guided foam sclerotherapy of symptomatic primary great saphenous varicose veins. Eur J Vasc Endovasc Surg 2010; 40:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/59\">",
"      Weiss RA, Weiss MA. Resolution of pain associated with varicose and telangiectatic leg veins after compression sclerotherapy. J Dermatol Surg Oncol 1990; 16:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/60\">",
"      Bradbury AW, Bate G, Pang K, et al. Ultrasound-guided foam sclerotherapy is a safe and clinically effective treatment for superficial venous reflux. J Vasc Surg 2010; 52:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/61\">",
"      Negl&eacute;n P, Einarsson E, Ekl&ouml;f B. The functional long-term value of different types of treatment for saphenous vein incompetence. J Cardiovasc Surg (Torino) 1993; 34:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/62\">",
"      Belcaro G, Nicolaides AN, Ricci A, et al. Endovascular sclerotherapy, surgery, and surgery plus sclerotherapy in superficial venous incompetence: a randomized, 10-year follow-up trial--final results. Angiology 2000; 51:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/63\">",
"      Belcaro G, Cesarone MR, Di Renzo A, et al. Foam-sclerotherapy, surgery, sclerotherapy, and combined treatment for varicose veins: a 10-year, prospective, randomized, controlled, trial (VEDICO trial). Angiology 2003; 54:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/64\">",
"      Rigby KA, Palfreyman SJ, Beverley C, Michaels JA. Surgery versus sclerotherapy for the treatment of varicose veins. Cochrane Database Syst Rev 2004; :CD004980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/65\">",
"      Chapman-Smith P, Browne A. Prospective five-year study of ultrasound-guided foam sclerotherapy in the treatment of great saphenous vein reflux. Phlebology 2009; 24:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/66\">",
"      Hamel-Desnos C, Desnos P, Wollmann JC, et al. Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatol Surg 2003; 29:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/67\">",
"      O'Donnell TF Jr. The present status of surgery of the superficial venous system in the management of venous ulcer and the evidence for the role of perforator interruption. J Vasc Surg 2008; 48:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/68\">",
"      Stuart WP, Adam DJ, Allan PL, et al. Saphenous surgery does not correct perforator incompetence in the presence of deep venous reflux. J Vasc Surg 1998; 28:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/69\">",
"      Kianifard B, Holdstock J, Allen C, et al. Randomized clinical trial of the effect of adding subfascial endoscopic perforator surgery to standard great saphenous vein stripping. Br J Surg 2007; 94:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/70\">",
"      Pang KH, Bate GR, Darvall KA, et al. Healing and recurrence rates following ultrasound-guided foam sclerotherapy of superficial venous reflux in patients with chronic venous ulceration. Eur J Vasc Endovasc Surg 2010; 40:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/71\">",
"      Darvall KA, Bate GR, Adam DJ, et al. Ultrasound-guided foam sclerotherapy for the treatment of chronic venous ulceration: a preliminary study. Eur J Vasc Endovasc Surg 2009; 38:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/12/13514/abstract/72\">",
"      O'Hare JL, Earnshaw JJ. Randomised clinical trial of foam sclerotherapy for patients with a venous leg ulcer. Eur J Vasc Endovasc Surg 2010; 39:495.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8206 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-9F9DC17642-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_12_13514=[""].join("\n");
var outline_f13_12_13514=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATIENT COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SCLEROTHERAPY AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Sodium tetradecyl sulfate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Polidocanol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hypertonic saline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H168866740\">",
"      Glycerin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PREPARATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Liquid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Foam",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Telangiectasias, reticular veins, varicose veins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Saphenous ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Perforator ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      FOLLOW UP CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ADVERSE REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Minor pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Ulceration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Thrombus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Telangiectatic matting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Hyperpigmentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Superficial thrombophlebitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Deep vein thrombophlebitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Visual and other neurologic disturbances",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      COMPRESSION THERAPY FOLLOWING SCLEROTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      VEIN CLEARANCE AND CLOSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      CLINICAL OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Venous clinical severity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Vein recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Venous ulcer healing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      COST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8206\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8206|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/46/36579\" title=\"figure 1A\">",
"      Superficial veins of leg anterior view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/42/42671\" title=\"figure 1B\">",
"      Superficial veins of lower leg posterior view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/56/43906\" title=\"figure 2\">",
"      Deep veins of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/14/36065\" title=\"figure 3\">",
"      Tessari method of foam sclerosant preparation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8206|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/46/1761\" title=\"picture 1A\">",
"      Ulceration and hyperpigmentation following sclerotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/2/5154\" title=\"picture 1B\">",
"      Hyperpigmentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/16/13568\" title=\"picture 2\">",
"      Telangiectatic matting following sclerotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8206|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/63/6142\" title=\"table 1\">",
"      Sclerosing agent for lower extremity venous disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/42/37547\" title=\"table 2\">",
"      Compression stockings in chronic venous disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/37/15963\" title=\"table 3\">",
"      Fitzpatrick skin phototypes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=related_link\">",
"      Approach to the diagnosis and therapy of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=related_link\">",
"      Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/29/11735?source=related_link\">",
"      Classification of lower extremity chronic venous disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/9/9370?source=related_link\">",
"      Laser and light therapy for cutaneous hyperpigmentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17031?source=related_link\">",
"      Laser and light therapy of lower extremity telangiectasias, reticular veins and small varicose veins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32410?source=related_link\">",
"      Medical management of lower extremity chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/29/21977?source=related_link\">",
"      Open surgical techniques for lower extremity vein ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34521?source=related_link\">",
"      Overview and management of lower extremity chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3593?source=related_link\">",
"      Patent foramen ovale",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/32/30210?source=related_link\">",
"      Patient information: Vein ablation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/5/30809?source=related_link\">",
"      Radiofrequency ablation for the treatment of lower extremity chronic venous disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/25/43417?source=related_link\">",
"      Superficial thrombophlebitis of the lower extremity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_12_13515="Skin manifestations PEG ribavir";
var content_f13_12_13515=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F82174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F82174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Potential dermatological manifestations associated with peginterferon and ribavirin",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        At injection site",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythema and induration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Painful nodules with central vesiculation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ulceration and necrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Contact allergy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Distant from injection site",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psoriasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lichen planus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitiligo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vasculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bullous pemphigus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Raynaud's",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Nezam H Afdhal, MD and T Barry Kelleher, MB, MRCPI.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_12_13515=[""].join("\n");
var outline_f13_12_13515=null;
var title_f13_12_13516="Pregnancy outcome B19 infection";
var content_f13_12_13516=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F69006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F69006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of studies on pregnancy outcome and parvovirus B19 infection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Study",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of pregnancies",
"       </td>",
"       <td class=\"subtitle1\">",
"        Total fetal losses",
"       </td>",
"       <td class=\"subtitle1\">",
"        Loss &lt;20 weeks",
"       </td>",
"       <td class=\"subtitle1\">",
"        Loss &gt;20 weeks",
"       </td>",
"       <td class=\"subtitle1\">",
"        Hydrops",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anand, A, et al. N Engl J Med 1987",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Schwartz, TF, et al. Lancet 1988",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rodis, JF, et al. Am J Obstet Gynecol 1990*",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        British Working Party, BMJ 1990*",
"       </td>",
"       <td>",
"        186",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Guidozzi, F, et al. J Reprod Med 1994*",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gratacos, E, et al. J Infect Dis 1995*",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enders, M, et al Prenat Diagn 2004",
"       </td>",
"       <td>",
"        1018",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        40",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Loss rate &lt;20 weeks 10 percent, &gt;20 weeks 0.9 percent.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_12_13516=[""].join("\n");
var outline_f13_12_13516=null;
var title_f13_12_13517="Agents opioid constipation";
var content_f13_12_13517=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F73845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F73845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Agents used for chronic opioid-induced constipation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Class",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mechanism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Use",
"       </td>",
"       <td class=\"subtitle1\">",
"        Problems",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bulk-forming laxatives (cellulose or psyllium seeds)",
"       </td>",
"       <td>",
"        <p>",
"         Increases mass and water content of stool",
"        </p>",
"        <p>",
"         Decreases transit time",
"        </p>",
"       </td>",
"       <td>",
"        Should always be considered; may be useful in changing character of the effluent from a functioning stoma",
"       </td>",
"       <td>",
"        May worsen flatulence and distention. Should be avoided in patients who are severely debilitated or suspected of early bowel obstruction.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Osmotic cathartics (magnesium salts, sodium salts, lactulose, and sorbitol, and polyethylene glycol)",
"       </td>",
"       <td>",
"        <p>",
"         Increases water in the bowel",
"        </p>",
"        <p>",
"         Decreases transit time",
"        </p>",
"        <p>",
"         Lactulose/sorbitol attracts water into colon, acidifies contents",
"        </p>",
"        <p>",
"         Polyethylene glycol attracts water into the colon",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Often used for bowel cleansing before medical procedures",
"        </p>",
"        <p>",
"         Lactulose and sorbitol have a slower onset and are commonly selected for long-term use; dose must be adjusted to effect",
"        </p>",
"        <p>",
"         Polyethylene glycol is not absorbed, has a slower onset, and the powder formulation also is commonly used for long-term therapy; dose must be adjusted to effect",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Severe diarrhea and dehydration may occur with overuse",
"        </p>",
"        <p>",
"         Rarely, causes serious electrolyte disorders or volume overload",
"        </p>",
"        <p>",
"         Patients with renal insufficiency or cardiac failure must be carefully monitored if sodium or magnesium salts are used",
"        </p>",
"        <p>",
"         Lactulose or sorbitol may increase flatulence.",
"        </p>",
"        <p>",
"         Lactulose should be avoided in patients who are lactose-intolerant.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Surfactants (docusate sodium)",
"       </td>",
"       <td>",
"        Facilitates mixture of fat and stool",
"       </td>",
"       <td>",
"        Usually combined with a contact cathartic as a first-line therapy for opioid-induced constipation",
"       </td>",
"       <td>",
"        Minimal risks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Contact cathartics diphenylmethane drugs (bisacodyl)",
"        </p>",
"        <p>",
"         Anthraquinone drugs (cascara, senna)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Increases peristalsis",
"        </p>",
"        <p>",
"         Reduces absorption of water and electrolytes from intraluminal contents",
"        </p>",
"       </td>",
"       <td>",
"        May be used for acute or chronic therapy. Often a first-line approach for long-term management, including prophylaxis when opioid therapy is initiated.",
"       </td>",
"       <td>",
"        <p>",
"         Risks associated with short term use are minimal",
"        </p>",
"        <p>",
"         \"Laxative bowel\", a condition characterized by dependence on laxatives for bowel function has been reported but is presumably rare",
"        </p>",
"        <p>",
"         Allergies to these substances have been reported",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Prokinetic agents",
"        </p>",
"        <p>",
"         Metoclopramide",
"        </p>",
"       </td>",
"       <td>",
"        Promotes transit through gastrointestinal tract",
"       </td>",
"       <td>",
"        Experience is limited and trial should be considered only when constipation has responded poorly to more conventional measures",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Opioid antagonists",
"        </p>",
"        <p>",
"         Subcutaneous methylnaltrexone",
"        </p>",
"        <p>",
"         Oral naloxone",
"        </p>",
"       </td>",
"       <td>",
"        Opioid antagonist",
"       </td>",
"       <td>",
"        <p>",
"         Goal is \"bowel withdrawal\" without concurrent systemic withdrawal",
"        </p>",
"        <p>",
"         Methylnaltrexone is approved for the indication of opioid-induced constipation in refractory cases. Available currently as an injectable, which may be useful when administered as a \"rescue,\" should routine therapies be ineffective, or every few days for long-term treatment of constipation. Does not cause systemic abstinence.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Limited evidence supporting efficacy of oral naloxone and some patients will absorb sufficient naloxone to develop uncomfortable signs of abstinence",
"        </p>",
"        <p>",
"         May cause abdominal cramping",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_12_13517=[""].join("\n");
var outline_f13_12_13517=null;
var title_f13_12_13518="Latex allergy diagnostic questionnaire";
var content_f13_12_13518=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F63643&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F63643&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Latex allergy diagnostic questionnaire",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td colspan=\"6\">",
"        Circle Y or N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"6\">",
"        Risk factor assessment:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Exposure history:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Are you a health care worker?",
"       </td>",
"       <td class=\"centered\">",
"        Y",
"       </td>",
"       <td class=\"centered\">",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Do you wear latex gloves regularly or are you otherwise exposed to latex regularly?",
"       </td>",
"       <td class=\"centered\">",
"        Y",
"       </td>",
"       <td class=\"centered\">",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Do you have a history of eczema or other rashes on your hands?",
"       </td>",
"       <td class=\"centered\">",
"        Y",
"       </td>",
"       <td class=\"centered\">",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Do you have a medical history of frequent surgeries or invasive medical procedures?",
"       </td>",
"       <td class=\"centered\">",
"        Y",
"       </td>",
"       <td class=\"centered\">",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Did these take place when you were an infant?",
"       </td>",
"       <td class=\"centered\">",
"        Y",
"       </td>",
"       <td class=\"centered\">",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Do you have a history of \"hay fever\" or other common allergies?",
"       </td>",
"       <td class=\"centered\">",
"        Y",
"       </td>",
"       <td class=\"centered\">",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Do your fellow workers wear latex gloves regularly?",
"       </td>",
"       <td class=\"centered\">",
"        Y",
"       </td>",
"       <td class=\"centered\">",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Do you take a beta-blocker medication?",
"       </td>",
"       <td class=\"centered\">",
"        Y",
"       </td>",
"       <td class=\"centered\">",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Circle any foods below that cause hives, itching of the lips or throat, or more severe symptoms when you eat or handle them:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        avocado",
"       </td>",
"       <td class=\"centered\">",
"        apple",
"       </td>",
"       <td class=\"centered\">",
"        pear",
"       </td>",
"       <td class=\"centered\">",
"        celery",
"       </td>",
"       <td class=\"centered\">",
"        carrot",
"       </td>",
"       <td class=\"centered\">",
"        hazelnut",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        kiwi",
"       </td>",
"       <td class=\"centered\">",
"        papaya",
"       </td>",
"       <td class=\"centered\">",
"        pineapple",
"       </td>",
"       <td class=\"centered\">",
"        peach",
"       </td>",
"       <td class=\"centered\">",
"        cherry",
"       </td>",
"       <td class=\"centered\">",
"        plum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        apricot",
"       </td>",
"       <td class=\"centered\">",
"        banana",
"       </td>",
"       <td class=\"centered\">",
"        melon",
"       </td>",
"       <td class=\"centered\">",
"        chestnut",
"       </td>",
"       <td class=\"centered\">",
"        nectarine",
"       </td>",
"       <td class=\"centered\">",
"        grape",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        fig",
"       </td>",
"       <td class=\"centered\">",
"        passion fruit",
"       </td>",
"       <td class=\"centered\">",
"        tomatoes",
"       </td>",
"       <td class=\"centered\">",
"        potatoes",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"6\">",
"        Contact dermatitis assessment (for patients who wear latex gloves frequently):",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        Do you have rash, itching, cracking, chapping, scaling, or weeping of the skin from latex glove use?",
"       </td>",
"       <td class=\"centered\">",
"        Y",
"       </td>",
"       <td class=\"centered\">",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        Have these symptoms recently changed or worsened?",
"       </td>",
"       <td class=\"centered\">",
"        Y",
"       </td>",
"       <td class=\"centered\">",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        Have you used different brands of latex gloves?",
"       </td>",
"       <td class=\"centered\">",
"        Y",
"       </td>",
"       <td class=\"centered\">",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        If so, have your symptoms persisted?",
"       </td>",
"       <td class=\"centered\">",
"        Y",
"       </td>",
"       <td class=\"centered\">",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        Have you used non-latex gloves?",
"       </td>",
"       <td class=\"centered\">",
"        Y",
"       </td>",
"       <td class=\"centered\">",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        If so, have you had the same or similar symptoms as with latex gloves?",
"       </td>",
"       <td class=\"centered\">",
"        Y",
"       </td>",
"       <td class=\"centered\">",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        Do these symptoms persist when you stop wearing all gloves?",
"       </td>",
"       <td class=\"centered\">",
"        Y",
"       </td>",
"       <td class=\"centered\">",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"6\">",
"        Contact urticaria (hives) assessment (for patients who wear latex gloves frequently):",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        When you wear or are around others wearing latex gloves do you get hives, red itchy swollen hands within 30 minutes or, \"water blisters\" on you hands within a day?",
"       </td>",
"       <td class=\"centered\">",
"        Y",
"       </td>",
"       <td class=\"centered\">",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"6\">",
"        Aerosol reaction assessment:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        When you wear or are around others wearing latex gloves, have you noted any:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Itchy, red eyes, fits of sneezing, runny or stuffy nose, itching of the nose or palate?",
"       </td>",
"       <td class=\"centered\">",
"        Y",
"       </td>",
"       <td class=\"centered\">",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Shortness of breath, wheezing, chest tightness or difficulty breathing?",
"       </td>",
"       <td class=\"centered\">",
"        Y",
"       </td>",
"       <td class=\"centered\">",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Other acute reactions, including generalized or severe swelling or shock",
"       </td>",
"       <td class=\"centered\">",
"        Y",
"       </td>",
"       <td class=\"centered\">",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"6\">",
"        History of reactions suggestive of latex allergy:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        Do you have a history of anaphylaxis or of intra-operative shock?",
"       </td>",
"       <td class=\"centered\">",
"        Y",
"       </td>",
"       <td class=\"centered\">",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        Have you had itching, swelling or other symptoms following dental, rectal or pelvic exams?",
"       </td>",
"       <td class=\"centered\">",
"        Y",
"       </td>",
"       <td class=\"centered\">",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        Have you experienced swelling or difficulty breathing after blowing up a balloon?",
"       </td>",
"       <td class=\"centered\">",
"        Y",
"       </td>",
"       <td class=\"centered\">",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        Do condoms, diaphragms or latex sexual aids cause itching or swelling?",
"       </td>",
"       <td class=\"centered\">",
"        Y",
"       </td>",
"       <td class=\"centered\">",
"        N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        Do rubber handles, rubber bands or elastic bands or clothing cause any discomfort?",
"       </td>",
"       <td class=\"centered\">",
"        Y",
"       </td>",
"       <td class=\"centered\">",
"        N",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Source: American College of Allergy, Asthma and Immunology. Sussman G, Gold M. Guidelines for the management of latex allergies and safe latex use in health care facilities, 1996.",
"     <a href=\"file://www.acaai.org\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"      www.acaai.org",
"     </a>",
"     . Reproduced with permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_12_13518=[""].join("\n");
var outline_f13_12_13518=null;
var title_f13_12_13519="Causes of maternal death in the UK";
var content_f13_12_13519=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 623px\">",
"   <div class=\"ttl\">",
"    Causes of maternal death in the UK",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 603px; height: 671px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Causes of maternal death in the United Kingdom (2003-2005). Direct maternal deaths are those resulting from conditions or complications or their management which are unique to pregnancy, occurring during the antenatal, intrapartum or postpartum period. Indirect maternal deaths are those resulting from previously existing disease or disease that develops during pregnancy, not due to direct obstetric causes, but which were aggravated by physiologic effects of pregnancy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Created with data from: Lewis G (Ed). The Confidential Enquiry into Maternal and Child Health (CEMACH). Saving Mothers' Lives: reviewing maternal deaths to make motherhood safer - 2003-2005. The Seventh Report on Confidential Enquiries into Maternal Deaths in the United Kingdom. CEMACH, London 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_12_13519=[""].join("\n");
var outline_f13_12_13519=null;
